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Abstract (English) 
This thesis details the synthesis of three classes of chiral octahedral metal complexes and their 
applications in asymmetric catalysis. 
In the first section, two new octahedral chiral-at-metal iridium(III) and rhodium(III) Lewis acid 
complexes with modified ligands were synthesized to expand the family of previous complexes in our 
group. While the newly synthesized complexes Λ/Δ-Ir/Rh(Se) did not demonstrate higher catalytic 
activities than the existing ones, we believe that these Lewis acid catalysts might be applied to other 
enantioselective reactions such as visible-light driven photocatalysis in the future. 
In the second section, four new bis-cyclometalated rhodium(III) and iridium(III) complexes were 
synthesized in a diastereomerically and enantiomerically pure fashion by employing chiral 
cyclometalating ligands. One of these complexes was identified to catalyze the enantioselective 
alkynylation of 2-trifluoroacetyl imidazoles with different substituted alkynes to provide the propargyl 
alcohols in good to excellent yields with excellent enantioselectivities (up to >99% ee). We found that 
the asymmetric induction in the course of creating a new stereogenic center is controlled by the 
metal-centered chirality not the chirality of the coordinating ligands. Moreover, the rhodium 
complexes display higher catalytic reactivity than our previous catalysts and thus our chiral catalyst 
library is further expanded. Importantly, the synthetic methodology provides a new strategy for the 
straightforward synthesis of enantiomerically pure octahedral complexes with metal-centered chirality. 
Lastly, the first example of an octahedral chiral-at-ruthenium complex bearing two 
N-(2-pyridyl)-subsituted N-heterocyclic carbene (PyNHC) ligands was successfully developed. It was 
demonstrated that the helically chiral catalyst catalyzes the enantioselective alkynylation of simple 
trifluoromethyl ketones to provide the corresponding propargylic alcohols with high efficiency at 
catalyst loading down to 0.2% and with excellent enantioselectivities of up to > 99% ee. A significant 
application of our new catalyst is the enantioselective catalytic synthesis of two key chiral 
intermediates of the anti-AIDS drug efavirenz. 
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Zusammenfassung (Deutsch) 
Die vorliegende Arbeit beschreibt die Synthese von drei Klassen von chiralen oktaedrischen 
Metallkomplexen und die Anwendung dieser Komplexe in asymmetrischer Katalyse. 
Der erste Teil behandelt zwei neue oktaedrische Iridium(III)- und 
Rhodium(III)-Lewis-Säure-Komplexe, deren Strukturen durch Ligandmodifikationen von den 
existierenden Komplexen entwickelt wurden, um das von der Gruppe MEGGERS entwickelte 
Katalysatorsystems zu erweitern. Die Synthese und die Anwendung dieser neuen Komplexe in 
asymmetrischer Katalyse wurde entwickelt. Obwohl die neuen Komplexe Λ/Δ-Ir/Rh(Se) entgegen der 
Erwartungen keine höhere Reaktivität aufwiesen als die bereits vorhandenen Katalysatoren, glauben 
wir, dass diese künftig in anderen asymmetrischen Reaktionen wie z.B. in der Photokatalyse mit 
sichtbarem Licht Anwendung finden könnten. 
Teil zwei behandelt vier neue Rhodium(III)- und Iridium(III)-Komplexe mit chiralen 
cyclometallierenden Liganden. Die Komplexe wurden diastereomeren- und enantiomerenrein 
synthetisiert und anschließend als chirale Katalysatoren eingesetzt. Einer dieser Komplexe ist in der 
Lage die enantioselektive Alkinylierung von 2-Trifluoroacetylimidazolen mit verschieden 
substituierten Alkinen zu den entsprechenden Propargylalkoholen mit exzellenten Ausbeuten sowie 
Enantioselektivitäten (bis >99% ee) zu katalysieren. Interessanterweise wird die asymmetrische 
Induktion bei der Erzeugung des neuen stereogenen Zentrums von der metallzentrierten Chiralität 
kontrolliert und nicht von der Chiralität der Liganden. Darüber hinaus zeigen die Rhodium-Komplexe 
eine höhere katalytische Reaktivität als vorhergehende Katalysatoren dieser Klasse, wodurch unsere 
Bibliothek an verschiedenen chiralen Katalysatoren weiter bereichert wird. Zudem konnte eine 
einfache Synthesestrategie für die Synthese von enantiomerenreinen chiralen oktaedrischen 
Komplexen mit metallzentrierter Chiralität entwickelt werden. 
Der dritte Teil behandelt einen oktaedrischen Ruthenium(II)-Komplex mit metallzentrierter 
Chiralität. Die Einführung von zwei N-(2-Pyridyl)-substituierten N-hetereocyclischen 
Carben-Liganden (PyNHC) ist entscheidend für die erfolgreiche Synthese dieses Komplexes. Der 
Ruthenium(II)-Komplex katalysiert die enantioselektive Alkinylierung von einfachen 
Trifluoromethylketonen zu den entsprechenden Propargylalkohlen mit hoher Effizienz 
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(Katalysatorbeladung bis 0.2 mol%) und mit exzellenten Enantiomerenüberschüssen (bis zu >99% ee). 
Der neue Katalysator ermöglicht einen Zugang zur enantioselektiven katalytischen Synthese von zwei 
Schlüsselintermediaten des HIV-Medikamentes Efavirenz. 
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Chapter 1: Theoretical Part 
1.1 Introduction 
  Research on enantiomerically pure chiral compounds has attracted a lot of attention, because of 
their wide applications in pharmaceuticals, agrochemicals and the flavor industries.
1
 The rapid growth 
of the market for enantiopure compounds is due to the fact that the different enantiomers or 
diastereomers of a molecule have quite different biological activities. Chemists have spent great efforts 
in developing methods to synthesize enantiopure chiral compounds. A variety of strategies are 
available to build enantiopure molecules, such as the classical resolution of racemates, however the 
drawback of affording desired molecules with a maximum of 50% yield makes this method apparently 
not attractive. Asymmetric synthesis by using stoichiometric amounts of chiral precursors from 
Nature’s chiral pool is also limited by the availability of starting materials with a great resemblance to 
the desired molecule. Asymmetric catalysis is therefore considered to be the most elegant and atom 
economic strategy to introduce chirality into a molecule,
2
 which is mainly realized by three kinds of 
catalysts: organocatalysts, enzymatic catalysts and chiral transition metal catalysts. 
The development of chiral transition metal catalysts has been one of the most important and 
interesting research areas.
3 
In 2001, the Nobel prize was awarded to Knowles and Noyori for their 
work on asymmetric catalytic hydrogenation,
4
 and to Sharpless for his work on asymmetric catalytic 
oxidation.
5 
In all their catalytic systems, chiral transition metal complexes were employed as chiral 
catalysts. For the most of chiral transition metal complexes, overall chirality originates from chiral 
ligands that coordinate to the metal center.
6
 Transition metal complexes can also derive their chirality 
exclusively from stereogenic metal centers. The octahedral coordination geometry constitutes one of 
the most popular coordination modes. Chiral octahedral complexes which feature a stereogenic metal 
center can be mainly divided into two classes based on the types of coordinating ligands: one class are 
chiral octahedral metal complexes with chiral ligands, in which the chiral ligands induce a stereogenic 
metal center and also control the absolute configuration; another class are octahedral chiral-at-metal 
complexes. “Chiral-at-metal” refers to chiral metal complexes in which the chirality origainates only 
from a stereogenic metal center, all coordinating ligands being achiral.
7
 Much less attention has been 
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devoted to such octahedral chiral-at-metal complexes.
8
 In the following, the synthesis and applications 
of chiral octahedral metal complexes containing a stereogenic metal center for use in asymmetric 
catalysis will be discussed. 
1.2 Chiral Octahedral Metal Complexes with Chiral Ligands 
The asymmetric synthesis of a chiral octahedral complex by transferring the chirality from a 
stereogenic carbon to a metal center was first reported by Alexander P. Smirnoff in 1920.
9 
From then 
on, numerous chiral ligands such as the CHIRAGEN ligands
10
 and the chiral salen ligands
11
 were 
empolyed to highly diastereoselective synthesis of chiral octahedral metal complexes which covered 
by several excellent reviews.
12 
Some examples of chiral octahedral metal complexes were also 
successfully applied to asymmetric catalytic reactions. These complexes can be classified into two 
types: 1.) inert chiral octahedral metal complexes, in which the central metal serves as a structural 
center, while catalysis is mediated through the organic ligand sphere; 2.) reactive chiral octahedral 
metal complexes, in which the metal center activates a substrate to facilitate further transformation. In 
this section, some representative examples of synthesis and applications of chiral octahedral 
complexes with chiral ligands are discussed.
 
1.2.1 Inert chiral octahedral metal complexes bearing chiral ligands 
The Belokon group reported a class of inert chiral octahedral metal complexes with two chiral 
tridentate ligands.
13,14
 These chiral Co(III) complexes combine metal-centered chirality with 
stereogenic carbons in the coordinating ligands. A high diastereomeric purity for these complexes can 
be obtained from the reaction of Na3[Co(CO3)3] and two chiral Schiff base ligands, prepared from the 
condensation of salicylaldehyde and deprotonated chiral -amino acids, followed by chromatographic 
separation and ion-exchange chromatography (Scheme 1).
13
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Scheme 1 Asymmetric synthesis of inert chiral octahedral cobalt complexes. 
These chiral complexes are used as catalysts for a variety of asymmetric reactions. The catalytic 
properties of these complexes can be tuned by varying the amino acid side chain. For example, the 
authors found that the chiral potassium cobaltate salt -(S,S)-Co-1 can efficiently catalyze the 
enantioselective trimethylsilylcyanation of benzaldehyde. In the presence of PPh3, the desired product 
was obtained in 89% yield with moderate enantioselectivity (77% ee) at room temperature (Figure 1). 
Interestingly, the diastereomer -(S,S)-Co-1, did not provide any enantioselectivity under the same 
reaction conditions, which implied that the centrochirality was responsible for the asymmetric 
induction in this transformation. The authors proposed that the carboxylate moieties in the chiral 
ligand coordinate with a potassium ion, which itself serves as a Lewis acid to activate benzaldehyde 
and the activated benzaldehyde can form a hydrogen bond with an indole NH group in the chiral 
ligand. At the same time, trimethylsilylcyanide can be activated by the nucleophilic carboxylate 
groups in the cobaltate anion. 
They later reported that the related lithium cobaltate complex -(S,S)-Co-2 can catalyze the 
asymmetric Michael addition of diethyl malonate to 2-cyclohexen-1-one in the presence of a strong 
base (PhOLi) in high yield and moderate enantioselectivity (69% ee).
14
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Figure 1 Asymmetric reactions catalyzed by inert chiral octahedral cobalt Schiff base complexes. 
Ohkuma and co-workers introduced another class of inert chiral octahedral ruthenium complex in 
which the chirality at the metal center was combined with chirality in the ligand sphere.
15
 In these 
ruthenium(II) complexes, in addition to chirality at the metal center, the axial chirality was provided 
from one (S)-2,2ʹ-bis(diphenylphosphino)-1,1’-binaphthyl ligand and chirality arising from stereogenic 
carbons was provided by two -amino acid ligands. In this unique system, the chiral ligands actually 
control the diastereoselective asymmetric implementation of the configuration of the metal center. 
Accordingly, the reaction of [RuCl2{(S)-binap}(N,N-dimethylformamide)]n (oligomeric form) with 
three equivalents of (S)-phenylglycine sodium salt in a mixture of DMF/CH3OH afforded -(S,S,S)-Ru 
in 74% yield as a single diastereoisomer. This complex can be purified by regular silica gel 
chromatography under an air atmosphere (Scheme 2). They also demonstrated that this new chiral 
complex could be easily modified by changing the chiral -amino acid ligands.16 
 
Scheme 2 Asymmetric synthesis of chiral octahedral ruthenium complex. 
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In the presence of Li2CO3, -(S,S,S)-Ru can act as a highly active and enantioselective catalyst in 
the cyanosilylation of aldehydes (Figure 2). Mechanistic studies indicated that the bimetallic Ru-Li 
intermediate was the real catalyst, which acted as a chiral Lewis acid catalyst in the transformation. 
The combined catalytic system also showed high reactivity in the asymmetric hydrocyanation of 
,-unsaturated ketones.17 Notably, the catalyst was so robust that it could be reused several times 
without any loss in the enantioselectivity of the reaction. 
 
Figure 2 Asymmetric reactions catalyzed by an inert chiral octahedral ruthenium complex. 
1.2.2 Reactive chiral octahedral metal complexes bearing a chiral ligand 
Chiral tetradentate ligands are one of most explored motifs used in the diastereomeric synthesis of 
chiral octahedral metal complexes. A complex bearing one chiral tetradentate ligand in a 
cis--topology or a cis--topology possesses metal-centered chirality. The tetradentate ligand around 
the octahedral coordination sphere allows for two labile sites to be available for substrate coordination 
which then undergoes further transformation. Carefully tailored chiral tetradentate ligands have been 
vigorously investigated in the asymmetric synthesis of reactive chiral octahedral metal complexes by 
several research groups. 
The “NOON” type of chiral tetradentate ligands have been explored in the asymmetric synthesis of 
reactive chiral octahedral metal complexes. In 1999, Belokon and North reported that the chiral 
(salen)TiCl2 complex can induce the asymmetric addition of trimethylsilyl cyanide to aldehydes.
18a
 
Interestingly, in their catalytic system, water had a significant influence on this reaction since under 
rigorously anhydrous conditions a much lower ee was produced. During their studies, it was found that 
the dimeric titanium oxo complex cis---Ti could be easily obtained upon the reaction of the chiral 
(salen)TiCl2 complex with water (Scheme 3). In the dimeric complex, the two bridging oxygen atoms 
adopt a cis conformation whereby the salen ligands cannot adopt a planar conformation around the 
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titanium center. Instead the salen ligands adopt a cis-- configuration around both titanium atoms.18b 
 
Scheme 3 Asymmetric synthesis of chiral dimeric titanium oxo complexes. 
The authors demonstrated that the dimeric oxo complexes were the real catalyst precursors because 
of its higher reactivity than the corresponding dichloride complex. Using cis---Ti-1 as a catalyst, the 
desired cyanohydrin trimethylsilyl ethers could be obtained with up to 92% ee after less than 1 hour at 
room temperature (Figure 3). 
 
Figure 3 Asymmetric trimethylsilylcyanation of aldehydes catalyzed by cis---Ti-1. 
The Yamamoto group used another chiral tetradentate ligand tethered bis(8-quinolinolato) to react 
with CrCl2, followed by air oxidation, to give the cis---Cr complex in quantitative yield. The 
complex was isolated as a single stereoisomer due to the rotational restriction of the chiral ligand 
(Scheme 4).
19
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Scheme 4 “NOON” tetradentate ligand controls of synthesis of reactive chiral octahedral chromium 
complex. 
The complex acted as an effective catalyst for a variety of asymmetric transformations including the 
pinacol coupling reaction, Nozaki-Hiyama allylation, Pudovik reaction and Stecker reaction.
20
 Figure 
4 shows one example in which the cis---Cr complex was used to catalyze the asymmetric pinacol 
coupling reaction with enantioselectivities observed up to 98% ee. 
 
Figure 4 Asymmetric pinacol coupling catalyzed by a reactive chiral octahedral chromium complex. 
  A “NNNN” type tetradentate chiral ligand has also been applied to efficiently control the relative 
and absolute configurations upon metal complexation.
21
 For example, Que Jr. et al. reported that the 
reaction of a bipyridinebipyrrolidine ligand with Fe(OTf)2·2MeCN provided exclusively the iron 
complex, cis-α-Δ-Fe, in 75% yield, in which the chiral ligand coordinated on the iron center adopts a 
cis- topology (Scheme 5).22 
 
Scheme 5 “NNNN” tetradentate ligand controls of synthesis of chiral octahedral iron complex. 
The authors then demonstrated that the complex could catalyze the dihydroxylation reaction of 
olefins using H2O2 to give the corresponding cis-diol products with high selectivity and high 
enantioselectivity (up to 97% ee) (Figure 5). 
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Figure 5 Oxidation of olefins with H2O2 catalyzed by chiral octahedral iron complex. 
1.3 Octahedral Chiral-at-Metal Complexes 
Octahedral chiral-at-metal complexes in which the chirality is solely a consequence of a stereogenic 
metal center are rare. These chiral complexes display structural simplicity because all the ligands are 
achiral, while the metal-centered chirality is only derived from the asymmetric coordination of the 
ligands around the metal center. These complexes have some attractive features, for example, without 
chiral ligands, there are more options regarding the tuning of the electronic and steric effects of the 
ligand sphere, and the metal-centered chirality is solely responsible for asymmetric induction without 
any other interference. Several methods have been developed for the enantioselective synthesis of 
chiral-at-metal complexes, including the resolution of racemic mixtures using chiral chromatography, 
the resolution of diastereomers using chiral counterions or the use of chiral auxiliaries. The 
applications of octahedral chiral-at-metal complexes are a very recent development. In this section, I 
will focus on the synthesis of octahedral chiral-at-metal complexes, including inert complexes and 
reactive complexes, and their applications in asymmetric synthesis. 
1.3.1 Inert octahedral chiral-at-metal complexes 
  In 1911, the Nobel Prize winner Alfred Werner reported the resolution of the two enantiomers of 
[Co(en)2(NH3)X]
2+
 (X = Cl and Br; en = ethylene diamine) using (+)-3-bromo-camphor-9-sulphonate 
as a chiral anion, which represented direct evidence of the existence of octahedral chiral-at-metal 
complexes (Figure 6).
23
 
 
Figure 6 The resolution of octahedral chiral-at-cobalt complexes with a chiral anion. 
Although the first example had already been reported for more than 100 years, the synthesis of 
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chiral-at-metal complexes is still challenging. Perhaps for this reason, their applications in asymmetric 
catalysis remain much less explored. In 2008, Gladysz et al. reported that the simple chiral-at-cobalt 
Werner complex, -[Co(1,2-ethylenediamine)3]
3+
, can serve as asymmetric H-bonding catalyst.
24
 This 
complex combined with the large tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BAr4F24) counter ion 
catalyzed the Michael addition of dimethyl malonate to 2-cyclopentene-1-one affording the Michael 
addition product in 78% yield and 33% ee in the presence of Et3N (Figure 7). 
 
Figure 7 Enantioselective Michael addition catalyzed by an inert chiral-at-cobalt complex. 
  The Fontecave group reported a new dinuclear ruthenium complex, in which the chiral octahedral 
ruthenium complex served as a “metalloligand” for another reactive ruthenium center.25 Accordingly, 
-[(bpy)2Ru(py)2][R] (R = O,Oʹ-dibenzoyl-L-tartrate), which was prepared according to procedures 
described in the literature,
26
 was reacted with bipyrimidine in hot ethylene glycol solution to give 
-[(bpy)2Ru(bpym)][PF6]2 in 81% yield. The subsequent reaction of -[(bpy)2Ru(bpym)][PF6]2 with 
[RuCl2(p-cymene)]2 followed by anion metathesis during the chromatographic purification step 
provided -[Ru(bpy)2(bpym)RuCl(p-cymene)][NO3]3 (-[Ru][Ru][NO3]3) in 78% yield (Scheme 6). 
 
Scheme 6 The synthesis of octahedral “metalloligands” ruthenium complex. 
This complex can catalyze the asymmetric transfer hydrogenation of arylketones giving the 
corresponding chiral alcohols with enantioselectivities up to 26% ee. It is worth noting that the 
inefficient asymmetric induction was attributed to the large distance between the chiral and catalytic 
metal centers (Figure 8).
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Figure 8 Asymmetric transfer hydrogenation catalyzed by octahedral “metalloligands” ruthenium 
complex. 
The Meggers group has recently made great contributions towards the synthesis of inert octahedral 
chiral-at-metal complexes. These complexes can also be successfully applied for some asymmetric 
transformations. In 2013, the Meggers group reported the synthesis of a series of highly sophisticated 
octahedral chiral-at-metal iridium complexes.
27
 The reaction of IrCl3 trihydrate with a cyclometalating 
ligand affords the di--chloro-bridged dimer. The dimer reacts with the chiral phenol thiazoline (S)-2 
as an auxiliary to provide two diastereomers, which can be separated using conventional silica gel 
column chromatography. Then, substitution of the chiral auxiliary with a pyridylpyrazole ligand upon 
protonation with NH4PF6 and the subsequent introduction of the BAr4F24 counter ion gave the 
enantiopure octahedral chiral-at-metal iridium complex with the retention of its configuration (Scheme 
7). 
 
Scheme 7 Chiral auxiliary-mediated asymmetric synthesis of inert octahedral chiral-at-iridium 
complex. 
Reactivity studies showed that these complexes were highly efficient catalysts for the asymmetric 
transfer hydrogenation of ,-disubstituted nitroalkenes in the presence of a Hantzsch ester used as the 
reducing agent (Figure 9). It was demonstrated that -Ir1 was a superior catalyst and could catalyze 
the transformation delivering the reduced products in excellent yield (89%–96%) with excellent 
enantioselectivity (93%–99% ee). 
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Figure 9 Asymmetric transfer hydrogenation catalyzed by an octahedral chiral-at-iridium complex. 
Encouraged by these results, the Meggers group continued to design and synthesize a series of 
substitutionally inert octahedral chiral-at-metal complexes, which were applied as Brønsted base 
catalysts and enamine catalysts. These complexes can serve as highly effective chiral catalysts for the 
Friedel–Crafts reaction, sulfa-Michael addition reaction, -amination of aldehydes and Henry 
reaction.
28
 
1.3.2 Reactive octahedral chiral-at-metal complexes 
In 2003, Fontecave and co-workers demonstrated that the reactive octahedral chiral-at-metal 
complexes, cis-[Δ-Ru(dmp)2(CH3CN)2][Λ-trisphat]2 or cis-[Λ-Ru(dmp)2(CH3CN)2][Δ-trisphat]2, could 
be selectively precipitated from the reaction of cis-[rac-Ru(dmp)2(CH3CN)2] with 
[n-Bu3NH][Λ-trisphat] or [n-Bu3NH][Δ-trisphat], respectively (Scheme 8).
7b,29
 
 
Scheme 8 The resolution of octahedral chiral-at-ruthenium complex with a chiral anion. 
The octahedral chiral-at-metal complex cis-[-Ru(dmp)2(CH3CN)2] can catalyze the oxidation of 
organic sulfides to sulfoxides with a maximal 18% ee. Although the obtained enantioselectivity was 
disappointing, it was the first example in which chiral information could be transferred from an 
octahedral chiral-at-metal complex during a catalytic asymmetric reaction (Figure 10). 
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Figure 10 Asymmetric oxidation catalyzed by chiral-at-ruthenium complex. 
In 2014, the Meggers group reported an example of a reactive octahedral chiral-at-metal complex.
30
 
This new chiral Lewis acid was structurally quite simple as all the coordinating ligands were achiral. A 
-Ir(O) or -Ir(O) metal center was cyclometalated using two achiral bidentate ligands and two 
labile acetonitrile ligands, which serve as the sole source of chirality. Accordingly, the reaction of 
IrCl3 trihydrate with the 5-tert-butyl-2-phenylbenzoxazole ligand afforded the corresponding 
di--chloro-bridged dimers, which exist as mixtures of the ΛΛ- and ΔΔ-isomers, respectively. 
Replacement of the two chlorides by introducing the chiral auxiliary (S)-2 results in pairs of 
diastereomers, which can be separated using conventional silica gel column chromatography. The 
auxiliary was then substituted by two acetonitrile molecules via protonation under acidic conditions 
affording the -isomer or -isomer with a complete retention of configuration (Scheme 9). 
 
Scheme 9 Asymmetric synthesis of chiral-at-metal complexes -Ir(O) and -Ir(O). 
As shown in Figure 11, this newly developed enantiopure complex Ir(O) can serve as a highly 
effective Lewis acid catalyst. The enantioselective Friedel–Crafts reaction of a variety of indoles to 
,-unsaturated 2-acyl imidazoles was catalyzed using - or -Ir(O) to afford the desired products in 
high yield (up to 99% yield) and excellent enantioselectivity (up to 98% ee) at a low catalyst loading. 
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Figure 11 Asymmetric Friedel-Crafts reaction catalyzed by chiral-at-metal Lewis acid catalyst Ir(O). 
  The Meggers group later reported another related complex, Ir(S), which was also synthesized using 
the auxiliary-mediated strategy upon replacement of the cyclometalated 2-phenylbenzoxazole with 
2-phenylbenzothiazole.
31
 They then tested this complex as the catalyst for a variety of asymmetric 
reactions including the Friedel–Crafts alkylation reaction, Michael addition reaction using CH-acidic 
compounds and a variety of cycloaddition reactions, and compared the catalytic properties of -Ir(S) 
with -Ir(O). 
   Ir(S) turned out to be a more effective catalyst than Ir(O) in several asymmetric transformations 
(Figure 12). Crystallographic studies show that the distance between the quaternary carbon atoms in 
the tert-butyl group and the plane though the iridium center and two acetonitrile molecules in Ir(S) 
was shorter than that in Ir(O), which may explains why Ir(S) gave higher asymmetric induction (see 
Xiaodong Shen’s PhD thesis for details). 
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Figure 12 Asymmetric reactions catalyzed by octahedral chiral-at-metal Lewis acid complexes -Ir(O) 
and -Ir(S). 
  In 2015, the Meggers group developed an example of an octahedral chiral-at-rhodium complex, 
which could be synthesized in an enantiopure fashion using proline-mediated synthesis and 
diastereoselective precipitation (Scheme 10).
32
 
 
Scheme 10 Asymmetric synthesis of the enantiopure Lewis acid complexes - and -Rh(O). 
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Catalytic reactivity studies indicated that the Rh(O) was often a better choice of catalyst than its 
iridium congener in the Michael addition reaction and cascade reactions (Figure 13). The higher 
reactivity of Rh(O) was mainly attributed to the higher lability of the two acetonitrile ligands, which 
was confirmed using acetonitrile exchange experiments (see Chuanyong Wang’s PhD thesis for 
details). 
 
Figure 13 Asymmetric reactions catalyzed by chiral-at-metal Lewis acid complexes -Ir(O) and 
-Rh(O). 
  The Meggers group was then intrigued to develop the Rh(O) derivative, Rh(S), with the hope that it 
would display stronger Lewis acidity and better asymmetric induction.
33
 After several chiral auxiliaries 
were screened, fluorinated phenol oxazoline was employed in the resolution of the - and -isomers 
giving the configurationally stable and highly enantiomerically pure catalysts. The improved 
properties of the Rh(S) catalyst were confirmed by the results obtained from two asymmetric reactions. 
In both the enantioselective Michael addition reaction and photo-excited enantioselective radical 
reaction,
34
 the observed enantioselectivities were higher for the benzothiazole (Rh(S)) catalyst than the 
benzoxazole (Rh(O)) catalyst (Figure 14). 
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Figure 14 Comparison of catalytic performances of chiral-at-metal Lewis acid complexes Rh(O) and 
Rh(S). 
  Recently, visible-light induced organic reactions have received a great deal of attention because they 
use an inexpensive and abundant form of energy.
35
 Bis-cyclometalated iridium complexes are well 
known for their photophysical and photochemical properties,
36 
and have also been used as photoredox 
catalysts for some transformations. The Meggers group wondered whether our chiral 
bis-cyclometalated iridium Lewis acid catalyst could also be used in visible-light-induced photoredox 
reactions. In 2014, the Meggers group found that the Ir(S) could serve as a highly effective chiral 
Lewis acid and at the same time as a photoredox catalyst for the visible-light induced enantioselective 
-alkylation of 2-acyl imidazoles using electron-deficient benzyl bromides or phenacyl bromides.37 
Figure 15 shows that the desired products could be delivered in high yield (up to 100%) and with 
excellent enantioselectivity (up to 99% ee) in the presence of 2 mol% of -Ir(S) under visible-light 
irradiation. 
 
Figure 15 Enantioselective α-alkylation of 2-acyl imidazoles catalyzed by -Ir(S). 
  The Meggers group then demonstrated that this single catalyst was sufficient for many reactions 
including the α-alkylation of 2-acyl imidazoles with perfluoroalkyl iodides,38 the 
α-trichoromethylation of 2-acyl imidazoles and 2-acyl pyridines,39 α-aminoalkylation40 in air and 
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radical/radical coupling reactions.
41 
It was fascinating that these simple iridium complexes are able to 
perform several functions and catalyze many asymmetric transformations. 
  Recently, the Grubbs group reported an example of a reactive octahedral chiral-at-ruthenium 
complex.
42
 This ruthenium(II) complex could be resolved using a chiral auxiliary-mediated strategy. 
Accordingly, the reaction of racemic iodide rac-Ru1 with chiral silver carboxylate 
(S)-AgO2CCH(Ph)(OMe) gave a 1:1 mixture of diastereomers, -Ru2 and -Ru2. Chromatographic 
separation of the mixture afforded enantiopure complex -Ru2 in 45% yield and >95:5 dr. Subsequent 
treatment of -Ru2 with p-toluenesulfonic acid and sodium nitrate delivered -Ru3 in 43% yield 
(Scheme 11). 
 
Scheme 11 Asymmetric synthesis of octahedral chiral-at-ruthenium complex. 
  The authors then demonstrated that this complex could act as an efficient catalyst for diastereo- and 
enantioselective ring-opening/cross-metathesis. Figure 16 shows that the diene product can be 
obtained in 64% yield with 95% Z selectivity and 93% ee in the presence of 1 mol% of -Ru3. The 
catalysis apparently occurred after dissociation of the nitrate ligand. 
 
Figure 16 Diastereo- and enantioselective ring-opening/cross-metathesis catalyzed by an octahedral 
chiral-at-ruthenium complex. 
1.4 Conclusions 
  Octahedral coordination geometry provides a unique structural opportunity for the synthesis of 
chiral complexes bearing a stereogenic metal center. In the above-described examples, chiral 
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octahedral complexes with chiral ligands can be simply and diastereoselectively synthesized though 
the restricted coordination of chiral ligands. However, these complexes are typically combined with 
carefully tailored chiral ligands for achieving high enantioselectivities in asymmetric catalysis. 
 Octahedral chiral-at-metal complexes, in which the coordinating ligands are all achiral, have been 
given less attention. These complexes can be resolved by using chiral counterion-mediated asymmetric 
synthesis or chiral auxiliary-mediated asymmetric synthesis. Only few examples with low to moderate 
enantioselectivities have been reported in this area. Recently, the Meggers group has successfully 
developed two classes of octahedral chiral-at-metal complexes by using chiral auxiliary-mediated 
strategy. These complexes can achieve excellent enantioselectivities even with very low catalyst 
loadings. It is promising to develop more examples of chiral octahedral metal complexes with different 
ligands and metals, and then apply them in various asymmetric transformations. We believe that this 
field will continue to grow rapidly. 
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Chapter 2: Aim of the Work 
1) Expanding the family of bis-cyclometalated octahedral chiral-at-metal iridium and 
rhodium complexes 
Asymmetric catalysis as an elegant and atom economic strategy provides a powerful tool to 
introduce chirality into a molecule in the field of asymmetric synthesis. Recently, our group developed 
reactive octahedral chiral-at-metal iridium and rhodium complexes as Lewis acid catalysts which can 
effectively catalyze a variety of different asymmetric reactions, such as, Friedel-Crafts reactions,
1
 
Michael additions
2
, cycloadditions
2
 and transfer hydrogenations
3
. 
Our previous studies showed that Ir(S) is a somehow superior catalyst compared to Ir(O) in many 
transformations,
2
 and the Rh(S) gives a higher enantioselectivity over Rh(O) in many light-activated 
reactions.
4
 This is probably attributed to the increased length of the C-S bond over C-O bond which 
further places the two tert-butyl groups closer to the two labile coordination sites and then provides a 
higher asymmetric induction. Based on these results, we hypothesize that further increasing the length 
of C-X bond might result in superior catalysts over Ir(S) and Rh(S) catalysts. Herein, we would like 
to synthesize octahedral chiral-at-metal Ir(Se) and Rh(Se) complexes in which the two bidentate 
ligands are replaced by two benzoselenazole ligands, and subsequently, investigate their catalytic 
reactivities. 
2) Introducing chiral cyclometalating ligands into chiral octahedral complexes and 
investigation of their catalytic activity 
Recently our group reported a new family of chiral-at-metal Lewis acid catalysts (/-Ir/Rh(O/S)) 
in which the metal center is chiral resulting from the asymmetric coordination of achiral ligands. They 
are synthetically accessible though auxiliary-mediated method which namely a chiral bidetate ligand is 
temporarily incorporated into the metal center by exchanging the two labile acetonitrile ligands to 
facilitate the resolution of racemic complexes by chromatography or precipitation. After protonation 
by acid, the chiral-at-metal complexes can be obtained in an enantiomerically pure fashion. 
However, all our developed Lewis acid catalysts are based on achiral ligands. So, the purposes of 
this part of the work are: Firstly, how the chiral cyclometalating ligands can influnce the catalytic 
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properties of chiral octahedral metal complexes, and secondly, we would like to simplify the synthetic 
route of chiral complexes featuring metal-centered chirality by employing chiral ligands. 
3) Exploring new chiral-at-ruthenium complexes 
Our group recently has successfully developed the chiral auxiliary-mediated strategy for the 
synthesis of octahedral chiral-at-metal Lewis acids iridium and rhodium catalysts. So, we were 
wondering whether our strategy is applicable to chiral octahedral metal complexes of other elements 
such as ruthenium. Although octahedral chiral-at-ruthenium complexes have already been investigated 
as catalysts for asymmetric reactions, only few examples were reported by now.
5
 Herein, we wish to 
apply our strategy to asymmetric synthesis of octahedral chiral-at-ruthenium complexes. Besides, the 
cost of ruthenium is significantly cheaper than iridium and rhodium. 
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Chapter 3: Results and Discussion 
3.1 Expanding the Family of Bis-Cyclometalated Octahedral 
Chiral-at-Metal Iridium and Rhodium Catalysts 
3.1.1 Design of catalysts 
   In recent years, the Meggers group has successfully developed a class of octahedral chiral-at-metal 
Ir(O)
1
, Ir(S)
2
, Rh(O)
3
 and Rh(S)
4
 complexes in which the metal center is cyclometalated by two 
achiral bidentate ligands and two labile acetonitrile ligands in a propeller type fashion and thereby 
provides the sole source of chirality. Our studies revealed that Ir(S) or Rh(S) is often superior over 
Ir(O) or Rh(O), providing better enantioselectivities.
5,6
 We owed the better asymmetric induction to 
the increased bond length of C-S over C-O, which places the two tert-butyl groups even closer to the 
substrate coordination sites. Encouraged by theses results, we were wondering that by replacing the 
C-S bond with longer C-Se bond might result in better chiral Lewis acid catalysts. Thus, we 
synthesized the analogous complexes Ir(Se) and Rh(Se), and compared their catalytic properties with 
our previous catalysts (Figure 17). 
 
Figure 17 Catalyst design for octahedral chiral-at-metal complexes. 
3.1.2 Synthesis of catalysts 
The 5-(tert-butyl)-2-phenylbenzo[d][1,3]selenazole (1) was smoothly synthesized in three steps (see 
5.2.1 for details). The complexes were prepared according to procedures similar to that used for the 
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synthesis of Ir(S)
5
 and Rh(S)
4
. Accordingly, IrCl3 or RhCl3 hydrate was reacted with 
5-(tert-butyl)-2-phenylbenzo[d][1,3]selenazole (1) in a mixture of 2-ethoxyethanol and water under 
reflux condition, followed by a treatment of 1.2 equivalents of AgPF6 in CH3CN to provide the iridium 
complex rac-Ir(Se) or rhodium complex rac-Rh(Se) respectively (Scheme 12, 13). The resolution of 
rac-Ir(Se) was conducted under our established method
5
. As shown in Scheme 12, the reaction of 
complex rac-Ir(Se) with chiral salicylthiazoline ligand (S)-2 afforded the two diastereomeric 
complexes -(S)-3 and -(S)-3 as a mixture which can be separated by standard silica gel 
chromatography. Upon protonation of -(S)-3 or -(S)-3 by NH4PF6 in acetonitrile at 50 
o
C resulted in 
a substitution of chiral auxiliary ligand by two acetonitrile ligands under complete retention of 
configuration afforded the enantiomers -Ir(Se) or -Ir(Se), respectively. 
 
Scheme 12 Chiral auxiliary-mediated synthesis of the enantiopure iridium(III) complexes -Ir(Se) and 
-Ir(Se). 
Similarly, the resolution of complex rac-Rh(Se) could be easily achieved by employing the 
(R)-3-fluoro-2-(4-phenyl-4,5-dihydrooxazol-2-yl)phenol ((R)-2ʹ) as chiral auxiliary which was used 
for the resolution of rac-Rh(S) (Scheme 13)
4
. Accordingly, the reaction of rac-Rh(Se) with (R)-2ʹ in 
the presence of K2CO3 in EtOH at 70 
o
C afforded the mixture of complexes -(R)-4 and -(R)-4 which 
can be separated by standard silica gel chromatography combined with washing procedure. Upon 
protonation of -(R)-4 and -(R)-4 by TFA in acetonitrile at room temperature resulted in a substitution 
of chiral auxiliary ligand by two acetonitrile ligands under complete retention of configuration, 
affording the enantiomers -Rh(Se) or -Rh(Se), respectively. 
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Scheme 13 Chiral auxiliary-mediated synthesis of the enantiopure rhodium(III) complexes -Rh(Se) 
and -Rh(Se). 
All these newly developed enantiopure complexes can also be purified by standard flash silica gel 
chromatography and are configurationally stable under air and in the presence of moisture. These four 
enantiopure complexes were verified by CD-spectroscopy (see appendices 6.6.2). A structure of 
rac-Ir(Se) was obtained by single crystal X-ray diffraction (Figure 18, right) which clearly shows that it 
possesses almost identical structure compared with Ir(O) and Ir(S). The selected bond lengths and 
bond angles for complexes Ir(O), Ir(S) and Ir(Se) are shown in Table 1. As expected, with the atom 
radium of the X (X = O/S/Se) atoms increasing, the lengths of the bonds between the transition metal 
iridium and N atoms from the cyclometalating ligands are increasing. The bonds to the N atoms from 
the coordinated acetonitrile ligands are much longer in Ir(Se) than that of in Ir(O) and Ir(S), indicating 
more exchange labile acetonitrile ligands in Ir(Se). Besides, the distance between the quaternary 
carbon atoms of the tert-butyl groups and the plane formed by Ir atom and two N atoms from the 
coordinated acetonitrile ligands in Ir(Se) (4.49 Å) is shorter than that in Ir(O) (5.12 Å) and Ir(S) (4.60 
Å) which indicates Ir(Se) might provide better asymmetric induction. 
 
 
 
 
 
Figure 18 Crystal structures of Ir(O) (left), Ir(S) (middle) and Ir(Se) (right). The hexafluorophosphate 
counteranion and hydrogen atoms are omitted for clarity. 
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Table 1 Selected bond lengths (Å) and bond angles (°) for complexes Ir(O), Ir(S) and Ir(Se). 
Complex Ir(O) Ir(S) Ir(Se) 
Bond lengths 
Ir(1)-N(1) 2.044(7) 2.065(6) 2.074(4) 
Ir(1)-N(20) 2.055(8) 2.072(7) 2.079(4) 
 Ir(1)-N(39) 2.101(8) 2.119(6) 2.126(5) 
 Ir(1)-N(42) 2.112(6) 2.123(7) 2.141(5) 
Bond angles 
N(1)- Ir(1)-N(20) 170.9(3) 169.6(3) 169.6(2) 
N(1)- Ir(1)-N(39) 90.1(3) 86.9(2) 84.62(18) 
N(1)- Ir(1)-N(42) 96.2(2) 101.4(3) 102.9(2) 
N(20)- Ir(1)-N(39) 97.2(3) 100.4(2) 102.62(18) 
N(20)- Ir(1)-N(42) 89.6(2) 86.2(3) 84.4(2) 
N(39)- Ir(1)-N(42) 87.6(3) 88.7(3) 92.0(2) 
3.1.3 Catalytic reactions 
Next, we investigated several well established reactions in our lab to compare the catalytic ability of 
homologous catalysts -Ir/Rh(O), -Ir/Rh(S) and -Ir/Rh(Se). 
1) Asymmetric Michael addition 
The Michael addition of 2-acyl imidazole 5 with malononitrile 6 was investigated firstly5. As shown 
in Figure 19, the addition of malononitrile 6 to 2-acyl imidazole 5 catalyzed by 1 mol% -Ir(O) in THF 
at room temperature afforded the adduct product (S)-7 in 96% yield with 88% ee. Our new -Ir(Se) 
resulted in the same ee but -Ir(S) gave 2% higher. 
 
Figure 19 Asymmetric Michael addition of malononitrile. 
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2) Asymmetric photoredox catalysis 
Several visible-light-induced reactions were also examined. Photoinduced enantioselective 
α-alkylation of 2-acyl imidazoles was investigated firstly.2 As shown in Figure 20, under visible-light 
irradiation, when -Ir(S) (2 mol%) was used as catalyst, the enantioselective α-alkylation of 2-acyl 
imidazole 8a with phenacyl bromide 9 provided the desired product (R)-10 in 91% yield and with 90% 
ee within 6 hours at 40 
o
C. However, when -Ir(Se) was employed as catalyst, the reaction became 
slower under the same conditions and the conversion was very low after 6 hours. Prolonging the 
reaction time to 22 hours gave 82% yield with only 78% ee. 
  
Figure 20 Asymmetric photoactivated α-alkylation of 2-acyl imidazole. 
As shown in Figure 21, visible light activated asymmetric aminoalkylation of 2-trifluoroacetyl 
imidazoles was also investigated.
8
 -Ir(S) (2 mol%) was able to catalyze the reaction of 
2-trifluoroacetyl imidazole 11a and tertiary amine 12 to give the adduct product (S)-13 in 75% yield 
and with high enantioselectivity of 95% ee under optimized conditions. However, by using -Ir(Se) 
as catalyst under the same reaction conditions, the reaction was much slower and the product was 
obtained only in 37% yield with identical enantioselectivity after 21 hours. 
 
Figure 21 Asymmetric photoactivated aminoalkylation of 2-trifluoroacetyl imidazole. 
Photoexcited asymmetric -amination of 2-acyl imidazoles was also examined as shown in Figure 
Chapter 3: Results and Discussion 
30 
 
22.
9
 Our previous study showed that -Rh(S) was a better catalyst than -Rh(O). The 
enantioselective radical amination of 2-acyl imidazole 8b with ODN-carbamate 14 could provide the 
corresponding product 15 in 96% yield and with >99.5% ee in the presence of -Rh(S). When 
-Rh(Se) was used as a catalyst, the target product 15 was obtained only in 82% yield and with 97% 
ee. 
 
Figure 22 Asymmetric photoactivated -amination of 2-acyl imidazole.  
In the above-described examples, all the results indicated that the benzoselenazole complexes Ir(Se) 
and Rh(Se) are not better asymmetric catalysts compared to our previous benzoxazole and 
benzothiazole complexes. 
3.1.4 Conclusions 
In conclusion, we successfully synthesized new octahedral chiral-at-metal benzoselenazole 
complexes Λ/Δ-Ir/Rh(Se) by following our established method. This work not only expanded the 
family of bis-cyclometalated iridium(III) and rhodium(III) complexes but also demonstrated that our 
methodology for the synthesis and resolution of racemic octahedral complexes are quite general and 
robust. Unfortunately, the new complexes Λ/Δ-Ir/Rh(Se) did not show better catalytic activity 
compared to benzoxazole complexes Λ/Δ-Ir/Rh(O) and benzothiazole complexes Λ/Δ-Ir/Rh(S) when 
applying them in asymmetric catalysis. The worse reactivity might be attributed to the sluggish 
coordination of substrate to catalyst. 
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3.2 Synthesis, Characterization and Reactivity of Bis-Cyclometalated 
Iridium(III)/Rhodium(III) Complexes Containing Pinene-Derived 
Ligands 
3.2.1 Design of catalysts 
Recently, our group introduced a new class of chiral Lewis acids in which a central iridium(III) or 
rhodium(III) is cyclometalated by two achiral ligands, thereby generating a propeller-type 
C2-symmetry with metal-centered chirality
1,2
 which constitutes the exclusive source of chirality 
(Figure 23).
3,4
 This structural element displays high constitutional and configurational stability, while 
two additional acetonitrile ligands are labile and provide coordinative access for substrates to 
coordinate to the Lewis acidic metal center. These complexes are powerful chiral Lewis acid catalysts 
for a variety of transformations, some activated by visible light. However, all so far synthesized 
catalysts (- and -configured Ir(O/S/Se) and Rh(O/S/Se)) are limited to achiral ligands as 
cyclometalating components. Our objective for this part of work was therefore twofold: Firstly, we 
wanted to investigate how the catalytic properties of these cyclometalated complexes depend on the 
the nature of the cyclometalating unit, and secondly, we were interested in simplifying the synthesis of 
these chiral complexes by employing chiral cyclometalating ligands instead of achiral ones, thereby 
drawing from a large body of work regarding diastereoselective coordination chemistry with chiral 
ligands and the resolution of diastereomeric mixtures of chiral metal complexes.
1
 After doing some 
literature research, we decided to use chiral arylpyridine as an adequate candidate, because it can be 
readily synthesized from natural product and be widely used in asymmetric transformations (Figure 
23).
5-9
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Figure 23 New design for the metal-centered chirality complexes with chiral ligands. 
3.2.2 Synthesis of catalysts 
The work was started by using readily available pinene-modified chiral pyridine ligands which 
were developed by von Zelewsky and others.
5-9
 Accordingly, the reaction of 
2-phenyl-5,6-(S,S)-pinenopyridine
7
 with RhCl3  hydrate or IrCl3  hydrate in a mixture of 
2-ethoxyethanol/water (3:1) at 125 °C for 36 hours afforded the respective chloro-bridged 
dimers /-2Rh or /-2Ir
9
 as mixtures of diastereomers (Scheme 14). Consistent with related 
studies using cyclometalating pinene-derived pryridine ligands, the dinuclear complexes are mainly 
formed as the homochiral - and -diastereomers and within the coordination sphere the kinetically 
favored trans arrangement of the pyridine ligands is observed exclusively.
8
 The assigned absolute 
configurations were confirmed by the crystal structures of bis-acetontrile complexes which were 
obtained from the corresponding dimers and also verified by CD-spectroscopies. The 
diastereomers -2Rh and -2Ir were formed in slight excess of their -counterparts according to 
the crude 
1
H NMR. Conveniently, the diastereomeric dimers could be easily seperated by standard 
silica gel chromatography using ethyl acetate/n-hexane (v/v = 1:20) as the mobile phase. The 
subsequent reaction of the individual diastereomers with AgPF6 in CH3CN at 40 °C converted the 
chloro-bridged dimers into the individual monomeric bis-acetonitrile 
complexes -RhPP, -RhPP, -IrPP and -IrPP. The high diastereomeric purity (>99% dr) of these 
Chapter 3: Results and Discussion 
34 
 
complexes was confirmed by 
1
H NMR and was verified by CD-spectroscopy (Figtures 24–27). Single 
crystals of all four complexes suitable for X-ray diffraction could be easily obtained by slow diffusion 
of n-hexane into CH2Cl2 solution and their crystal stuctures are shown in Figures 28–31, which 
confirm their relative and absolute configurations and reveal the propeller-type ligand arrangement 
with a combination of metal-centered and ligand-derived chirality. All complexes display high 
constitutional and configurational stability without any significant decomposition or isomerization 
upon leaving the complexes dissolved in CH2Cl2 on the benchtop for several weeks or stored in 
refrigerator for several months.
 
 
Scheme 14 Two steps synthesis of chiral octahedral iridium(III) and rhodium(III) complexes. 
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Figure 24 CD spectra of complexes ΛΛ-2Rh and -2Rh recorded in CH3OH (0.2 mM). 
 
Figure 25 CD spectra of complexes ΛΛ-2Ir and -2Ir recorded in CH3OH (0.2 mM). 
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Figure 26 CD spectra of complexes Λ-RhPP and -RhPP recorded in CH3OH (0.2 mM). 
 
Figure 27 CD spectra of complexes Λ-IrPP and -IrPP recorded in CH3OH (0.2 mM). 
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Figure 28 Crystal structure of -RhPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Figure 29 Crystal structure of -RhPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
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Figure 30 Crystal structure of -IrPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Figure 31 Crystal structure of -IrPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
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3.2.3 Catalytic reactions 
With the four diastereomerically and enantiomerically pure transition metal complexes in hand, we 
next investigated their catalytic ability by testing several reactions. Firstly, the Friedel-Crafts addition 
of 2-acyl imidazole with indole was examined as shown in Figure 32.
3c
 The new catalyst -IrPP can 
catalyze the addition of indole to α,β-unsaturated 2-acyl imidazole 5 affording the Friedel-Crafts 
product (S)-16 in only 38% yield and 35% ee after 24 h, This result was quite disappointing compared to 
the previous results (-Ir(S) as catalyst, 40 h, 94% yield and 99% ee).  
 
Figure 32 Comparison of different Lewis acid catalysts -Ir(S) and -IrPP for asymmetric conjugate 
addition. 
The Michael addition of 2-acyl imidazole with malononitrile was next investigated.
4c
 Figure 33 
shows that the addition of malononitrile 6 to substrate 5 catalyzed by 1 mol% -Ir(S) in THF at room 
temperature afforded the adduct 7 with 95% yield and 90% ee after 24 hours. Although our new 
catalysts only provided 78% ee (by -IrPP) and less than 10% ee (by -IrPP) respectively, we gladly 
found that the reactions were much faster. The substrate 5 was completely consumed only within one 
hour. That probably means that the rate of ligand exchange in IrPP is much faster than that in Ir(S). 
 
Figure 33 Comparison of different Lewis acid catalysts for asymmetric conjugate additions. 
We therefore tried two following reactions regarding weak coordinating substrates (Figure 34). For 
the addition of malononitrile to the substrate 17, no desired product was observed even after 48 hours 
at room temperature. Surprisingly, for the alkynylation of trifluoropyruvates 18 with phenylacetylene, 
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14% isolated yield of product 19 was obtained in the presence of 3 mol% rac-RhPP and KOAc (3 eq). 
After intensive screening of reaction parameters such as different bases, solvents, concentrations and 
temperatures and so on, the best results we can achieve were 41% yield and 38% ee with 3 mol% 
-RhPP as a catalyst. 
 
Figure 34 Two reactions with weak coordinating substrates. 
When 1-phenyl-2-trifluoroacetyl imidazole (11a) was chosen as substrate instead of 
trifluoropyruvate 18, as shown in Table 2, we found that RhPP can serve as an excellent catalyst for the 
enantioselective alkynylation of 1-phenyl-2-trifluoroacetyl imidazole (11a).
10-13
 
The reaction of ketone 11a with phenylacetylene at room temperature for 24 hours provided the 
propargyl alcohol (R)-20a in 89% yield and with 95% ee by using 3 mol% of -RhPP in the presence of 
1.2 equivalents of Et3N (Table 2, entry 1). Replacing the N-phenyl substituent with an isopropyl group 
(11b) improved the yield of (R)-20b to 94% and enantioselectivity to 97% ee (entry 2). The best results 
were achieved with 1-phenyl-2-trifluorocetyl imidazole (11c), providing the propargyl alcohol (R)-20c 
in 92% yield and with 99% ee (entry 3). It is noteworthy that using the diastereomeric catalyst -RhPP 
afforded the mirror-imaged product (S)-20c with an identical enantioselectivity of 99% ee and only with 
a slightly reduced yield of 90% (entry 4). This comparison of -RhPP with -RhPP unambiguously 
demonstrates that the asymmetric induction in the course of the catalysis is mainly controlled by the 
metal-centered chirality and not the chirality of the ligand. Notably control experiments confirmed that 
both the catalyst and a base were necessary for achieving a conversion (entries 5 and 6). Reduced 
loadings of -RhPP (entries 7 and 8) and the base triethylamine (entry 9) did not affect the 
enantioselectivity but the reaction rate. Conveniently, the catalytic reaction can even be performed in an 
open flask since it is not sensitive to air or small amount of water (entries 10 and 11). For comparison, 
the iridium-congeners - and -IrPP (entries 12 and 13) provided inferior results whereas our 
Chapter 3: Results and Discussion 
41 
 
previously developed catalysts Rh(O), Ir(O) or Ir(S) were not able to catalyze the transformation at all 
(entries 14–16). Thus, although the absolute configuration at the ligand does not affect the rate and 
degree of asymmetric induction, the nature of the ligand is obviously crucial for an effective catalysis as 
cyclometalated phenylbenzoxazoles (Rh(O) and Ir(O)) or phenylbenzothiazoles (Ir(S)) do not provide 
active catalysts. 
Table 2 Initial Experiments
[a] 
 
Entry Catalyst
[b]
 Substrate Base Conditions T (h) 
Yield 
(%)
[c]
 
ee (%)
[d]
 
1 -RhPP (3.0) 11a Et3N (1.2 eq) nitrogen 24 89 95 (R) 
2 -RhPP (3.0) 11b Et3N (1.2 eq) nitrogen 24 94 98 (R) 
3 -RhPP (3.0) 11c Et3N (1.2 eq) nitrogen 24 92 99 (R) 
4 -RhPP (3.0) 11c Et3N (1.2 eq) nitrogen 24 90 99 (S) 
5 -RhPP (3.0) 11c none nitrogen 24 0 n.a. 
6 none 11c Et3N (1.2 eq) nitrogen 24 0 n.a. 
7 -RhPP (2.0) 11c Et3N (1.2 eq) nitrogen 24 80 99 (R) 
8 -RhPP (1.0) 11c Et3N (1.2 eq) nitrogen 24 51 99 (R) 
9 -RhPP (3.0) 11c Et3N (0.3 eq) nitrogen 24 60 99 (R) 
10 -RhPP (3.0) 11c Et3N (1.2 eq) air 24 93 99 (R) 
11 -RhPP (3.0) 11c Et3N (1.2 eq) air, 1% H2O 24 88 99 (R) 
12 -IrPP (3.0) 11c Et3N (1.2 eq) nitrogen 24 37 29 (R) 
13 -IrPP (3.0) 11c Et3N (1.2 eq) nitrogen 24 84 15 (S) 
14 /-Rh(O) (3.0) 11c Et3N (1.2 eq) nitrogen 24 0 n.a. 
15 /-Ir(O) (3.0) 11c Et3N (1.2 eq) nitrogen 24 0 n.a. 
16 /-Ir(S) (3.0) 11c Et3N (1.2 eq) nitrogen 24 0 n.a. 
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[a]
Conditions: trifluoromethyl ketone (0.20 mmol), phenylacetylene (0.60 mmol) and catalyst (3.0 
mol%) in THF (0.2 mL) were stirred at room temperature for 24 hours. 
[b]
Catalyst loading in mol% 
provided in brackets. 
[c]
Isolated yields. 
[d]
Chiral HPLC analysis. n.a. = not applicable. 
After these promising initial results regarding the enantioselective alkynylation with -RhPP, we 
performed a substrate scope evaluation under optimized conditions with the trifluoroketone 11c and a 
variety of arylacetylenes. As shown in Figure 35, our method tolerates a variety of substituted 
phenylacetylenes, containing alkyl and aryl with electron-donating and electron-withdrawing 
substituents. Heteroarylacetylenes such as 2-pyridylacetylene and 3-thiophenylacetylene are also 
suitable substrates for this asymmetric transformation. Overall, yields range from 79−99% and 
enantioselectivities from 97−99% ee for the propargyl alcohols (R)-20c-p. 
 
Figure 35 Substrate scope with respect to arylacetylenes. 
-RhPP also catalyzes the reaction of trifluoroketone 11c with aliphatic acetylenes as shown in 
Figure 36 to provide the propargyl alcohols (R)-20q-v in satisfactory yields (55−88%) and with 
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excellent enantioselectivities (94−99% ee). Next several other substrates with respect to the imidazole 
substrates are also investigated under the same or some modified conditions (Figure 37). 
 
Figure 36 Substrate scope with respect to alkylacetylenes and trimethylsilylacethylene. 
The benzimidazole substrate 11d can also react with phenylacetylene to give the corresponding 
alcohol 20w in moderate yield and with excellent enantioselectivity (99% ee). The substrate 11e with 
methoxyphenyl group on imidazole moiety can provide satisfying results (95% yield, 94% ee). 
Importantly, the CF3 group can be replaced by a CF2CF3 group, affording the expected product 20y in 
good yield and with excellent enantioselectivity (97% ee) by prolonging the reaction time to 48 h and 
at the same time increasing the temperature to 60 
o
C. 
 
Figure 37 Substrate scope with respect to other 2-fluoroacetyl imidazoles. 
However, it is important to note that satisfactory yields and excellent enantioselectivities of this 
reaction are limited to ketones which contain both the CF3 group as well as the imidazole moiety. For 
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example, replacing the imidazole moiety with a phenyl or ethylcarboxylate or benzoyl leads to get no or 
low yield and enantioselectivity, while changing the CF3 group with an ethyl group completely 
abolishes the conversion (Figure 38). These results imply that a successful catalysis relies on a strong 
electronic activation of the carbonyl group by a neighboring CF3 in combination with the efficient 
coordination of the substrate to the rhodium catalyst. 
 
Figure 38 Control experiments with other substrates. 
Since our previously developed chiral-at-metal complexes Ir(O) and Ir(S) had been proven as 
multi-function catalysts for photoredox catalysis, we wondered whether our new IrPP could perform 
the same properties or not. Two light-activated asymmetric reactions which had been well established 
in our group were investigated as shown in Figure 39. Firstly, the enantioselective α-alkylation of 
2-acyl imidazole 8c with benzyl bromide 21 catalyzed by the complex -Ir(S) (2 mol%), under 
visible-light irradiation, provided the desired product (R)-22 in 98% yield and with 99% ee within 2 
hours at 40 
o
C.
3b
 However, the reaction became very slow when -IrPP was employed as a catalyst. 
The reaction did not finish after 2 hours and only 30% ee was obtained. 
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Figure 39 Comparison of -Ir(O) and -IrPP for enantioselective α-alkylation of 2-acyl imidazole 
with benzyl bromide. 
Secondly, visible light induced asymmetric -aminoalkylation of 2-acyl imidazole was also 
examined (Figure 40).
3e
 The reaction of 2-acyl imidazole 8d and silyl amine 23 gave the addition 
product (R)-24 in 92% yield and with high enantioselectivity of 97% ee within 6.5 hours when -Ir(O) 
(2 mol%) was employed as catalyst. However, employing -IrPP as catalyst, the reaction became 
very sluggish. Prolonging the reaction time to 21 hours, the product was only obtained in 17% yield 
and with very low enantioselectivity (7% ee) under the same reaction conditions. 
 
Figure 40 Comparison of -Ir(O) and -IrPP for asymmetric -aminoalkylation of 2-acyl imidazole. 
3.2.4 Conclusions 
In conclusion, we developed four new bis-cyclometalated rhodium(III) and iridium(III) complexes 
and found that the rhodium complex could serve as a highly effective catalyst for the catalytic 
enantioselective alkynylation of 2-trifluoroacetyl imidazoles. The rhodium complex contains 
pinene-derived chiral ligands that permit the straightforward synthesis of the complexes as 
enantiomerically pure single diastereomers. Interestingly, although the asymmetric induction over the 
course of the catalysis is mainly controlled by the metal-centered chirality, the synthesized rhodium 
complexes feature a catalytic activity that is surprisingly distinct from our previous benzoxazole- and 
benzothiazole-based catalysts. 
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3.3 Octahedral Chiral-at-Ruthenium Complexes for Asymmetric Catalysis 
3.3.1 Design of catalysts 
Transition metal complexes represent one of the most powerful and versatile classes of homogeneous 
catalysts. Applied to asymmetric catalysis, metal ions are typically combined with carefully tailored 
chiral ligands.
1
 In a more simplistic design, only achiral ligands are employed but their assembly around 
the central metal creates metal-centered chirality
2
 which is then responsible for the asymmetric 
induction during catalysis.
3
 Our group recently realized this approach with the design of 
bis-cyclometalated iridium
4
 and rhodium
5
 complexes as chiral Lewis acids which provide excellent 
enantioselectivities and high turnover numbers for a variety of reactions. However, at the onset of this 
work it was unclear to what extend this design principle is general and applicable to chiral octahedral 
metal complexes of other elements. In pioneering work, Fontecave and co-workers reported that - and 
-[Ru(2,9-dimethyl-1,10-phenanthroline)(MeCN)2]
2+
 catalyzed the oxidation of organic sulfides to 
their sulfoxides, albeit with a maximum of just 18% ee.
3a
 Much higher enantioselectivities for the 
synthesis of sulfoxides were achieved by Ye using chiral-at-metal - and 
-[Ru(2,2’-bipyridine)2(py)2]
2+
 as recyclable chiral auxiliaries.
6
 Hartung and Grubbs reported a 
chiral-at-ruthenium catalyst for diastereo- and enantioselective ring-opening/cross-metathesis. The 
complex contains additional carbon-centered stereogenicity and catalysis is supposed to occur via a 
trigonal bipyramidal intermediate.
7
 After a period of efforts, we finally chose the inert and strong 
-donating N-heterocyclic carbenes (NHCs) as ligands which might make the ruthenium complex is 
configurationally stable and has more labile acetonitrile ligands due to its strong trans-effect (Figure 
41). 
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Figure 41 Design of octahedral chiral-at-ruthenium catalysts. 
3.3.2 Synthesis of catalysts 
The racemic complex rac-Ru1 was synthesized according to the procedure reported by Hahn and 
co-workers with some modifications.
8
 Accordingly, the octahedral ruthenium complex rac-Ru1 was 
synthesized by reacting RuCl3 hydrate with the N-(2-pyridyl)-imidazolium salt 25 in ethylene glycol at 
200 °C, followed by treatment with AgPF6 to afford the racemic complex rac-Ru1 in 92% yield 
(Scheme 15). The single crystals of rac-Ru1 suitable for X-ray were obtained by diffusion of hexane in 
CH2Cl2 solution at room temperature (Figure 42). This racemic mixture was then reacted with the chiral 
salicyloxazoline ligand (S)-2ʹʹ to provide -(S)-Ru1 as a single diastereomer in 36% yield after the 
standard chromatography. In analogy, using the auxiliary (R)-2ʹʹ instead, the complex -(R)-Ru1 was 
obtained. The individual diastereomerically pure complexes were next treated with TFA in CH3CN to 
generate Ru1 as individual - and -enantiomer. -Ru2 and - Ru2 can be obtained by the same 
protocol (see chapter 5.3 for details). CD spectra of -Ru1 and - Ru1 are shown in Figure 44 and 
were used to assign the absolute configuration by comparison with related enantiopure ruthenium 
complexes,
9
 and confirmed by an X-ray crystal structure of a derivative of -Ru2 (Figure 43). 
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Scheme 15 Synthesis of enantiopure complexes - and -Ru. 
 
Figure 42 Crystal structure of rac-Ru1. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion and all hydrogens are omitted for clarity. 
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Figure 43 Crystal structure of -Ru2-DPPE. ORTEP drawing with 50% probability thermal ellipsoids. 
The hexafluorophosphate counteranion and all hydrogens are omitted for clarity. 
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Figure 44 CD spectra of - and -Ru1(0.2 mM in CH3OH). 
Importantly, we found that the enantiopure complexes are constitutionally and configurationally 
surprisingly stable. For example, a solution of -Ru1 (20 mg) in 3 mL THF was stirred at 60 oC for 3 
days. After cooling to room temperature, 2 drops of CH3CN were added, and the solvent was removed, 
then the residue was analyzed by 
1
H NMR which shows no obvious change (Figure 45). The resulting 
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complex was also used to catalyze the model reaction (see 3.3.4 for details) under the same conditions, 
giving the almost identical results (94% yield, 99% ee). 
 
Figure 45 
1
H NMR spectra of -Ru1 recorded in CD2Cl2 (fresh and 3 days in CD2Cl2). 
3.3.3 Studies of the trans-effect in the ruthenium complexes 
The trans-effect of the NHC-ligands in the catalysts Ru1 and Ru2 was investigated by comparison with 
the related complex [Ru(2,2’-bipyridine)2(MeCN)2]
2+
. 
 
Figure 46 The structures of ruthenium complexes. 
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a.) Structural trans-effect 
We determined the X-ray crystal structure of the racemic catalyst rac-Ru1 (see 3.3.1). Several X-ray 
crystal structures are available for the complex [Ru(bpy)2(MeCN)2]
2+
 with different counterions as listed 
in Table 3.
10-13
 The comparison demonstrates that the Ru-N coordinative bonds with the MeCN ligands in 
[Ru(bpy)2(MeCN)2]
2+
 are in the range of 2.012−2.049 Å and thereby significantly shorter compared to the 
Ru-N (MeCN) bonds in rac-Ru1 (2.098 Å). This is clear evidence of the structural trans-effect exerted by 
the two NHC-ligands in trans to the two MeCN ligands. 
Table 3 Investigation of the structural trans-effect by comparison of the Ru-N bond lengths of the 
coordinated MeCN ligands. 
Complexes Ru-N bonds to MeCN (Å) References 
[Ru(bpy)2(MeCN)2](PF6)2 2.033, 2.033 Heeg, et al.,
10
 
[Ru(bpy)2(MeCN)2](PF6)2 2.012, 2.012 Xu, et al.,
11
 
[Ru(bpy)2(MeCN)2](BF4)2 2.042, 2.049 Wang, et al.,
12
 
[Ru(bpy)2(MeCN)2](ClO4)2 2.0397, 2.0447 Chattopydhyay, et al.,
13
 
rac-Ru1 2.098, 2.098 Our work 
b.) Kinetic trans-effect 
We compared rac-Ru2 and [Ru(bpy)2(MeCN)2]
2+
 with respect to the rate of replacing the MeCN 
ligands with the bidentate ligand 2,2’-bipyridine. For this, a mixture of [Ru(bpy)2(MeCN)2](PF6)2 or 
rac-Ru2 (20.0 mg), and 2,2'-bipyridine (1.75 eq) in CD2Cl2 (1.0 mL or 0.8 mL) was stirred at room 
temperature and then analyzed by 
1
H NMR spectroscopy after 0.5 h, 3 h, 8 h, and 24 h, respectively. As 
shown in Figure 47, there is no ligand replacement of the coordinated MeCN ligands by 2,2’-bipyridine 
can be monitored at room temperature for [Ru(bpy)2(MeCN)2](PF6)2 even after 24 hours, whereas the 
complex rac-Ru2 under the same conditions displays a significant conversion already after 30 min. This 
much higher lability of the CH3CN ligands in rac-Ru2 can be attributed to the kinetic trans-effect of the 
NHC ligands in rac-Ru2. 
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Figure 47 The acetonitrile exchange experiments in the presence of bipyridine. 
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Figure 48 Investigation of kinetic trans-effect. 
3.3.4 Catalytic reactions 
With the chiral catalysts in hand, we firstly tested the reaction of 2-trifluoroacetly imidazole 11c 
with phenylacetylene. However, the reaction cannot give any traces of desired product 20c under our 
optimal conditions. 
 
Figure 49 Alkynylation of 2-trifluoroacetyl imidazole catalyzed by rac-Ru1. 
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Since our new catalysts have very strong trans-effect that means they might active more general 
substrates. Therefore, trifluoroacetophenone 25a was employed to examine. To our delight, we found 
that Ru1 is an excellent catalyst for the enantioselective alkynylation of trifluoromethyl ketones.
14,15
 
Table 4 Initial Catalysis Experiments
[a] 
 
Entry Catalyst Loading (mol%) Time (h) Yield (%)
[b]
 ee (%)
[c]
 
1 -Ru1 3 16 97 99 (S) 
2 -Ru1 1 16 93 99 (S) 
3 -Ru1 0.5 16 95 99 (S) 
4 -Ru1 0.2 30 98 99(S) 
5 - Ru1 0.5 16 95 99 (R) 
6 -Ru2 0.5 16 93 97 (S) 
7 -Ir(S) 3 20 15 15 (R) 
8 -Rh(S) 3 20 28 93 (R) 
[a]
Conditions: 25a (0.20 mmol), phenylacetylene (0.60 mmol) with catalyst (0.2–3.0 mol%) and 
Et3N (20 mol%) in THF (0.4 mL) were stirred at 60 
o
C. 
[b]
Isolated yields. 
[c]
Chiral HPLC analysis. 
As shown in Table 4, the reaction of trifluoroacetophenone (25a) with phenylacetylene in the 
presence of Et3N (0.2 eq) and 3.0 mol% -Ru1 provides the propargyl alcohol (S)-26a in 97% yield 
and with 99% ee (entry 1). The catalyst loading can be reduced down to 0.2 mol% without any loss in 
yield or enantioselectivity (entries 2−4). As to be expected, mirror-imaged -Ru1 provides the 
mirror-imaged product (R)-26a with otherwise identical performance (entry 5). The catalyst devoid of 
the 3,5-Me2Ph substituents (-Ru2) leads to a reduced enantioselectivity of 97% ee (entry 6), 
confirming the steric role of the substituents at the pyridine ligands. Interestingly, previously reported 
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chiral-at-metal iridium and rhodium catalysts only display very sluggish reactivity for the alkynylation 
of trifluoromethyl ketones and a diminished enantioselectivity even at catalyst loadings of 3.0 mol% 
(entries 7 and 8). 
A substrate scope with respect to terminal alkynes is shown in Figure 50, providing the 
propargylalcohols (S)-26b-m in yields of 66-99% and with outstanding enantioselectivities of 96 
to >99% ee. The catalyst tolerates equally well phenylacetylenes with substituents in the phenyl 
moiety, 2-ethynylthiophene, the conjugated alkenyl acetylene 1-ethynylcyclohexene, aliphatic 
acetylenes, and trimethylsilylacetylene. Typically, catalyst loadings of just 0.5 mol% -Ru1 are 
sufficient except for ortho-substituted phenylacetylenes which react more sluggish, presumably due to 
steric reasons. 
 
Figure 50 Substrate scope with respect to terminal alkynes.
 a
1.0 mol% catalyst loading instead. 
The scope of this reaction with respect to trifluoromethyl ketones is outlined in Figure 51. 
Trifluoroacetophenone with different substituents in the phenyl moiety provided the corresponding 
propargyl alcohols in high yields and with almost perfect enantioselectivity except for ortho-methyl 
trifluoroacetophenone which reacts sluggish, reinforcing that the catalyst is sensitive to steric effects. 
It is also noteworthy that an aliphatic trifluoromethyl ketone and ethyl trifluoropyruvate are not 
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suitable substrate for this catalysis. However, replacing one fluorine of the trifluormethyl group with 
chlorine by using 2-chloro-2,2-difluoroacetophenone as the substrate yields the corresponding 
propargyl alcohol in 99% yield and 99% ee. 
 
Figure 51 Substrate scope with respect to trifluoromethyl ketones. 
a
1.0 mol% catalyst loading instead. 
  3.3.5 Applications 
After getting these exciting results, we turned our attention to search for some applications. The 
synthetic methodology we developed here is very valuable because propargylic alcohols constitute 
highly versatile synthetic building blocks
16
; furthermore, fluorinated compounds play an increasingly 
important role in drug development. For example, efavirenz
17
, containing a quaternary stereocenter 
bearing a CF3 and alkynyl group, is a potent HIV reverse transcriptase inhibitor and a key drug for the 
treatment of AIDS. So, we decided to pursue this direction. 
  Initially, we identified the reaction of 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone (27a) 
with cyclopropylacetylene in the presence of Et3N (0.2 eq) in THF (0.5 M) at 60 
o
C for 48 h catalyzed 
by chiral-at-metal -Ru1 (3 mol%) provided the Merck intermediate (S)-28a with 58% yield and 91.6% 
ee (Table 5, entry 1). Although this method provides a convenient catalytic, enantioselective access to 
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the key Merck intermediate (S)-28a, the yield and the enantioselectivity are only modest and we were 
not able to significantly improve these results. Unexpectedly, excellent enantioselectivity (99.0% ee) 
was obtained when -Ru2 was employed as catalyst under the same reaction conditions, although the 
yield was disappointingly very low (entry 2). We therefore switched our attention to a related substrate 
in which the electron donating amino group (27a) is replaced with an electron withdrawing nitro group 
(27b), with the expectation that this modification would accelerate the alkynylation 27b(S)-28b and 
a straightforward iron-based reduction of (S)-28b to (S)-28a has been reported.
18
 Gratifyingly, using 
just 0.5 mol% -Ru1, the propargylic alcohol (S)-2c was obtained in a yield of 93% with 99.6% ee 
after 16 hours at 60 °C (entry 3). Interestingly, using a simplified catalyst devoid of the two 
3,5-dimethylphenyl moieties (-Ru2), almost unchanged yield and enantioselectivity were observed 
(entry 4). Since the synthesis of -Ru2 is less time consuming and less expensive compared to -Ru1, 
the simplified catalyst -Ru2 is apparently the catalyst of choice for the conversion 27b(S)-28b. 
Even at a reduced catalyst loading of 0.2 mol%, a yield of 95% with 99.4% ee was obtained (entry 5), 
while at a further reduced catalyst loading of 0.1 mol% the yield deteriorated (entry 6). Interestingly 
for practical reasons, at a catalyst loading of 0.5 mol% -Ru2, the reaction can be executed at room 
temperature to afford (S)-2c with 96% yield and 99.4% ee after 16 hours (entry 7). A lower catalyst 
loading of 0.2 mol% leads to a decreased yield (entry 8). The reaction is sensitive to air (entry 9) but 
not to the presence of small amounts of water (entry 10). 
 
Scheme 16 The synthesis of intermediates of the drug efavirenz with chiral-at-ruthenium complexes. 
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Table 5 Optimization of the reaction conditions with substrates 27a and 27b
[a] 
Entry Catalyst
[b]
 X T (ºC) t (h) Yield (%)
[c]
 ee (%)
[d]
 
1
[e]
 -Ru1 (3.0) NH2 60 48 58 91.6 
2
[e]
 -Ru2 (3.0) NH2 60 48 25 99.0 
3 -Ru1 (0.5) NO2 60 16 93 99.6 
4 -Ru2 (0.5) NO2 60 16 92 99.4 
5 -Ru2 (0.2) NO2 60 16 95 99.4 
6 -Ru2 (0.1) NO2 60 64 42 99.2 
7 -Ru2 (0.5) NO2 r.t. 16 96 99.4 
8 -Ru2 (0.2) NO2 r.t. 48 55 99.4 
9
[f]
 -Ru2 (0.2) NO2 60 16 21 98.2 
10
[g]
 -Ru2 (0.2) NO2 60 16 96 99.0 
[a]
Reaction conditions: 27a or 27b (0.20 mmol), cyclopropylacetylene (0.60 mmol), catalyst, and 
Et3N (20 mol%) in THF (0.4 mL, 0.5 M). 
[b]
Catalyst loadings in mol% provided in brackets. 
[c]
Isolated yields. 
[d]
Determined by HPLC on a chiral stationary phase. 
[e]
2 mmol 
cyclopropylacetylene was used instead. 
[f]
Performed under air. 
[g]
Performed in the presence of 1% 
H2O. 
Lonza intermediate is also an important intermediate which can be converted to efavirenz in one 
step
19
. So we next investigated the catalytic, enantioselective alkynylation of the chlorinated Lonza 
intermediate 27c with cyclopropylacetylene. Accordingly, with -Ru1 at 0.5 mol% catalyst loading, 
the reaction of 27c with cyclopropylacetylene at 60 °C provided the propargylic alcohol (S)-28c in 99% 
yield and with 90% ee (Table 6, entry 1). Interestingly, same as for the nitro substrate 27b, the 
simplified catalyst -Ru2 provides superior results (entries 2−6). With a catalyst loading of just 0.2 
mol% at room temperature, (S)-28c provided in 95% yield and with 95% ee (entry 5). Attempts to 
lower the catalyst loading to 0.1 mol% led to a decreased yield, even after prolonging the reaction time 
to 64 hours (entry 6). Control experiments reveal that the reaction is sensitive to air (entry 7) but not to 
small amounts of water (entry 8) which means that the reaction must be performed under inert gas 
conditions but the solvents do not need to be dry. 
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Table 6 Optimization of the reaction conditions with substrate 27c
[a]
 
Entry Catalyst
[b]
 T (ºC) t (h) Yield (%)
[c]
 ee (%)
[d]
 
1 -Ru1 (0.5) 60 16 99 90.2 
2 -Ru2 (0.5) 60 16 99 93.8 
3 -Ru2 (0.2) 60 24 93 93.7 
4 -Ru2 (0.5) r.t. 16 99 95.2 
5 -Ru2 (0.2) r.t. 16 95 95.0 
6 -Ru2 (0.1) r.t. 64 71 95.0 
7
[e]
 -Ru2 (0.2) r.t. 16 11
[f]
 n.d.
 [g]
 
8
[h]
 -Ru2 (0.2) r.t. 16 96 95.2 
[a]
Reaction conditions: 27c (0.20 mmol), cyclopropylacetylene (0.60 mmol), catalyst, and Et3N (20 
mol%) in THF (0.4 mL, 0.5 M) were stirred at indicated temperature for the indicated time. 
[b]
Catalyst 
loadings in mol% provided in brackets. 
[c]
Isolated yields. 
[d]
Determined by HPLC on a chiral stationary 
phase. 
[e]
Performed under air. 
[f]
NMR yield with tetrachloroethane as internal standard. 
[g]
Not 
determined. 
[h]
Performed in the presence of 1mol% H2O. 
Two gram-scale reactions were carried out to highlight the practical utility of this protocol. As 
shown in Figure 52, employing 27b or 27c as substrate under the optimal conditions, respectively, the 
reaction exhibited excellent efficiency, providing the propargylic alcohol products in high isolated 
yield without any loss of enantioselectivity. 
 
Figure 52 Gram-scale reactions under optimized reaction conditions. 
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3.3.6 Proposed mechanism 
Mechanistically, we propose that the reaction proceeds through an intermediate ruthenium acetylide 
which then tranfers the acetylide to the presumable ruthenium-coordinated trifluoroketone (Figure 
53).
16a
 The observed excellent asymmetric induction suggests that the trifluoromethyl ketone substrate 
coordinates to the ruthenium ahead of the acetylide transfer. During this transfer, the metal-centered 
chirality provides a suprisingly high asymmetric induction, thus reinforcing our catalyst design 
strategy. The rigidity of the propeller-type coordination sphere most likely contributes to the observed 
excellent enantioselectivities but is also responsible for sensitivity to steric effects. It is worth noting 
that catalytic amounts of base are necessary in this reaction, which apparently serves as a proton 
shuttle. 
 
Figure 53 Proposed mechanism.  = vacant coordination site. 
3.3.7 Conclusions 
In summary, the first example of an octahedral chiral-at-metal ruthenium complex with high 
catalytic activity and excellent enantioselectivity was presented. Key components of this new class of 
asymmetric catalysts are the two N-(2-pyridyl)-subsituted N-heterocyclic carbene (PyNHC) chelate 
ligands.
20,21
 First, the PyNHC ligands are tightly coordinating ligands which provide a strong ligand 
field important for the constitutional and configurational stability of the bis-(PyNHC)Ru unit. Second, 
the propeller shape and high rigidity of the bis-(PyNHC)Ru provides an excellent asymmetric 
induction. And third, the strong -donating NHC-ligands22 in trans to the coordinated acetonitrile 
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ligands are crucial for labilizing the coordinated acetonitrile ligands (trans-effect) thereby ensuring a 
high catalytic activity. We also demonstrated that highly efficient catalytic enantioselective synthesis 
of key chiral propargylic alcohol intermediates toward enantiomerically pure efavirenz. The Merck 
propargylic alcohol intermediate (S)-28a can be obtained indirectly after reduction of the 
nitro-derivative (S)-28b, which itself is formed through a catalytic, enantioselective alkynylation in 97% 
yield and with 99% ee. The Lonza propargylic alcohol intermediate (S)-28c can be accessed through a 
catalytic, enantioselective alkynylation in 99% yield and with 95% ee with a turnover number 
reaching almost 500 and relying only on the addition of catalytic amounts of the base triethylamine. 
These synthetic routes might constitute significant improvements over existing protocols and could 
contribute to lowering the cost for the production of the important anti-HIV drug efavirenz. 
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Chapter 4: Summary and Outlook 
4.1 Summary 
1) Expanding the family of bis-cyclometalated octahedral chiral-at-metal iridium and 
rhodium catalysts 
Several octahedral chiral-at-metal complexes Ir(Se) and Rh(Se) were successfully synthesized for 
expanding our previously developed Lewis acid catalysts based on our established procedures. 
Accordingly, the chiral Lewis acid complexes /-Ir(Se) and /-Rh(Se) were synthesized though 
the chiral auxiliary-mediated strategy which was developed by our group. The reaction of rac-Ir(Se) 
or rac-Rh(Se) with the appropriate chiral auxiliary afforded the corresponding auxiliary complexes 
-(S)-3 and -(S)-3 or -(R)-4 and -(R)-4 as a mixture of diastereomers, respectively. The generated 
diastereomeric complexes could be resolved by standard silica gel chromatography. Then the 
individual enantiomers /-Ir(Se) and /-Rh(Se) were generated after the protonation by acid. 
 
Figure 54 Expansion of catalysts library. 
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Scheme 17 Chiral auxiliary-mediated asymmetric synthesis of the enantiopure chiral-at-metal 
complexes. 
  We then investigated some reactions to compare their catalytic reactivity with the previous ones. 
Michael addition reaction and three photo-induced reactions were tested as summarized below. 
Unfortunately, the new catalysts did not have better or even similar performance. Except for Michael 
addition reaction, -Ir(Se) or -Rh(Se) showed worse activity. We assumed that maybe the 
coordination of substrate with Ir(Se) or Rh(Se) is more difficult than its congeners due to higher steric 
hinderance. 
 
Figure 55 Comparison of catalytic reactions catalyzed by Lewis acid catalysts. 
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2)  Synthesis, characterization and reactivity of bis-cyclometalated iridium(III)/rhodium(III) 
complexes containing pinene-derived ligands 
Chiral ligands mediated four new bis-cyclometalated rhodium(III) and iridium(III) complexes were 
firstly synthesized in a diastereomerically and enantiomerically pure fashion in our group. Reactivity 
studies demonstrated that the rhodium complex contains pinene-derived chiral ligands can serve as a 
highly effective catalyst to catalyze the enantioselective alkynylation of 2-trifluoroacetly imidazoles. 
The propargyl alcohols were obtained in 55–99% yields with excellent enantioselectivities (94–>99% 
ee). Interestingly, the asymmetric induction is mainly controlled by the metal-centered chirality not the 
chirality of ligands during the catalytic cycle, and at the same time the rhodium complexes show 
higher catalytic activity compared to our previous achiral ligand-based catalysts. Besides, the 
introduction of chiral ligand shortens the asymmetric synthesis of chiral octahedral complexes. 
 
Scheme 18 Synthesis of chiral octahedral iridium(III) and rhodium(III) complexes with chiral ligands. 
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Figure 56 Selected examples of asymmetric alkynylation of 2-trifluoroacetly imidazoles. 
3) Octahedral chiral-at-ruthenium complexes for highly effective asymmetric catalysis 
The first example of an octahedral chiral-at-metal ruthenium complex with stable constitution and 
configuration was introduced here. The success of the synthesis of these new catalysts is attributed to 
the introduction of two PyNHC ligands. On the one hand, the PyNHC ligands as rigid coordinating 
ligands provide a suitable environment for the formation of the stable bis-(PyNHC)Ru complex. On 
the other hand, the strong -donating NHC-ligands make the coordinated acetonitrile ligands labile 
enough to accelerate the ligand exchange through the trans-effect. As a result, we found that the new 
class of catalysts can efficiently catalyze the enantioselective alkynylation of trifluoromethyl ketones 
to provide the propargylic alcohols in high yields (up to 99% yield) with excellent enantioselectivities 
(up to > 99% ee). Importantly, our new catalysts can be applied to access two kinds of propargylic 
alcohol intermediates which can convert to enantiomerically anti-HIV drug efavirenz easily. The 
Merck intermediate and the Lonza intermediate were obtained in high yields and with high 
enantioselectivities. The gram-scale reactions indicated that the synthetic routes might contribute to 
lowering the cost for the production of the important anti-HIV drug efavirenz. 
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Figure 57 Selected examples of asymmetric alkynylation of trifluoroacetly ketones. 
 
Figure 58 Gram-scale synthesis of key intermediates of the anti-HIV drug efavirenz. 
Chapter 4. Summary and Outlook 
71 
 
4.2 Outlook 
My thesis work mainly focused on the development of new octahedral metal complexes with 
metal-centered chirality and their applications in asymmetric catalysis. Several further 
investigations can be considered as follows: 
1) Explore C(sp3)-H activation reactions catalyzed by octahedral chiral-at-ruthenium 
complexes: Asymmetric C(sp
3
)-H activation is one of the most attractive and promising projects 
in organic catalysis nowadays. Ruthenium imido complexes and ruthemium oxo complexes as 
high reactivity intermediates responsible for C(sp
3
)-H activation. Since our newly developed 
chiral-at-ruthenium complexes show highly strong trans-effect, it is promising to try some 
chiral-at-ruthenium involved asymmetric C(sp
3
)-H activation reactions. 
2) Explore asymmetric photoreactions catalyzed by octahedral chiral-at-ruthenium 
complexes: Ru(bpy)3
2+
 has been widely used as photoredox catalyst and combined with an 
asymmetric catalyst, such as organocatalysts or metal-based complexes, to provide the required 
stereocontrol and the activation of one substrate in asymmetric photoreactions. It is worthy to 
investigate the coordination behaviors of octahedral chiral-at-ruthenium complexes and measure 
the redox potentials of ruthenium-based complexes, including the substrate-coordinated 
complexes. Then we can adjust the redox potential of them through introducing electron rich or 
deficient groups at the fixed position of achiral ligand. And finally, our chiral-at-ruthenium 
complexes might serve as a single catalyst to catalyze some asymmetric photoreactions. 
3) Explore octahedral base-metal centered catalysts: Recently, the development of first-row 
transition metals catalysts became more attractive topic because they are nontoxic, inexpensive 
and earth-abundant. Despite the fact that many base-metal catalysts display high reactivity and 
selectivity, chiral octahedral complexes of base metals such as iron, cobalt and nickel which 
furnish asymmetric catalysis is far less studied. Based on our experiences on asymmetric 
synthesis of octahedral chiral-at-metal complexes, it is promising to apply our strategies for the 
synthesis of base-metal centered complexes and then inverstigate their properties. 
  
Chapter 5: Experimental Part 
72 
 
Chapter 5: Experimental Part 
5.1 Materials and Methods 
All reactions were carried out under an atmosphere of nitrogen with magnetic stirring unless indicated 
otherwise. The catalytic reactions were performed in Schlenk tube. 
 
Solvents and Reagents 
Solvents were distilled under nitrogen from calcium hydride (CHCl3, CH2Cl2, CH3CN and DMF), 
magnesium turnings/iodine (MeOH) or sodium/benzophenone (Et2O, THF and toluene). HPLC grade 
solvents, such as 2-methoxyethanol, ethanol, ethylene glycol and DMSO are used directly without 
further drying. All reagents were purchased from Acros, Alfa aesar, Sigma Aldrich, TCI, ChemPur and 
Fluorochem and used without further purification. 
 
Chromatographic Methods 
The course of the reactions and the column chromatographic elution were monitored by thin layer 
chromatography (TLC) [Macherey-Nagel (ALUGRAM®Xtra Sil G/UV254)]. Flash column 
chromatography was performed with silica gel from Merck (particle size 0.040-0.063 mm). 
  
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1
H NMR, proton decoupled 
13
C NMR, and proton coupled 
19
F NMR spectra were recorded on Bruker 
Avance 300 system (
1
H NMR: 300 MHz, 
13
C NMR: 75 MHz, 
19
F NMR: 282 MHz) spectrometers at 
ambient temperature. Chemical shifts are given in ppm on the  scale, and were determined after 
calibration to the residual signals of the solvents, which were used as an internal standard. NMR 
standards were used are as follows: 
1
H NMR spectroscopy: δ = 7.26 ppm (CDCl3), δ = 5.32 ppm 
(CD2Cl2), δ = 3.31 ppm (CD3OD); 
13
C NMR spectroscopy: δ = 77.0 ppm (CDCl3), δ = 54.0 ppm 
(CD2Cl2), δ = 118.26, 1.32 ppm (CD3CN), δ = 49.0 ppm (CD3OD). 
19
F NMR spectroscopy: δ = 0 ppm 
(CFCl3). The characteristic signals were specified from the low field to high field with the chemical 
shifts (δ in ppm). 1H NMR spectra peak multiplicities indicated as singlet (s), doublet (d), doublet of 
doublet (dd), doublet of doublet of doublet (ddd), triplet (t), doublet of triplet (dt), quartet (q), 
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multiplet (m). The coupling constant J indicated in hertz (Hz).  
 
High-Performance Liquid Chromatography (HPLC) 
Chiral HPLC was performed with an Agilent 1200 Series or Agilent 1260 Series HPLC System. All 
the HPLC conditions were detailed in the individual procedures. The type of the columns, mobile 
phase and the flow rate were specified in the individual procedures. 
 
Infrared Spectroscopy (IR) 
IR measurements were recorded on a Bruker Alpha-P FT-IR spectrometer. The absorption bands were 
indicated a wave numbers v (cm
1
). All substances were measured as films or solids. 
 
Mass Spectrometry (MS) 
High-resolution mass spectra were recorded on a Bruker En Apex Ultra 7.0 TFT-MS instrument using 
ESI or APCI or FD technique. Ionic masses are given in units of m/z for the isotopes with the highest 
natural abundance. 
 
Circular Dichroism Spectroscopy (CD) 
CD spectra were recorded on a JASCO J-810 CD spectropolarimeter. The parameters we used as 
follows: from 600 nm to 200 nm; data pitch (0.5 nm); band with (1 nm); response (1 second); 
sensitivity (standard); scanning speed (50 nm/min); accumulation (3 times). The concentration of the 
compounds for the measurements was 0.2 mM. The formula for converting θ to ε is shown as below. 
 
)()/(32980
deg][
cmLLmolc
m



 
c = concentration of the sample; L = thickness of the measurement vessel 
 
Crystal Structure Analysis 
Crystal X-ray measurements and the crystal structure analysis were carried out by Dr. Klaus Harms 
(Chemistry Department, Philipps University of Marburg). X-ray data were collected with a Bruker 3 
circuit D8 Quest diffractometer with MoKa radiation (microfocus tube with multilayer optics) and 
Photon 100 CMOS detector. Scaling and absorption correction was performed by using the SADABS
1
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software package of Bruker. Structures were solved using direct methods in SHELXS
2
 and refined 
using the full matrix least squares procedure in SHELXL-2013
3
 or SHELXL-2014
4
. The Flack 
parameter is a factor used to estimate the absolute configuration of the coumounds.
5
 The hydrogen 
atoms were placed in calculated positions and refined as riding on their respective C atom, and Uiso(H) 
was set at 1.2 Ueq(Csp
2
) and 1.5 Ueq(Csp
3
). Disorder of PF6 ions, solvent molecules or methylene 
groups were refined using restraints for both the geometry and the anisotropic displacement factors. 
 
Optical Rotation Polarimeter 
Optical rotations were measured on a Krüss P8000-T or Perkin-Elmer 241 polarimeter with []D
25
 
values reported in degrees with concentrations reported in g/100 mL. 
 
 Melting Point determination Apparatus 
The uncorrected melting points were determined on a Mettler Toledo MP 70 using one end closed 
capillary tubes. 
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5.2 Expanding the Family of Bis-Cyclometalated Chiral-at-Metal Iridium 
and Rhodium Catalysts 
1) Synthesis of benzoselenazole ligand 
5-(tert-butyl)-2-phenylbenzo[d][1,3]selenazole (1) 
 
The compound S1 was synthesized following a published procedure with slight modifications.
6
 To a 
solution of p-TsOH·H2O (7.70 g, 44.7 mmol) in CH3CN (60 mL) was added 
4-(tert-butyl)-2-nitroaniline (2.894 g, 14.7 mmol). The resulting suspension of amine salt was cooled 
to 10–15 °C and to this was added, gradually, a solution of NaNO2 (2.06 g, 29.8 mmol) and KI (6.18 g, 
37.2 mmol) in H2O (9 mL). The reaction mixture was stirred at room temperature and monitored by 
TLC until the starting material was completely consumed. The reaction mixture was then poured into 
H2O. Saturated aqueous solution of NaHCO3 was added until pH reached 9–10. Then the mixture was 
treated with Na2S2O3 (2 M, 30 mL).The resulted mixture was extracted with CH2Cl2 and purified by 
flash chromatography to obtain the product S1 (4.023 g, 13.2 mmol, yield: 88%, Rf = 0.85, 
EtOAc/n-hexane = 1:5) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 2.3 Hz, 1H), 7.28 (dd, J = 4.9, 2.5 
Hz, 1H), 1.33 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 153.6, 153.1, 141.5, 131.0, 122.8, 82.4, 35.1, 31.0. 
IR (film): ν (cm1) 2962, 2871, 1526, 1471, 1349, 1283, 1254, 1115, 1016, 892, 828, 749, 699, 663, 
516. 
HRMS (ESI, m/z) calcd for C10H12INO2Na1 [M+Na]
+
: 327.9805, found: 327.9805. 
 
The compound S2 was synthesized following a published procedure with slight modifications.
7
 AcOH 
(46 mL) was added to the mixture of S1 (3.27 g, 10.8 mmol) and Fe power (3.2 g, 57.3 mmol) in 
EtOH (46 mL). The mixture was degassed for 15 min, and then heated at 100 
o
C for 40 min. The 
reaction mixture was diluted with 100 mL water and extracted with CH2Cl2 and purified by flash 
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chromatography to obtain the product S2 (2.089 g, 7.59 mmol, yield: 70%, Rf = 0.8, EtOAc/n-hexane 
= 1:5) as a white solid. 
1
H NMR (300 MHz, CDCl3) δ 7.58–7.52 (m, 1H), 6.79 (d, J = 2.2 Hz, 1H), 6.54 (dd, J = 8.4, 2.3 Hz, 
1H), 4.04 (s, 2H), 1.28 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 153.2, 146.5, 138.6, 117.9, 112.3, 80.7, 34.6, 31.3. 
IR (film): ν (cm1) 3463, 3369, 2958, 2867, 1604, 1558, 1478, 1404, 1363, 1310, 1238, 1202, 1155, 
1114, 1074, 1005, 930, 862, 800, 698, 641, 586, 546, 455. 
HRMS (ESI, m/z) calcd for C10H15IN [M+1]
+
: 276.0244, 277.0276, found: 276.0248, 277.0282. 
 
The compound 1 was synthesized following a published procedure with slight modifications.
8
 To a 
solution of S2 (1.376 g, 5.0 mmol) and benzaldehyde (0.637mg, 6 mmol) in dry DMSO (15 mL), Se 
power (1.18g, 15 mmol), Cu power (31.8 mg, 0.5 mmol) and KOH (0.561 mg, 10.0 mmol) were added. 
The resulting was degassed for 15 min and stirred at 120 
o
C for 24 h under N2 atmosphere. The 
reaction mixture was cooled to room temperature and diluted with saturated aq. NH4Cl and extracted 
with CH2Cl2. The organic layer was dried over Na2SO4 and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography to obtain the product 1 (1.136 g, 3.6 mmol, 
yield: 72%, Rf = 0.9, EtOAc/n-hexane = 1:5) as a yellow solid. 
1
H NMR (300 MHz, CDCl3) δ 8.19 (d, J = 1.9 Hz, 1H), 8.08–7.98 (m, 2H), 7.86 (d, J = 8.4 Hz, 1H), 
7.53–7.45 (m, 3H), 7.40 (dd, J = 8.4, 2.0 Hz, 1H), 1.44 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 172.5, 156.2, 150.1, 136.4, 135.0, 130.9, 129.1, 127.9, 124.2, 123.4, 
121.5, 34.9, 31.6. 
IR (film): ν (cm1) 2957, 2865, 1540, 1511, 1475, 1448, 1400, 1361, 1307, 1281, 1248, 1207, 1159, 
1098, 1074, 1045, 1024, 945, 914, 882, 847, 814, 761, 722, 685, 652, 614, 583, 476. 
HRMS (ESI, m/z) calcd for C17H18N1Se1 [M+1]
+
: 316.0600, found: 316.0604. 
 
2) Synthesis of benzoselenazole iridium and rhodium complexes rac-Ir(Se) and rac-Rh(Se) 
rac-Ir(Se): The new complex rac-Ir(Se) was synthesized according to a procedure reported by our 
group with slight modification.
9
 Accordingly, 5-tert-butyl-2-phenylbenzo[d]selenazole 1 (100 mg, 
0.318 mmol) was added to IrCl3•3H2O (54.8 mg, 0.155 mmol) in a mixture of 2-ethoxyethanol and 
water (3:1, 6.88 mL). The reaction mixture was heated at 120 °C for 24 h under an atmosphere of 
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nitrogen. The resulting precipitate was collected by centrifugation, washed with methanol and dried to 
obtain a mixture as a pale orange solid. To the orange solid in CH3CN (20 mL) was added AgPF6 (59 
mg, 0.233 mmol) in one portion, and then stirred at 60 °C overnight. After cooling to room 
temperature, the mixture was filtered. The filtrate was collected, evaporated to dryness and purified by 
column chromatograph on silica gel (CH2Cl2/CH3CN = 100:1 to 20:1) to give rac-Ir(Se) (55.1 mg, 
0.053 mmol, 34% yield for two steps, Rf = 0.4, CH3CN/CH2Cl2 = 1:10) as an orange solid. 
1
H NMR (300 MHz, CD2Cl2) δ 8.51 (d, J = 1.8 Hz, 2H), 8.04 (d, J = 8.5 Hz, 2H), 7.70–7.61 (m, 4H), 
6.96 (td, J = 7.5, 1.0 Hz, 2H), 6.75 (td, J = 7.6, 1.3 Hz, 2H), 6.26 (d, J = 7.6 Hz, 2H), 2.31 (s, 6H), 
1.46 (s, 18H). 
13
C NMR (75 MHz, CD2Cl2) δ 187.4, 152.9, 151.7, 144.5, 142.1, 133.1, 131.8, 130.1, 127.3, 126.3, 
125.4, 124.0, 122.1, 119.1, 35.7, 31.9, 4.2. 
19
F NMR (282 MHz, CD2Cl2) δ –71.7, –74.2. 
IR (film): ν (cm1) 3053, 2957, 2868, 1618, 1580, 1551, 1441, 1410, 1364, 1286, 1249, 1159, 1100, 
1024, 982, 927, 833, 759, 731, 717, 662, 553, 460. 
HRMS (ESI, m/z) calcd for C34H32IrN2Se2 [M]
+
: 819.0524, found: 819.0528. 
 
rac-Rh(Se): The metal complex rac-Rh(Se) was synthesized according to a procedure reported by our 
group with some modification.
10
 Accordingly, 5-tert-butyl-2-phenylbenzo[d]selenazole 1 (213 mg, 
0.678 mmol) was added to RhCl3•3H2O (69 mg, 0.331 mmol) in a mixture of 2-ethoxyethanol and 
water (3:1). The reaction mixture was heated at 110 °C for 24 h under an atmosphere of nitrogen. 
Cooling to room temperatue and water was added. The resulting precipitate was collected by 
centrifugation, dried to obtain a mixture as a pale brown solid. To the brown solid in CH3CN (5 mL) 
was added AgPF6 (125.6 mg, 0.496 mmol) in one portion, and then stirred at 60 °C overnight. After 
cooling to room temperature, the mixture was filtered. The filtrate was collected, evaporated to 
dryness and purified by column chromatograph on silica gel (CH2Cl2/CH3CN = 20:1) to give 
rac-Rh(Se) (92 mg, 0.113 mmol, 34% yield for two steps, Rf = 0.4, CH3CN/CH2Cl2 = 1:10) as a pale 
yellow solid. 
1
H NMR (300 MHz, CD2Cl2) δ 8.62 (s, 2H), 8.04 (d, J = 8.5 Hz, 2H), 7.71–7.59 (m, 4H), 7.03 (td, J = 
7.5, 0.9 Hz, 2H), 6.85 (td, J = 7.7, 1.4 Hz, 2H), 6.29 (d, J = 7.8 Hz, 2H), 2.15 (s, 6H), 1.44 (s, 18H). 
13
C NMR (75 MHz, CD2Cl2) δ 182.7, 152.9, 151.5, 143.7, 133.9, 131.4, 130.8, 127.6, 126.0, 125.5, 
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125.0, 122.6, 122.5, 119.4, 35.7, 31.8, 3.7. 
19
F NMR (282 MHz, CD2Cl2) δ –71.6, –74.1. 
HRMS (ESI, m/z) calcd for C34H32N2RhSe
2+
 [M–PF6]
+
: 730.9945, found: 730.9952. 
IR (film): ν (cm1) 3573, 2958, 2867, 1618, 1577, 1468, 1436, 1364, 1289, 1253, 1160, 1102, 1025, 
979, 926, 836, 755, 712, 660, 554, 456. 
3) Iridium auxiliary complexes -(S)-3 and -(S)-3 
 
The new iridium auxiliary complexes Λ-(S)-3 and Δ-(S)-3 were synthesized according to our reported 
method with some modification.
9
 To a solution of rac-Ir(Se) (164 mg, 0.16 mmol) in CH2Cl2 (8.0 mL), 
the chiral auxiliary (S)-2 (35.5 L, 0.188 mmol) and Et3N (65.6 L, 0.470 mmol) were added. The 
mixture was stirred at room temperature overnight. The solvent was removed and the residue was 
subjected to a flash silica gel chromatography (EtOAc/n-hexane = 1:25 to 1:10) to separate the two 
diastereomers. The first eluting diastereomer was assigned as Λ-(S)-3 (red solid, 64.6 mg, 0.062 mmol, 
39%, Rf = 0.75, EtOAc/n-hexane = 1:5) and the second eluting diastereomer was assigned as -(S)-3 
(red solid, 68.9 mg, 0.066 mmol, 42%, Rf = 0.5, EtOAc/n-hexane = 1:5). 
 
-(S)-3: 1H NMR (300 MHz, CD2Cl2) δ 9.30 (d, J = 1.8 Hz, 1H), 7.86 (dd, J = 12.7, 5.1 Hz, 2H), 7.74 
(dd, J = 11.6, 8.1 Hz, 2H), 7.61 (d, J = 7.6 Hz, 1H), 7.42 (ddd, J = 8.3, 4.3, 1.7 Hz, 2H), 7.00 (d, J = 
7.8 Hz, 2H), 6.90 (dd, J = 7.9, 7.2 Hz, 3H), 6.69 (dt, J = 15.0, 7.5 Hz, 2H), 6.55 (d, J = 8.5 Hz, 1H), 
6.24 (d, J = 7.7 Hz, 1H), 6.04 (t, J = 7.4 Hz, 1H), 4.39 (dd, J = 7.7, 2.2 Hz, 1H), 3.43–3.30 (m, 1H), 
2.96 (dd, J = 11.7, 1.8 Hz, 1H), 1.47 (s, 9H), 1.17 (s, 9H), 0.40 (d, J = 7.0 Hz, 3H), 0.10 (d, J = 6.9 Hz, 
3H). 
13
C NMR (75 MHz, CD2Cl2) δ 186.5, 185.3, 171.0, 170.1, 154.0, 152.9, 152.1, 152.0, 151.0, 149.9, 
146.5, 145.9, 137.1, 133.5, 132.8, 132.5, 130.7, 129.9, 129.4, 129.0, 127.7, 127.5, 125.5, 124.8, 124.3, 
124.0, 123.6, 122.54, 122.47, 121.2, 120.7, 118.2, 113.6, 83.7, 35.5, 35.4, 32.1, 31.7, 30.3, 28.6, 20.3, 
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15.1. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 463 (25), 345 (+43), 315 (15), 287 (12), 269 (+16), 253 (7), 
241 (+17), 229 (43), 215 (+146). 
-(S)-3: 1H NMR (300 MHz, CD2Cl2) δ 9.05 (d, J = 1.8 Hz, 1H), 8.03 (d, J = 1.7 Hz, 1H), 7.89 (d, J = 
8.4 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.59 (dt, J = 8.1, 4.1 Hz, 1H), 7.46 (dd, 
J = 8.5, 1.9 Hz, 1H), 7.37 (dd, J = 8.5, 1.8 Hz, 1H), 7.26 (dd, J = 8.0, 1.7 Hz, 1H), 6.94–6.79 (m, 3H), 
6.72 (td, J = 7.5, 1.2 Hz, 1H), 6.66–6.57 (m, 2H), 6.50–6.44 (m, 1H), 6.33 (d, J = 7.5 Hz, 1H), 
6.22–6.14 (m, 1H), 3.51 (ddd, J = 8.5, 7.3, 4.4 Hz, 1H), 2.95 (dd, J = 11.2, 7.1 Hz, 1H), 2.50 (dd, J = 
11.2, 8.7 Hz, 1H), 1.28 (s, 9H), 1.12 (s, 9H), 0.75 (d, J = 6.7 Hz, 3H), 0.24 (d, J = 7.0 Hz, 3H). 
13
C NMR (75 MHz, CD2Cl2) δ 187.1, 186.0, 171.2, 168.9, 153.5, 153.1, 152.6, 151.0, 148.9, 145.7, 
145.6, 136.1, 133.6, 132.7, 132.1, 130.7, 130.6, 129.7, 129.6, 127.8, 127.0, 125.2, 125.0, 124.4, 124.3, 
123.9, 122.4, 122.3, 121.12, 121.09, 119.8, 113.3, 84.1, 35.6, 35.5, 31.9, 31.6, 31.2, 29.7, 21.1, 18.5. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 350 (34), 319 (+19), 285 (+16), 271 (8), 253 (+11), 229 (+88), 
216 (127). 
IR (film): ν (cm1) 3050, 2953, 2863, 1732, 1591, 1552, 1522, 1460, 1435, 1408, 1354, 1284, 1238, 
1197, 1151, 1121, 1010, 976, 925, 883, 844, 809, 746, 732, 715, 661, 634, 579, 557. 
HRMS (ESI, m/z) calcd for C46H46IrN3OSSe2Na [M+Na]
+
: 1062.1221, found: 1062.1221. 
3) Rhodium auxiliary complexes -(R)-4 and -(R)-4 
 
The new rhodium auxiliary complexes Λ-(R)-4 and Δ-(R)-4 were synthesized according to a reported 
method with some modification.
10
 A mixture of rac-Rh(Se) (72.2  mg, 0.076 mmol), the chiral 
auxiliary (R)-2ʹ (23.8 mg, 0.084 mmol) and K2CO3 (31.3 mg, 0.226 mmol) in EtOH (6.7 mL) was 
heated at 70 °C for 18 h. Afterwards, the reaction mixture was cooled to room temperature and 
concentrated to dryness. The residue was extracted by CH2Cl2, and the filtrate was evaporated to give 
the mixture of two diastereoisomers, which was then washed by EtOH (8 × 8 mL) to give Δ-(R)-4 
(17.1 mg, 0.016 mmol, 42% yield, Rf = 0.5, EtOAc/n-hexane = 1:4) as a yellow solid. The filtrate was 
concentrated and subjected to a flash chromatography on silica gel (n-hexane/CH2Cl2 = 1:10) to give 
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Λ-(R)-4 (18.3 mg, 0.017 mmol, 45% yield, Rf = 0.35, EtOAc/n-hexane = 1:4) as a yellow solid. Note: 
Λ-(R)-4 is soluble in EtOH; Δ-(R)-4 is insoluble in EtOH. 
Λ-(R)-4: 1H NMR (300 MHz, CD2Cl2) δ 9.34 (d, J = 1.9 Hz, 1H), 8.53 (d, J = 1.8 Hz, 1H), 7.95 (d, J = 
8.4 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.59 (dd, J = 7.6, 1.2 Hz, 1H), 7.50 (dd, J = 8.5, 2.0 Hz, 1H), 
7.43 (dd, J = 8.5, 1.9 Hz, 1H), 7.06 (dd, J = 7.5, 1.4 Hz, 1H), 6.98–6.89 (m, 4H), 6.87–6.78 (m, 3H), 
6.75–6.67 (m, 1H), 6.58–6.46 (m, 2H), 6.37–6.30 (m, 2H), 6.22 (d, J = 8.6 Hz, 1H), 5.76 (ddd, J = 
11.5, 7.9, 0.9 Hz, 1H), 4.41–4.27 (m, 1H), 4.14–4.05 (m, 1H), 3.88 (dd, J = 12.5, 8.3 Hz, 1H), 1.37 (s, 
9H), 1.23 (s, 9H). 
13
C NMR (75 MHz, CD2Cl2) δ 182.11, 182.07, 175.4, 175.3, 169.4, 169.0, 168.5, 168.1, 167.6, 164.9, 
161.5, 152.8, 152.8, 151.3, 144.3, 143.8, 138.2, 135.4, 133.6, 133.1, 132.9, 130.3, 130.13, 130.07, 
129.7, 128.3, 127.9, 127.6, 127.4, 127.1, 125.2, 125.1, 124.63, 124.56, 123.5, 122.6, 121.1, 119.4, 
119.31, 119.27, 104.5, 104.4, 98.8, 98.5, 75.0, 70.7, 35.8, 35.6, 31.9, 31.7. 
Δ-(R)-4: 1H NMR (300 MHz, CD2Cl2) δ 9.14 (d, J = 1.7 Hz, 1H), 8.06 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 
8.5 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 7.1 Hz, 1H), 7.52–7.41 (m, 2H), 7.37 (dd, J = 8.5, 
1.8 Hz, 1H), 7.02–6.70 (m, 8H), 6.43–6.30 (m, 4H), 5.97 (d, J = 7.7 Hz, 1H), 5.71 (dt, J = 30.2, 15.2 
Hz, 1H), 4.96–4.78 (m, 2H), 4.10–3.89 (m, 1H), 1.46 (s, 9H), 1.28 (s, 9H). 
13
C NMR (75 MHz, CD2Cl2) δ 183.01, 182.97, 181.39, 181.35, 175.5, 175.4, 170.6, 170.2, 168.2, 
167.8, 166.33, 166.29, 165.4, 162.0, 153.1, 152.8, 151.6, 151.2, 144.8, 141.4, 136.1, 133.6, 133.1, 
132.9, 131.1, 130.0, 129.8, 129.6, 128.3, 128.0, 127.4, 127.2, 125.5, 124.4, 124.0, 123.9, 123.5, 122.9, 
122.4, 120.3, 120.2, 118.6, 98.9, 98.5, 76.2, 69.7, 35.4, 31.91, 31.86. 
IR (film): ν (cm1) 3053, 2955, 2862, 1618, 1577, 1530, 1441, 1369, 1286, 1219, 1156, 1094,  
1026, 972, 919, 843, 812, 787, 749, 697, 661, 624, 578, 527, 458. 
HRMS (ESI, m/z) calcd for C49H44FN3O2RhSe2 [M+H]
+
: 988.0810, found: 988.0809. 
Λ-(R)-4: 
CD (MeOH): λ, nm (Δε, M-1cm-1) 429 (23), 343 (+18), 300 (43), 276 (+27), 263 (+19), 255 (22). 
Δ-(R)-4: 
CD (MeOH): λ, nm (Δε, M-1cm-1) 422 (+27), 351 (46), 304 (+47), 277 (30), 264 (9), 244 (39). 
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4) Synthesis of non-racemic iridium/rhodium catalysts 
 
A suspension of the iridium auxiliary complex -(S)-3 (61.7 mg, 0.060 mmol) or -(S)-3 (65.3 mg, 
0.063 mmol) and NH4PF6 (96.8 mg, 0.6 mmol) or NH4PF6 (102.7 mg, 0.63 mmol) in acetonitrile (10.0 
mL) was heated at 50 C for 16 h. The reaction mixture was concentrated to dryness and subjected to 
flash silica gel chromatography (CH2Cl2/CH3CN = 100:1 to 15:1) to give the enantiopure catalyst 
-Ir(Se) (52.7 mg, 0.058 mmol, 98%) or -Ir(Se) (55.1 mg, 0.061 mmol, 97%) as a orange solid. All 
other spectroscopic data of enantiopure ruthenium catalysts were in agreement with the racemic 
catalysts. The absolute configurations were assigned by comparison with the analogue complexes 
-Ir(S) and -Ir(S).9 
-Ir(Se): CD (MeOH): λ, nm (Δε, M-1cm-1) 469 (15), 362 (+43), 293 (34), 260 (+17), 228 (87), 
216 (+199). 
-Ir(Se): CD (MeOH): λ, nm (Δε, M-1cm-1) 470 (+14), 362 (45), 292 (+32), 260 (21), 228 (+84), 
216 (209). 
To a suspension of -(S)-4 (47.0 mg, 0.048 mmol) or -(R)-4 (32.2 mg, 0.033 mmol), in CH3CN (3 
mL) was added TFA (10 eq) in one portion and stirred at room temperature for 0.5 h. The reaction 
mixture was evaporated to dryness, redissolved in CH3CN, followed by the addition of excess NH4PF6 
(30 eq), and then stirred at room temperature for another 0.5 h. The mixture was filtered by a thin pad 
of silica gel, the pale yellow filtrate was concentrated, and then subjected to the column 
chromatography on silica gel (CH2Cl2/CH3CN = 100:1 to 5:1) to give the enantiopure catalysts 
-Rh(Se) (38.4 mg, 0.047 mmol, 98% yield) or -Rh(Se) (26.0 mg, 0.032 mmol, 98% yield) as pale 
yellow solid. All other spectroscopic data of enantiopure ruthenium catalysts were in agreement with 
the racemic catalysts. The absolute configurations were assigned by comparison with the analogue 
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complexes -Rh(S) and -Rh(S).10 
-Rh(Se): CD (MeOH): λ, nm (Δε, M-1cm-1) 412 (47), 371 (+71), 358 (+65), 306 (112), 269 (+34), 
246 (+55), 231 (31), 212 (+93). 
-Rh(Se): CD (MeOH): λ, nm (Δε, M-1cm-1) 413 (+38), 371 (63), 355 (58), 305 (+92), 266 (32), 
244 (50), 230 (+22), 212 (83). 
5.3 Synthesis, Characterization and Reactivities of Bis-Cyclometalated 
Iridium(III)/Rhodium(III) Complexes Containing Pinene-Derived Ligands 
5.3.1 Synthesis of the iridium and rhodium catalysts IrPP and RhPP 
a) Synthesis of the 2-phenyl-5,6-(S,S)-pinenopyridine ligand 
 
Pinocarvone: Pinocarvone was synthesized following a published procedure with some 
modifications.
11
 Acetic anhydride (1.324 g, 13.0 mmol) and pyridine (0.500 g, 6.3 mmol) were added 
to the mixture of tetraphenylporphine (TPP) (8.0 mg, 1.3 mol), DMAP (31.0 mg, 0.3 mmol) and 
(1R)-(+)-α-pinene (1.720 g, 12.6 mmol) in CH2Cl2 (11 mL). The suspension was stirred at room 
temperature for 18 h under 
1
O2 which is generated by 2  20W white lights. The mixture was then 
diluted with CH2Cl2 and washed successively with saturated NaHCO3, 1 N HCl, and saturated CuSO4. 
The organic fraction was thoroughly washed with water and dried over Na2SO4. After concentration, 
the residue was purified by silica gel column (EtOAc/n-hexane = 1:30) to yield pinocarvone as a 
purple oil (1.416 g, 9.4 mmol, 75%, Rf = 0.5, EtOAc/n-hexane = 1:10). 
1
H NMR (300 MHz, CD2Cl2) δ 5.90 (d, J = 1.8 Hz, 1H), 4.99 (d, J = 1.8 Hz, 1H), 2.83–2.58 (m, 3H), 
2.57–2.40 (m, 1H), 2.23–2.17 (m, 1H), 1.36 (s, 3H), 1.28 (d, J = 10.3 Hz, 1H), 0.80 (s, 3H). 
13
C NMR (75 MHz, CD2Cl2) δ 199.9, 150.1, 117.2, 49.0, 43.0, 41.3, 39.3, 33.0, 26.3, 21.9. 
All spectroscopic data are in agreement with the literature.
12
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(S,S)-PP: (S,S)-PP was synthesized following a published procedure with slight modifications.
12
 The 
mixture of phenacylpyridinium bromide (2.781 g, 10.0 mmol), anhydrous ammonium acetate (6.630 g, 
86.0 mmol) and pinocarvone (1.362 g, 9.1 mmol) in acetic acid (6.6 mL) was heated at 110 °C for 24 h. 
After cooling to room temperature, water was then added and the mixture was extracted with ethyl 
acetate. The combined organic layers were washed successively with water, brine and dried over 
Na2SO4 and concentrated. The residue was purified by silica gel chromatograph (EtOAc/n-hexane = 
1:30) to yield 2-phenyl-5,6-(S,S)-pinenopyridine (S,S)-PP as a white solid (1.917 g, 7.7 mmol, 85%, Rf 
= 0.5, EtOAc/n-hexane = 1:10). 
1
H NMR (300 MHz, CDCl3) δ 7.99 (dd, J = 8.3, 1.3 Hz, 2H), 7.57–7.33 (m, 4H), 7.33–7.21 (m, 1H), 
3.23 (d, J = 2.7 Hz, 2H), 2.81 (t, J = 5.7 Hz, 1H), 2.73 (dt, J = 9.4, 5.8 Hz, 1H), 2.52–2.29 (m, 1H), 
1.45 (s, 3H), 1.34 (d, J = 9.5 Hz, 1H), 0.72 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 156.9, 154.9, 140.5, 140.1, 133.7, 128.7, 128.3, 126.8, 117.3, 46.5, 40.4, 
39.7, 36.9, 32.1, 26.2, 21.5. 
All spectroscopic data are in agreement with the literature.
13
 
b) Synthesis of the metal complexes 
Iridium dimer complexes: Iridium dimer complexes were synthesized following a published 
procedure with slight modifications.
14
  The mixture of (S,S)-PP (374.0 mg, 1.50 mmol) and iridium 
chloride hydrate (176.3 mg, 0.50 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 23 mL) was 
heated at 125 °C for 36 h under nitrogen. After removal of the solvent, the residue was subjected to 
flash silica gel chromatography (EtOAc/n-hexane = 1:20) to separate the diastereomers. The first 
eluting diastereomer was assigned as -2Ir (red solid, 106.4 mg, 0.073 mmol, 29%) and the second 
eluting diastereomer was assigned as -2Ir (red solid, 134.8 mg, 0.093 mmol, 37%). The - and - 
configurations of the diastereomers were confirmed by the single crystal structures of -IrPP and 
-IrPP. 
-2Ir:
 1
H NMR (300 MHz, CD2Cl2) δ 7.66 (d, J = 8.0 Hz, 4H), 7.54 (dd, J = 7.8, 1.3 Hz, 4H), 7.42 (d, 
J = 8.0 Hz, 4H), 6.95–6.83 (m, 4H), 6.71–6.60 (m, 4H), 6.04 (dd, J = 7.9, 0.9 Hz, 4H), 4.69 (dd, J = 
18.5, 2.4 Hz, 4H), 2.90 (t, J = 5.7 Hz, 4H), 2.77 (dd, J = 18.6, 3.0 Hz, 4H), 2.71–2.61 (m, 4H), 
2.31–2.25 (m, 4H), 1.42 (s, 12H), 1.23 (d, J = 9.6 Hz, 4H), 0.93 (s, 12H). 
13
C NMR (75 MHz, CD2Cl2) δ 164.3, 161.1, 145.6, 142.8, 135.5, 134.9, 133.3, 128.5, 123.8, 122.7, 
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115.6, 47.6, 41.0, 39.3, 37.9, 32.5, 26.0, 22.4. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 386 (67), 352 (+120), 306 (71), 285 (94), 255 (+157), 230 
(+25). 
-2Ir: 
1
H NMR (300 MHz, CD2Cl2) δ 7.68 (d, J = 8.0 Hz, 4H), 7.56 (dd, J = 7.8, 1.4 Hz, 4H), 7.45 (d, 
J = 8.0 Hz, 4H), 6.90 (ddd, J = 8.3, 7.5, 1.1 Hz, 4H), 6.68–6.56 (m, 4H), 6.11–6.00 (m, 4H), 4.72 (dd, 
J = 18.5, 3.3 Hz, 4H), 2.91 (t, J = 5.7 Hz, 4H), 2.81–2.71 (m, 4H), 2.66 (dd, J = 18.5, 2.4 Hz, 4H), 
2.32–2.26 (m, 4H), 1.47 (d, J = 9.6 Hz, 4H), 1.40 (s, 12H), 0.70 (s, 12H). 
13
C NMR (75 MHz, CD2Cl2) δ 163.8, 160.7, 145.5, 142.9, 135.6, 135.3, 133.8, 128.2, 123.9, 122.7, 
115.6, 47.4, 40.9, 40.3, 37.2, 31.8, 26.3, 21.9.   
CD (MeOH): λ, nm (Δε, M-1cm-1) 386 (+84), 351 (99), 307 (+66), 284 (+73), 255 (146), 231 (+2). 
IR (film): ν (cm1) 3049, 2922, 2868, 2019, 1595, 1576, 1462, 1437, 1420, 1385, 1218, 1122, 1074, 
1028, 949, 836, 822, 773, 734, 719, 669, 449. 
HRMS (ESI, m/z) calcd for C72H72Cl1N2Ir2 [M/2Cl]
+
: 689.2508, found: 689.2517. 
Rhodium dimer complexes: The mixture of (S,S)-PP (748.0 mg, 3.0 mmol) and rhodium chloride 
hydrate (209.3 mg, 0.79 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 46 mL) was heated at 
125 °C for 36 h under nitrogen. After removal of the solvent, the residue was subjected to flash silica 
gel chromatography (EtOAc/n-hexane = 1:20) to separate the diastereomers. The first eluting 
diastereomer was assigned as -2Rh (orange solid, 115.3 mg, 0.091 mmol, 23%) and the second 
eluting diastereomer as -2Rh (orange solid, 156.9 mg, 0.124 mmol, 31%). The - and - 
configurations of the diastereomers were confirmed by the single crystal structures of -RhPP and 
-RhPP. 
-2Rh:
 1
H NMR (300 MHz, CD2Cl2) δ 7.72–7.58 (m, 8H), 7.50–7.41 (m, 4H), 7.00 (tt, J = 12.6, 6.3 
Hz, 4H), 6.83–6.71 (m, 4H), 6.18 (dt, J = 13.0, 6.5 Hz, 4H), 4.63 (dd, J = 18.6, 2.5 Hz, 4H), 2.90–2.82 
(m, 8H), 2.72–2.65 (m, 4H), 2.33–2.27 (m, 4H), 1.42 (s, 12H), 1.21 (d, J = 9.6 Hz, 4H), 0.90 (s, 12H). 
13
C NMR (75 MHz, CD2Cl2) δ 161.3, 160.5, 159.2, 158.7, 145.4, 143.2, 135.5, 134.7, 128.8, 124.1, 
123.8, 115.9, 47.6, 40.8, 39.5, 37.9, 32.7, 26.0, 22.3. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 436 (20), 367 (+15), 336 (+76), 289 (23), 264 (+77), 211 (+143). 
-2Rh :
 1
H NMR (300 MHz, CD2Cl2) δ 7.72–7.61 (m, 8H), 7.49 (d, J = 8.0 Hz, 4H), 7.02 (td, J = 7.6, 
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1.1 Hz, 4H), 6.77 (td, J = 7.6, 1.5 Hz, 4H), 6.25 (dt, J = 7.9, 1.1 Hz, 4H), 4.71 (dd, J = 18.6, 3.3 Hz, 
4H), 2.90 (t, J = 5.7 Hz, 4H), 2.84–2.68 (m, 8H), 2.35–2.29 (m, 4H), 1.47 (d, J = 9.7 Hz, 4H), 1.41 (s, 
12H), 0.70 (s, 12H). 
13
C NMR (75 MHz, CD2Cl2) δ 161.1, 160.2, 159.5, 159.0, 145.3, 143.3, 135.7, 135.1, 128.6, 124.2, 
123.9, 116.0, 47.4, 40.9, 40.2, 37.2, 31.9, 26.2, 21.9. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 434 (+24), 367 (33), 335 (50), 289 (+23), 264 (80), 212 (120). 
IR (film): ν (cm1) 3052, 2922, 1735, 1592, 1574, 1466, 1436, 1420, 1385, 1219, 1123, 1073, 1022, 
948, 837, 822, 773, 734, 666, 650, 625, 427. 
HRMS (ESI, m/z) calcd for C72H72Cl2N2Rh2 [MCl]
+
: 1233.3550, found: 1233.3554. 
-IrPP and -IrPP: A suspension of -2Ir (103.0 mg, 0.07 mmol) and AgPF6 (45.0 mg, 0.18 mmol) 
in acetonitrile (14.2 mL, 5 mM), or -2Ir (73.0 mg, 0.05 mmol) and AgPF6 (32.0 mg, 0.13 mmol) in 
acetonitrile (10.0 mL, 5 mM) was heated at 40 C overnight under nitrogen in the dark. The reaction 
mixture was concentrated to dryness and subjected to flash silica gel chromatography (CH2Cl2/CH3CN 
= 100:1 to 20:1) to give the diastereomeric pure catalyst -IrPP (125.0 mg, 0.14 mmol, 96%, Rf = 0.3, 
CH3CN/CH2Cl2 = 1:20) or -IrPP (90.0 mg, 0.10 mmol, 98%, Rf = 0.3, CH3CN/CH2Cl2 = 1:20) as a 
yellow solid. 
-IrPP: 1H NMR (300 MHz, CD2Cl2) δ 7.68 (d, J = 8.1 Hz, 2H), 7.56–7.43 (m, 4H), 6.90 (td, J = 7.6, 
1.2 Hz, 2H), 6.73 (td, J = 7.5, 1.3 Hz, 2H), 6.16 (dd, J = 7.7, 0.9 Hz, 2H), 3.55 (dd, J = 18.2, 2.7 Hz, 
2H), 3.37 (dd, J = 18.2, 3.1 Hz, 2H), 2.96 (t, J = 5.7 Hz, 2H), 2.88–2.74 (m, 2H), 2.56–2.50 (m, 2H), 
2.20 (s, 6H), 1.50 (s, 6H), 1.39 (d, J = 9.7 Hz, 2H), 0.80 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 166.0, 160.8, 146.2, 143.3, 140.9, 137.0, 132.1, 129.6, 124.0, 123.4, 
116.8, 47.6, 41.2, 41.0, 39.2, 31.9, 25.6, 21.3, 3.5. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 432 (9), 334 (+38), 288 (10), 263 (+39), 211 (+70). 
-IrPP: 1H NMR (300 MHz, CD2Cl2) δ 7.69 (d, J = 8.1 Hz, 2H), 7.55–7.47 (m, 4H), 6.90 (td, J = 7.6, 
1.1 Hz, 2H), 6.70 (td, J = 7.5, 1.3 Hz, 2H), 6.22 (dd, J = 7.7, 0.9 Hz, 2H), 3.64 (dd, J = 18.2, 3.2 Hz, 
2H), 3.23 (dd, J = 18.2, 2.6 Hz, 2H), 3.01–2.90 (m, 2H), 2.88–2.77 (m, 2H), 2.54–2.48 (m, 2H), 2.21 
(s, 6H), 1.48 (s, 6H), 1.34 (d, J = 9.8 Hz, 2H), 0.86 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 165.9, 160.7, 146.3, 143.4, 141.0, 137.1, 132.6, 129.3, 124.0, 123.4, 
116.8, 47.7, 41.4, 40.8, 38.9, 32.3, 26.0, 21.8, 3.4. 
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CD (MeOH): λ, nm (Δε, M-1cm-1) 432 (+12), 334 (28), 288 (+12), 264 (43), 211 (65). 
IR (film): ν (cm1) 2927, 1596, 1470, 1440, 1388, 1218, 1190, 1127, 1032, 833, 782, 747, 556.  
HRMS (ESI, m/z) calcd for C36H36IrN2 [M(CH3CN)2PF6]
+
: 689.2508, found: 689.2519. 
 
-RhPP and -RhPP: A suspension of -2Rh (135.0 mg, 0.11 mmol) and AgPF6 (67.0 mg, 0.27 
mmol) in acetonitrile (20.5 mL, 5 mM), or -2Rh (107.0 mg, 0.08 mmol) and AgPF6 (53.0 mg, 0.21 
mmol) in acetonitrile (16.8 mL, 5 mM), was heated at 40 C overnight under nitrogen in the dark. The 
reaction mixture was concentrated to dryness and subjected to a flash silica gel chromatography 
(CH2Cl2/CH3CN = 100:1 to 20:1) to give the diastereomeric pure catalyst -RhPP (168.0 mg, 0.20 
mmol, 96%, Rf = 0.3, CH3CN/CH2Cl2 = 1:20) or -RhPP (133.0 mg, 0.16 mmol, 96%, Rf = 0.3, 
CH3CN/CH2Cl2 = 1:20) as a yellow solid. 
-RhPP: 1H NMR (300 MHz, CD2Cl2) δ 7.69 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.0 Hz, 4H), 6.98 (td, J 
= 7.5, 1.1 Hz, 2H), 6.79 (td, J = 7.7, 1.4 Hz, 2H), 6.18 (d, J = 7.8 Hz, 2H), 3.56 (dd, J = 18.3, 2.5 Hz, 
2H), 3.35 (dd, J = 18.3, 3.0 Hz, 2H), 2.96 (t, J = 5.7 Hz, 2H), 2.89–2.69 (m, 2H), 2.64–2.39 (m, 2H), 
2.05 (s, 6H), 1.49 (s, 6H), 1.36 (d, J = 9.7 Hz, 2H), 0.79 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 162.5, 159.9, 159.4, 159.0, 145.6, 143.9, 136.7, 133.1, 129.6, 124.2, 
124.1, 121.3, 117.0, 47.6, 40.8, 39.9, 39.2, 32.1, 25.7, 21.4, 3.2. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 389 (31), 352 (57), 328 (+43), 305 (32), 286 (42), 258 (+73). 
-RhPP: 1H NMR (300 MHz, CD2Cl2) δ 7.71 (d, J = 8.0 Hz, 2H), 7.66–7.45 (m, 4H), 6.99 (td, J = 7.6, 
1.1 Hz, 2H), 6.77 (td, J = 7.7, 1.4 Hz, 2H), 6.25 (d, J = 7.8 Hz, 2H), 3.63 (dd, J = 18.3, 3.1 Hz, 2H), 
3.23 (dd, J = 18.3, 2.4 Hz, 2H), 2.96 (t, J = 5.7 Hz, 2H), 2.88–2.76 (m, 2H), 2.51 (dt, J = 9.0, 2.9 Hz, 
2H), 2.06 (s, 6H), 1.47 (s, 6H), 1.32 (d, J = 9.8 Hz, 2H), 0.83 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 162.3, 159.9, 159.7, 159.2, 145.6, 143.8, 136.7, 133.3, 129.3, 124.3, 
124.1, 121.1, 117.1, 47.6, 41.1, 39.8, 39.1, 32.4, 26.0, 21.8, 3.1. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 386 (+43), 351 (50), 328 (32), 307 (+34), 286 (+37), 258 (72). 
IR (film): ν (cm1) 2937, 1595, 1577, 1471, 1439, 1422, 1219, 1126, 1029, 833, 780, 746, 556, 431. 
HRMS (ESI, m/z) calcd for C36H36RhN2 [M(CH3CN)2PF6]
+
: 599.1934, found: 599.1930. 
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5.3.2. Synthesis of 2-fluoroacetyl imidazoles 
General procedure for the preparation of the 2-trifluoroacetyl imidazoles: 11a was synthesized 
according to our recently published procedure.
15 
11b-11f were synthesized according to reported 
procedures with some modifications.
16
 Accordingly, trifluoroacetic anhydride (1.2 eq) was added 
dropwisely to a stirred solution of imidazole in toluene (0.1 M referring to the imidazole) at 20 °C 
over 20 min, and then Et3N (1.2 eq) was added slowly. After stirring for 6–8 h, the resulting mixture 
was slowly warmed to room temperature and stirred overnight. After removal of the solvent in vacuo, 
the residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1:10 to 1:5). 
2,2,2-Trifluoro-1-(1-isopropyl-1H-imidazol-2-yl)ethanone (11b) 
  
Following the general procedure, 1-isopropyl-1H-imidazole (1.102 g, 10.0 mmol) was converted to 
11b (1.630 g, 7.9 mmol, yield: 79%, Rf = 0.5, EtOAc/n-hexane = 2:1) as a colorless oil. 
1
H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 0.5 Hz, 1H), 7.40–7.30 (m, 1H), 5.36 (hept, J = 6.6 Hz, 1H), 
1.45 (dd, J = 6.7, 3.2 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ 170.5 (q, J = 35 Hz), 137.3, 132.4, 124.0, 116.5 (q, J = 287.5 Hz), 50.2, 
23.2. 
19
F NMR (282 MHz, CDCl3) δ –72.1 (s, 3F). 
IR (film): ν (cm1) 3117, 2986, 1694, 1463, 1402, 1343, 1260, 1196, 1149, 1091, 942, 901, 837, 785, 
738, 682, 654, 612, 552, 522. 
HRMS (EI, m/z) calcd for C8H9F3N2O [M]
+
: 206.0667, found: 206.0660. 
 
2,2,2-Trifluoro-1-(1-methyl-1H-imidazol-2-yl)ethanone (11c) 
 
Following the general procedure, 1-methyl-1H-imidazole (0.821 g, 10.0 mmol) was converted to 11c 
(1.478 g, 8.3 mmol, yield: 83%, Rf = 0.55, EtOAc/n-hexane = 2:1) as a white solid. 
1
H NMR (300 MHz, CDCl3) δ 7.37 (d, J = 0.9 Hz, 1H), 7.23 (d, J = 0.9 Hz, 1H), 4.07 (s, 3H).   
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13
C NMR (75 MHz, CDCl3) δ 138.2, 132.0, 129.2, 118.3, 114.4, 36.3.   
All spectroscopic data are in agreement with the literature.
16 
 
2,2,2-Trifluoro-1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethanone (11d) 
 
Following the general procedure, 1-methyl-1H-benzoimidazol (0.661 g, 5.0 mmol) was converted to 
2-acyl imidazole 11d (1.034 g, 4.5 mmol, yield: 90%, Rf = 0.3, EtOAc/n-hexane = 2:1) as a white 
solid. 
1
H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 8.3 Hz, 1H), 7.65–7.31 (m, 3H), 4.17 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 174.1 (q, J = 35 Hz), 142.6, 140.9, 137.2, 128.2, 125.01, 121.4 (q, J = 
155 Hz), 118.3, 114.5, 110.8, 32.5. 
19
F NMR (282 MHz, None) δ –72.8 (s, 3F). 
IR (film): ν (cm1) 3538, 1719, 1478, 1457, 1194, 1173, 1150, 1117, 1077, 1011, 950, 912, 750, 737, 
633, 551, 536, 448, 402. 
HRMS (APCI, m/z) calcd for C10H7F3N2OH [M+H]
+
: 229.0583, found: 229.0582. 
 
2,2,2-Trifluoro-1-(1-(4-methoxyphenyl)-1H-imidazol-2-yl)ethanone (11e) 
 
Following the general procedure, 1-(4-methoxyphenyl)-1H-imidazole (1.742 g, 10.0 mmol) was 
converted to 2-acyl imidazole 11e (0.811 g, 3.0 mmol, yield: 30%, Rf = 0.5, EtOAc/n-hexane = 2:1) as 
a white solid. 
1
H NMR (300 MHz, CDCl3) δ
 
7.47 (d, J = 0.9 Hz, 1H), 7.33 (d, J = 0.9 Hz, 1H), 7.25–7.18 (m, 2H), 
7.01–6.94 (m, 2H), 3.87 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 160.3, 138.0, 132.2, 129.7, 129.5, 126.8, 123.8, 118.2, 114.4, 55.6. 
19
F NMR (282 MHz, None) δ –73.4 (s, 3F). 
IR (film): ν (cm1) 3208, 3154, 2942, 2841, 1699, 1605, 1510, 1456, 1355, 1252, 1134, 1073, 933, 828, 
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777, 633, 538. 
HRMS (APCI, m/z) calcd for C12H9F3N2O2H [M+H]
+
: 271.0689, found: 271.0688. 
 
2,2,3,3,3-Pentafluoro-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (11f) 
 
Following the general procedure, using perfluoropropionic acid anhydride instead, 
1-(4-methoxyphenyl)-1H-imidazole (1.441 g, 10.0 mmol) was converted to 2-acyl imidazole 11f 
(1.587 g, 5.5 mmol, yield: 55%, Rf = 0.3, EtOAc/n-hexane = 2:1) as a white solid. 
1
H NMR (300 MHz, CDCl3) δ 7.49–7.36 (m, 4H), 7.28 (s, 1H), 7.26–7.15 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 172.1, 138.5, 137.1, 132.3, 129.6, 129.4, 125.7, 120.0, 116.2, 112.1, 
108.3, 104.8. 
19
F NMR (282 MHz, None) δ –81.0 (s, 3F), –116.7 (s, 2F). 
IR (film): ν (cm1) 3099, 1692, 1591, 1497, 1453, 1402, 1349, 1306, 1204, 1141, 1091, 994, 920, 826, 
757, 682, 531, 424. 
HRMS (APCI, m/z) calcd for C12H7F5N2OH [M+H]
+
: 291.0551, found: 291.0549. 
5.3.3. Rhodium-catalyzed alkynylation reactions 
 
General catalytic procedure: A dried 10 mL Schlenk tube was charged with the catalyst -RhPP 
(3–6 mol%) and the corresponding trifluoromethyl ketones (0.20 mmol, 1.0 eq). The tube was purged 
with nitrogen and THF (0.2 mL), and then Et3N (33.27 µL, 1.2 eq) was added via syringe, followed by 
the corresponding alkynes (3.0 eq or 10.0 eq). The tube was sealed and the reaction was stirred at the 
indicated temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. 
Afterwards, the solvent was removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:10 to 1:5) to afford the products 20a-y. Racemic 
samples were obtained by carrying out the reactions with rac-RhPP. The enantiomeric excess was 
determined by chiral HPLC analysis. 
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(R)-1,1,1-Trifluoro-4-phenyl-2-(1-phenyl-1H-imidazol-2-yl)but-3-yn-2-ol (20a) 
 
Starting from trifluoromethyl ketone 11a (48.0 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 0.60 
mmol) according to the general procedure to give 20a as a white solid (61.0 mg, 0.178 mmol, yield: 
89%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess was established by HPLC analysis using 
a Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 
1.0 mL/min, 25 C, tr (major) = 8.8 min, tr (minor) = 25.2 min). []D
25
 = +102.3 (c 0.7, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.58–7.38 (m, 5H), 7.37–7.20 (m, 6H), 7.14–7.08 (m, 1H). 
13
C NMR (75 MHz, CD3OD) δ 142.9, 139.8, 132.8, 130.5, 130.0, 129.7, 129.4, 128.7, 127.9, 126.6, 
122.8, 122.3, 89.4, 83.7, 71.0 (q, J = 33.0 Hz). 
19
F NMR (282 MHz, CD3OD) δ 78.56 (s, 3F). 
IR (film): ν (cm1) 2291, 1595, 1497, 1467, 1418, 1259, 1202, 1172, 1133, 1125, 1071, 1043, 1027, 
994, 936, 903, 785, 761, 746, 722, 689, 584, 562, 538, 529, 502. 
HRMS (ESI, m/z) calcd for C19H14F3N2O [M+H]
+
: 343.1053, found: 343.1058. 
 
(R)-1,1,1-Trifluoro-2-(1-isopropyl-1H-imidazol-2-yl)-4-phenylbut-3-yn-2-ol (20b) 
 
Starting from trifluoromethyl ketone 11b (41.2 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 0.60 
mmol) according to the general procedure to give 20b as a white solid (58.2 mg, 0.189 mmol, yield: 
94%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 
mL/min, 25 C, tr (minor) = 6.6 min, tr (major) = 10.1 min). []D
25
 = +41.2 (c 0.6, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.62–7.49 (m, 2H), 7.47–7.31 (m, 4H), 6.99 (d, J = 1.0 Hz, 1H), 
5.46–5.29 (m, 1H), 1.46 (d, J = 6.7 Hz, 6H). 
13
C NMR (75 MHz, CD3OD) δ 141.5, 132.9, 130.6, 129.7, 128.3, 124.7 (q, J = 284.0 Hz), 122.4, 
120.0, 88.6, 84.0, 71.6 (q, J = 33.8 Hz), 50.3, 24.0, 23.7. 
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19
F NMR (282 MHz, CD3OD) δ –79.04 (s, 3F). 
IR (film): ν (cm1) 2981, 2254, 1493, 1467, 1248, 1185, 1170, 1125, 1109, 1017, 941, 908, 789, 752, 
705, 692, 650, 640, 628, 580, 554, 529, 456, 425. 
HRMS (ESI, m/z) calcd for C16H16F3N2O [M+H]
+
: 309.1209, found: 309.1214. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-phenylbut-3-yn-2-ol (20c) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 0.60 
mmol) according to the general procedure to give 20c as a white solid (51.4 mg, 0.18 mmol, yield: 
92%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 99.6% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 
1.0 mL/min, 25 C, tr (minor) = 7.1 min, tr (major) = 9.2 min). []D
25
 = +42.5 (c 0.6, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.62–7.49 (m, 2H), 7.47–7.29 (m, 3H), 7.13 (d, J = 1.2 Hz, 1H), 6.96 
(d, J = 1.2 Hz, 1H), 3.94 (s, 3H).   
13
C NMR (75 MHz, CD3OD) δ 142.1, 133.0, 130.6, 129.6, 127.6, 125.9, 124.8 (q, J = 284.3 Hz), 
122.5, 88.7, 83.8, 71.9 (q, J = 33.8 Hz), 35.7. 
19
F NMR (282 MHz, CD3OD) δ –80.99 (s, 3F). 
IR (film): ν (cm1) 2233, 1482, 1402, 1284, 1242, 1209, 1192, 1172, 1157, 1120, 1106, 1034, 1018, 
999, 942, 912, 788, 756, 709, 683, 616, 582, 531, 551, 421, 398. 
HRMS (ESI, m/z) calcd for C14H12F3N2O [M+H]
+
: 281.0902, found: 281.0899. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(p-tolyl)but-3-yn-2-ol (20d) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-4-methylbenzene (69.7 
mg, 0.60 mmol) according to the general procedure to give 20d as a white solid (55.6 mg, 0.189 mmol, 
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yield: 95%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99.4% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 8.9 min, tr (major) = 13.3 min). []D
25
 = +32.7 (c 0.4, 
CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.43 (d, J = 13.3 Hz, 2H), 7.18 (d, J = 7.9 Hz, 2H), 7.12 (d, J = 1.2 Hz, 
1H), 7.02–6.89 (m, 1H), 3.93 (s, 3H), 2.34 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 142.2, 141.2, 132.9, 130.3, 127.6, 125.9, 124.9 (q, J = 284.0 Hz) 119.4, 
89.0, 83.1, 71.9 (q, J = 33.0 Hz), 35.7, 21.5. 
19
F NMR (282 MHz, CD3OD) δ –79.43 (s, 3F). 
IR (film): ν (cm1) 2240, 1512, 1482, 1411, 1278, 1244, 1190, 1173, 1150, 1103, 1057, 1027, 1019, 
942, 912, 820, 759, 702, 676, 612, 551, 532, 523, 504, 453, 427, 411. 
HRMS (ESI, m/z) calcd for C15H14F3N2O [M+H]
+
: 295.1053, found: 295.1057. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(m-tolyl)but-3-yn-2-ol (20e) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-3-methylbenzene (69.7 
mg, 0.60 mmol) according to the general procedure to give 20e as a white solid (55.8 mg, 0.190 mmol, 
yield: 95%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee > 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow 
rate 1.0 mL/min, 25 C, tr = 29.0 min). []D
25
 = +43.1 (c 0.6, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.45–7.30 (m, 2H), 7.30–7.18 (m, 2H), 7.13 (d, J = 1.1 Hz, 1H), 6.95 
(d, J = 1.0 Hz, 1H), 3.94 (s, 3H), 2.32 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 142.2, 139.6, 133.4, 131.4, 130.1, 129.5, 127.6, 125.9, 124.8 (q, J = 
283.8 Hz), 122.3, 89.0, 83.4, 71.9 (q, J = 33.0 Hz), 35.6, 21.2. 
19
F NMR (282 MHz, CD3OD) δ –79.81 (s, 3F). 
IR (film): ν (cm1) 2234, 1485, 1247, 1172, 1149, 1105, 1034, 943, 915, 894, 796, 765, 691, 682, 635, 
426.   
HRMS (ESI, m/z) calcd for C15H14F3N2O [M+H]
+
: 295.1053, found: 295.1057. 
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(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(o-tolyl)but-3-yn-2-ol (20f) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-2-methylbenzene (69.7 
mg, 0.60 mmol) according to the general procedure to give 20f as a white solid (57.5 mg, 0.196 mmol, 
yield: 98%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99.4% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 10.5 min, tr (major) = 12.3 min). []D
25
 = +45.9 (c 0.7, 
CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.57–7.41 (m, 1H), 7.34–7.15 (m, 3H), 7.12 (d, J = 1.2 Hz, 1H), 6.95 
(d, J = 1.2 Hz, 1H), 3.95 (s, 3H), 2.43 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 142.2, 142.1, 133.2, 130.7, 130.6, 127.6, 126.8, 125.8, 123.0, 122.1, 
119.2, 87.8, 87.7, 71.9 (q, J = 33.0 Hz), 35.6, 20.6. 
19
F NMR (282 MHz, CD3OD) δ –79.63 (s, 3F). 
IR (film): ν (cm1) 2924, 2853, 2229, 1535, 1415, 1301, 1285, 1245, 1216, 1193, 1168, 1154, 1121, 
1088, 1012, 887, 861, 826, 794, 766, 749, 711, 682, 638, 611, 569, 548, 494, 430, 389.  HRMS (ESI, 
m/z) calcd for C15H13F3N2ONa [M+Na]
+
: 317.0883, found: 317.0872. 
 
(R)-4-(4-(tert-Butyl)phenyl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20g) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-(tert-butyl)-4-ethynylbenzene 
(94.9 mg, 0.60 mmol) according to the general procedure to give 20g as a white solid (67.1 mg, 0.199 
mmol, yield: 99%, Rf = 0.6, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee > 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr = 12.4 min). []D
25
 = +32.1 (c 0.8, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.54–7.44 (m, 2H), 7.44–7.37 (m, 2H), 7.12 (d, J = 1.1 Hz, 1H), 6.95 
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(d, J = 1.0 Hz, 1H), 3.94 (s, 3H), 1.30 (s, 9H). 
13
C NMR (75 MHz, CD3OD) δ 154.2, 142.3, 132.8, 127.5, 126.6, 125.9, 123.0, 119.5, 88.9, 83.2, 71.8 
(q, J = 33.0 Hz), 35.70, 35.66, 31.50. 
19
F NMR (282 MHz, CD3OD) δ –79.38 (s, 3F). 
IR (film): ν (cm1) 2963, 2235, 1506, 1478, 1391, 1253, 1185, 1170, 1118, 1104, 1052, 1024,  942, 
909, 833, 751, 713, 688, 657, 615, 563, 530, 513. 
HRMS (ESI, m/z) calcd for C18H20F3N2O [M+H]
+
: 337.1533, found: 337.1523. 
 
(R)-4-([1,1'-Biphenyl]-4-yl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20h) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 4-ethynyl-1,1'-biphenyl (106.4 mg, 
0.60 mmol) according to the general procedure to give 20h as a white solid (66.5 mg, 0.187 mmol, 
yield: 93%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 13.3 min, tr (major) = 22.6 min). []D
25
 = +20.4 (c 0.8, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.65–7.54 (m, 6H), 7.50–7.37 (m, 2H), 7.36–7.27 (m, 1H), 7.12 (d, J 
= 1.2 Hz, 1H), 7.01–6.92 (m, 1H), 3.94 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 143.5, 142.1, 141.2, 133.5, 130.0, 129.0, 128.1, 127.9, 127.6, 126.7, 
126.0, 123.0, 121.3, 88.6, 84.4, 72.2, 71.8, 72.0 (q, J = 31.0 Hz), 35.7. 
19
F NMR (282 MHz, CD3OD) δ –80.26 (s, 3F). 
IR (film): ν (cm1) 2924, 2233, 1448, 1290, 1251, 1173, 1087, 1029, 1014, 944, 912, 838, 757, 692, 
618, 559, 517, 504, 458. 
HRMS (ESI, m/z) calcd for C20H16F3N2O [M+H]
+
: 357.1209, found: 357.1214. 
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(R)-1,1,1-Trifluoro-4-(4-methoxyphenyl)-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20i) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-4-methoxybenzene 
(79.6 mg, 0.60 mmol) according to the general procedure to give 20i as a white solid (59.3 mg, 0.191 
mmol, yield: 96%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 99.4% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 13.1 min, tr (major) = 18.6 min). []D
25
 = +34.9 (c 
0.6, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.57–7.40 (m, 2H), 7.12 (d, J = 1.2 Hz, 1H), 7.03–6.87 (m, 3H), 3.94 
(s, 3H), 3.80 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 162.2, 142.3, 134.6, 127.5, 125.9, 124.9 (q, J = 284.3 Hz), 115.2, 114.4, 
89.0, 82.4, 71.8 (q, J = 33.0 Hz), 55.9, 35.6. 
19
F NMR (282 MHz, CD3OD) δ –79.46 (s, 3F). 
IR (film): ν (cm1) 2969, 2941, 2844, 2233, 1606, 1568, 1512, 1480, 1462, 1446, 1407, 1296, 1253, 
1211, 1192, 1181, 1157, 1120, 1075, 1051, 993, 967, 943, 887, 837, 819, 760, 748, 737, 677, 611, 564, 
501, 457, 421. 
HRMS (ESI, m/z) calcd for C15H14F3N2O2 [M+H]
+
: 311.1013, found: 311.1004. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-benzo[d]imidazol-2-yl)-4-phenylbut-3-yn-2-ol (20j) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-4-fluorobenzene (61.3 
mg, 0.60 mmol) according to the general procedure to give 20j as a white solid (47.0 mg, 0.157 mmol, 
yield: 79%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee > 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow 
rate 1.0 mL/min, 25 C, tr = 11.4 min). []D
25
 = +42.6 (c 0.4, CH2Cl2). 
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1
H NMR (300 MHz, CD3OD) δ 7.71–7.51 (m, 2H), 7.21–7.05 (m, 3H), 6.96 (d, J = 1.2 Hz, 1H), 3.94 
(s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 166.3, 163.0, 142.0, 135.4, 135.3, 127.6, 126.0, 124.8 (q, J = 282.8 
Hz), 118.8, 117.0, 116.7, 87.6, 83.7, 72.0 (q, J = 33.0 Hz), 35.7. 
19
F NMR (282 MHz, CD3OD) δ –81.04 (s, 3F), –112.13 (s, 1F). 
IR (film): ν (cm1) 2227, 1600, 1509, 1227, 1213, 1188, 1177, 1140, 1081, 1016, 947, 916, 840, 769, 
754, 711, 677, 613, 535, 503, 478, 466, 392. 
HRMS (ESI, m/z) calcd for C14H11F3N2O [M+H]
+
: 299.0802, found: 299.0805. 
 
(R)-4-(4-Chlorophenyl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20k) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-chloro-4-ethynylbenzene (61.3 
mg, 0.60 mmol) according to the general procedure to give 20k as a white solid (60.8 mg, 0.194 mmol, 
yield: 97%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99.0% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
flow rate 1.0 mL/min, 25 C, tr (minor) = 8.5 min, tr (major) = 13.1 min). []D
25
 = +30.4 (c 0.6, 
CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.62–7.48 (m, 2H), 7.48–7.34 (m, 2H), 7.13 (d, J = 1.2 Hz, 1H), 6.96 
(d, J = 1.0 Hz, 1H), 3.93 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 141.9, 136.7, 134.5, 129.9, 127.7, 126.0, 124.8 (q, J = 284.0 Hz), 
121.2, 87.4, 84.9, 72.1 (q, J = 33.0 Hz), 35.7. 
19
F NMR (282 MHz, CD3OD) δ –80.14 (s, 3F). 
IR (film): ν (cm1) 2235, 1592, 1491, 1480, 1400, 1291, 1246, 1194, 1107, 1089, 1017, 986, 916, 895, 
831, 793, 762, 716, 687, 648, 607, 581, 530, 469, 438, 424. 
HRMS (ESI, m/z) calcd for C14H11ClF3N2O [M+H]
+
: 315.0507, found: 315.0509. 
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(R)-4-(4-Bromophenyl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20l) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-bromo-4-ethynylbenzene (61.3 
mg, 0.60 mmol) according to the general procedure to give 20l as a white solid (70.0 mg, 0.195 mmol, 
yield: 97%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 9.0 min, tr (major) = 15.0 min). []D
25
 = +30.3 (c 0.8, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.61–7.51 (m, 2H), 7.47 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 1.1 Hz, 1H), 
7.01–6.91 (m, 1H), 3.93 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 141.9, 134.6, 132.9, 127.7, 126.0, 124.8, 124.7 (q, J = 284.3 Hz), 
121.6, 87.5, 85.0, 72.1 (q, J = 33.8 Hz), 35.7. 
19
F NMR (282 MHz, CD3OD) δ –79.47 (s, 3F). 
IR (film): ν (cm1) 3120, 2805, 2244, 1486, 1243, 1188, 1175, 1151, 1103, 1072, 1023, 942, 912, 836, 
822, 794, 757, 681, 622, 526, 460, 417. 
HRMS (ESI, m/z) calcd for C14H11BrF3N2O [M+H]
+
: 359.0012, found: 359.0002. 
 
(R)-1,1,1-Trifluoro-4-(2-fluorophenyl)-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20m) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynyl-2-fluorobenzene (72.1 
mg, 0.60 mmol) according to the general procedure to give 20m as a white solid (59.2 mg, 0.199 
mmol, yield: 99%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.6 min, tr (major) = 8.7 min). []D
25
 = +34.5 (c 0.5, 
CH2Cl2).  
1
H NMR (300 MHz, CD3OD) δ 7.63–7.52 (m, 1H), 7.50–7.39 (m, 1H), 7.20–7.10 (m, 3H), 6.95 (d, J 
= 1.0 Hz, 1H), 3.95 (s, 3H). 
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13
C NMR (75 MHz, CD3OD) δ 164.6, 161.3, 140.5, 133.5, 131.4, 131.3, 126.2, 124.5, 124.1, 123.8 (q, 
J = 284.0 Hz), 115.4, 115.1, 109.6, 109.3, 87.4, 80.9, 70.4 (q, J = 33.8 Hz), 34.2.  
19
F NMR (282 
MHz, CD3OD) δ –80.07 (s, 3F), –111.56 (s, 1F). 
IR (film): ν (cm1) 2240, 1574, 1492, 1450, 1284, 1249, 1226, 1176, 1091, 1060, 1011, 916, 891, 837, 
763, 707, 683, 636, 614, 579, 532, 503, 479, 436, 408. 
HRMS (ESI, m/z) calcd for C14H11N2O [M+H]
+
: 299.0802, found: 299.0806. 
 
(R)-4-(3,5-Bis(trifluoromethyl)phenyl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-o
l (20n) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 
1-ethynyl-3,5-bis(trifluoromethyl)benzene (142.9 mg, 0.60 mmol) according to the general procedure 
to give 20n as a white solid (82.8 mg, 0.199 mmol, yield: 99%, Rf = 0.5, EtOAc/n-hexane = 1:2). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee > 99% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 1.0 mL/min, 25 C, tr = 10.4 min). []D
25
 = 4.8 
(c 0.7, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 8.23–8.15 (m, 2H), 8.04 (d, J = 13.6 Hz, 1H), 7.15 (d, J = 1.1 Hz, 1H), 
6.99 (d, J = 1.2 Hz, 1H), 3.94 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 141.5, 133.4 (m), 127.9, 126.4, 125.3, 124.7 (q, J = 284.5 Hz), 124.3 
(q, J = 270.5 Hz), 123.9 (m), 87.5, 85.2, 72.6 (q, J = 33.5 Hz), 35.8. 
19
F NMR (282 MHz, CD3OD) δ –64.4 (s, 6F), –80.0 (s, 3F). 
IR (film): ν (cm1) 2925, 2236, 1593, 1577, 1463, 1437, 1380, 1277, 1176, 1132, 1105, 1054, 1030, 
945, 918, 898, 775, 740, 700, 683, 616, 589, 438, 422, 404, 394. 
HRMS (ESI, m/z) calcd for C16H10F9N2O [M+H]
+
: 417.0655, found: 417.0648. 
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(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(pyridin-2-yl)but-3-yn-2-ol (20o) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 2-ethynylpyridine (61.9 mg, 0.60 
mmol) according to the general procedure to give 20o as a yellow oil (46.3 mg, 0.165 mmol, yield: 
82%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee > 99% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 
mL/min, 25 C, tr = 5.6 min). []D
25
 = +37.4 (c 0.6, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 8.55 (ddd, J = 5.0, 1.7, 0.9 Hz, 1H), 7.87 (td, J = 7.8, 1.8 Hz, 1H), 
7.70 (dt, J = 7.9, 1.0 Hz, 1H), 7.45 (ddd, J = 7.7, 5.0, 1.2 Hz, 1H), 7.15 (d, J = 1.1 Hz, 1H), 6.97 (d, J 
= 1.2 Hz, 1H), 3.95 (s, 3H). 
13
C NMR (75 MHz, CD3OD) δ 150.9, 142.3, 141.6, 138.6, 129.4, 127.8, 126.1, 125.7, 124.7 (q, J = 
284.3 Hz), 71.9 (q, J = 33.3 Hz), 87.0, 84.0, 35.7. 
19
F NMR (282 MHz, CD3OD) δ –79.55 (s, 3F). 
IR (film): ν (cm1) 2236, 1585, 1483, 1465, 1430, 1279, 1250, 1175, 1109, 1092, 1055, 1027, 942, 912, 
844, 777, 738, 717, 682, 635, 617, 594, 537, 503, 401. 
HRMS (ESI, m/z) calcd for C13H11F3N3O [M+H]
+
: 282.0849, found: 282.0853. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(thiophen-3-yl)but-3-yn-2-ol (20p) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 3-ethynylthiophene (64.9 mg, 0.60 
mmol) according to the general procedure to give 20p as a white solid (53.9 mg, 0.188 mmol, yield: 
94%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak OJ-H column, ee = 99.0% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow rate 
1.0 mL/min, 25 C, tr (minor) = 11.4 min, tr (major) = 14.2 min). []D
25
 = +44.1 (c 0.6, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.80–7.70 (m, 1H), 7.50–7.38 (m, 1H), 7.21 (dd, J = 5.0, 1.0 Hz, 1H), 
7.12 (d, J = 1.0 Hz, 1H), 6.95 (d, J = 0.9 Hz, 1H), 3.93 (s, 3H). 
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13
C NMR (75 MHz, CD3OD) δ 142.1, 132.0, 130.7, 127.6, 127.1, 125.9, 124.8 (q, J = 284.3 Hz), 71.9 
(q, J = 33.0 Hz), 121.5, 84.2, 83.3, 35.6. 
19
F NMR (282 MHz, CD3OD) δ –79.41 (s, 3F). 
IR (film): ν (cm1) 2236, 1478, 1285, 1244, 1194, 1173, 1080, 1050, 1027, 1002, 941, 912, 885, 872, 
789, 760, 722, 688, 658, 626, 610, 532, 500, 417. 
HRMS (ESI, m/z) calcd for C12H10F3N2OS [M+H]
+
: 287.0460, found: 287.0468. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)oct-3-yn-2-ol (20q). 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and hex-1-yne (164.3 mg, 2.0 mmol) 
according to the general procedure to give 20q as a white solid (45.5 mg, 0.175 mmol, yield: 88%, Rf 
= 0.3, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a Chiralpak 
AD-H column, ee = 97% (HPLC: AD-H, 220 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 
25 C, tr (minor) = 8.4 min, tr (major) = 11.7 min). []D
25
 = +35.0 (c 0.5, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.09 (d, J = 1.2 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 2.33 (t, 
J = 6.9 Hz, 2H), 1.62–1.37 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CD3OD) δ 142.7, 127.3, 125.6, 124.8 (q, J = 283.7 Hz), 90.4, 75.3, 71.1 (q, J = 
33.0 Hz), 35.6, 31.2, 22.9, 19.0, 13.8. 
19
F NMR (282 MHz, CD3OD) δ –79.64 (s, 3F). 
IR (film): ν (cm1) 2960, 2936, 2874, 2247, 1688, 1484, 1466, 1257, 1165, 1141, 1072, 991, 943, 915, 
906, 839, 751, 718, 699, 683, 614. 
HRMS (ESI, m/z) calcd for C12H16F3N2O [M+H]
+
: 261.1220, found: 261.1210. 
 
(R)-4-Cyclohexyl-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20r) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and ethynylcyclohexane (216.4 mg, 
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2.0 mmol) according to the general procedure to give 20r as a white solid (38.8 mg, 0.136 mmol, yield: 
68%, Rf = 0.3, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 94% (HPLC: AD-H, 220 nm, hexane/isopropanol = 95:5, flow rate 1.0 
mL/min, 25 C, tr (minor) = 7.7 min, tr (major) = 11.0 min). []D
25
 = +5.7 (c 0.5, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.09 (d, J = 1.2 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 
2.62–2.45 (m, 1H), 1.90–1.80 (m, 2H), 1.79–1.62 (m, 2H), 1.62–1.44 (m, 3H), 1.44–1.23 (m, 3H). 
13
C NMR (75 MHz, CD3OD) δ 142.7, 127.3, 125.6, 124.8 (q, J = 283.7 Hz), 94.1, 75.4, 71.0 (q, J = 
33.0 Hz), 35.6, 33.1, 30.1, 26.9, 25.7. 
19
F NMR (282 MHz, CD3OD) δ –80.30 (s, 3F). 
IR (film): ν (cm1) 2936, 2925, 2856, 2245, 1488, 1443, 1389, 1191, 1157, 1093, 1046, 1013, 941, 924, 
906, 848, 759, 708, 688, 591, 536, 514, 456. 
HRMS (ESI, m/z) calcd for C14H18F3N2O [M+H]
+
: 287.1377, found: 287.1363. 
 
(R)-4-Cyclopropyl-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20s) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and ethynylcyclopropane (132.2 mg, 2 
mmol) according to the general procedure to give 20s as a white solid (41.0 mg, 0.168 mmol, yield: 
84%, Rf = 0.2, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 94% (HPLC: AD-H, 220 nm, hexane/isopropanol = 95:5, flow rate 1.0 
mL/min, 25 C, tr (minor) = 6.9 min, tr (major) = 8.3 min). []D
25
 = +48.7 (c 0.5, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.08 (d, J = 1.2 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 3.87 (s, 3H), 
1.44–1.35 (m, 1H), 0.90–0.80 (m, 2H), 0.79–0.71 (m, 2H). 
13
C NMR (75 MHz, CD3OD) δ 142.6, 127.3, 125.7, 124.8 (q, J = 283.8 Hz), 93.4, 71.2 (q, J = 33.0 
Hz), 70.1, 35.6, 8.6, 8.5, 0.01. 
19
F NMR (282 MHz, CD3OD) δ –80.41(s, 3F). 
IR (film): ν (cm1) 2236, 1494, 1454, 1362, 1288, 1277, 1191, 1172, 1164, 1143, 1088, 1035, 947, 925, 
907, 848, 816, 758, 738, 714, 687, 610, 491. 
HRMS (ESI, m/z) calcd for C11H12F3N2O [M+H]
+
: 245.0907, found: 245.0897. 
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(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-5-phenylpent-3-yn-2-ol (20t) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and prop-2-yn-1-ylbenzene (69.7 mg, 
0.60 mmol) according to the general procedure to give 20t as a white solid (32.4 mg, 0.110 mmol, 
yield: 55%, Rf = 0.4, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 99% (HPLC: AD-H, 220 nm, hexane/isopropanol = 90:10, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 8.6 min, tr (major) = 14.3 min). []D
25
 = +25.0 (c 0.3, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.45–7.25 (m, 4H), 7.25–7.16 (m, 1H), 7.08 (d, J = 1.2 Hz, 1H), 6.92 
(d, J = 1.2 Hz, 1H), 3.86 (s, 3H), 3.75 (s, 2H). 
13
C NMR (75 MHz, CD3OD) δ 142.5, 137.0, 129.6, 129.0, 127.8, 127.4, 125.7, 124.8 (q, J = 284 Hz), 
88.2, 77.3, 71.4 (q, J = 33.8 Hz), 35.6, 25.5. 
19
F NMR (282 MHz, CD3OD) δ –79.55 (s, 3F). 
IR (film): ν (cm1) 2256, 1604, 1495, 1453, 1409, 1338, 1285, 1187, 1165, 1142, 1061, 945, 926, 909, 
762, 723, 693, 619, 607, 535, 478, 456. 
HRMS (ESI, m/z) calcd for C15H14F3N2O [M+H]
+
: 295.1064, found: 295.1053. 
 
(R)-1,1,1-Trifluoro-2-(1-methyl-1H-imidazol-2-yl)-4-(trimethylsilyl)but-3-yn-2-ol (20u) 
 
Starting from trifluoromethyl ketone 11c (53.5 mg, 0.30 mmol) and ethynyltrimethylsilane (88.4 mg, 
0.90 mmol) according to the general procedure to give 20u as a white solid (52.7 mg, 0.191 mmol, 
yield: 64%, Rf = 0.4, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak OD-H column, ee > 99% (HPLC: OD-H, 220 nm, hexane/isopropanol = 98:2, flow 
rate 1.0 mL/min, 25 C, tr = 10.7 min). []D
25
 = +54.5 (c 0.6, CH2Cl2). 
1
H NMR (300 MHz, CD3OD) δ 7.10 (d, J = 1.2 Hz, 1H), 6.92 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 0.22 (s, 
9H). 
13
C NMR (75 MHz, CD3OD) δ 141.9, 127.5, 125.8, 124.6 (q, J =283.8 Hz), 99.3, 94.7, 71.2 (q, J = 
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33.0 Hz), 35.5, 0.6. 
19
F NMR (282 MHz, CD3OD) δ –79.64 (s, 3F). 
IR (film): ν (cm1) 2965, 2240, 1491, 1380, 1288, 1277, 1265, 1251, 1205, 1192, 1172, 1140, 1110, 
1055, 1030, 947, 913, 844, 764, 749, 730, 709, 699, 603, 520, 460, 418. 
HRMS (ESI, m/z) calcd for C11H16F3N2OSi [M+H]
+
: 277.0979, found: 277.0982. 
 
(R)-4-(Cyclohex-1-en-1-yl)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)but-3-yn-2-ol (20v) 
 
Starting from trifluoromethyl ketone 11c (35.6 mg, 0.20 mmol) and 1-ethynylcyclohex-1-ene (64.9 mg, 
0.60 mmol) according to the general procedure to give 20v as a white solid (49.5 mg, 0.174 mmol, 
yield: 87%, Rf = 0.4, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 220 nm, hexane/isopropanol = 95:5, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 10.3 min, tr (major) = 12.8 min). []D
25
 = +36.5 (c 0.5, CH2Cl2).   
1
H NMR (300 MHz, CD3OD) δ 7.09 (d, J = 1.2 Hz, 1H), 6.91 (d, J = 1.1 Hz, 1H), 6.34–6.19 (m, 1H), 
3.89 (s, 3H), 2.40–1.93 (m, 4H), 1.87–1.40 (m, 4H). 
13
C NMR (75 MHz, CD3OD) δ 142.4, 138.6, 127.4, 125.7, 124.8 (q, J = 283.8 Hz), 120.6, 90.6, 81.2, 
71.5 (q, J = 33.3 Hz), 35.6, 29.5, 26.6, 23.2, 22.4. 
19
F NMR (282 MHz, CD3OD) δ –79.93 (s, 3F). 
IR (film): ν (cm1) 3138, 2944, 2852, 2216, 1721, 1484, 1361, 1288, 1189, 1173, 1137, 1090, 1054, 
1013, 947, 910, 765, 734, 720, 695, 533. 
HRMS (ESI, m/z) calcd for C14H16F3N2O [M+H]
+
: 285.1209, found: 285.1207. 
 
(R)- 1,1,1-Trifluoro-2-(1-methyl-1H-benzo[d]imidazol-2-yl)-4-phenylbut-3-yn-2-ol (20w) 
 
Starting from trifluoromethyl ketones 11d (45.6 mg, 0.2 mmol) and phenylacetylene (61.3 mg, 0.60 
mmol) according to the general procedure to give 20w as a white solid (48.4 mg, 0.146 mmol, yield: 
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73%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 98.8% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 
1.0 mL/min, 25 C, tr (major) = 13.2 min, tr (minor) = 16.2 min). []D
25
 = 34.6 (c 0.4, CH2Cl2). 
1
H NMR (300 MHz, MeOD) δ 7.74 (d, J = 7.5 Hz, 1H), 7.61–7.49 (m, 3H), 7.46–7.24 (m, 5H), 4.12 (s, 
3H). 
13
C NMR (75 MHz, MeOD) δ 148.5, 142.2, 138.0, 133.0, 130.5, 129.6, 125.1, 124.8 (q, J = 284.3), 
124.0, 122.9, 120.6, 111.2, 89.5, 83.3, 72.4 (q, J = 33.0 Hz), 32.7. 
19
F NMR (282 MHz, None) δ –78.78 (s). 
IR (film): ν (cm1) 2243, 1492, 1474, 1445, 1385,1331, 1287, 1244, 1186, 1167, 1113, 1072, 1029, 
1020, 1007, 997, 946, 818, 762, 734, 691, 636, 618, 587, 553, 539, 480, 437, 418. 
HRMS (ESI, m/z) calcd for C18H13F3N2OH [M+H]
+
: 331.1053, found: 331.1056. 
 
(R)-1,1,1-Trifluoro-2-(1-(4-methoxyphenyl)-1H-imidazol-2-yl)-4-phenylbut-3-yn-2-ol (20x) 
 
Starting from trifluoromethyl ketones 11e (54.0 mg, 0.2 mmol) and phenylacetylene (61.3 mg, 0.60 
mmol) according to the general procedure to give 20x as a white solid (70.7 mg, 0.190 mmol, yield: 
95%, Rf = 0.5, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 94.3% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 
1.0 mL/min, 25 C, tr (minor) = 8.8 min, tr (major) = 13.1 min). []D
25
 = 85.9 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, MeOD) δ 7.44–7.20 (m, 1H), 7.17 (d, J = 1.2 Hz, 1H), 7.08 (d, J = 1.0 Hz, 1H), 
6.96–6.86 (m, 1H), 3.75 (s, 1H). 
13
C NMR (75 MHz, MeOD) δ 161.4, 143.0, 132.8, 132.3, 130.4, 129.9, 129.4, 127.7, 126.7, 124.6 (q, 
J = 284.3 Hz), 122.4, 114.9, 89.5, 83.7, 70.8 (q, J = 33.0 Hz), 56.00. 
19
F NMR (282 MHz, None) δ –78.56. 
IR (film): ν (cm1) 2336, 1512, 1491, 1463, 1443, 1301, 1251, 1202, 1166, 1070, 941, 898, 834, 757, 
726, 718, 687, 629, 560, 542, 529, 502, 462. 
HRMS (ESI, m/z) calcd for C20H15F3N2O2H [M+H]
+
: 373.1158, found: 373.1169. 
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(R)- 4,4,5,5,5-Pentafluoro-1-phenyl-3-(1-phenyl-1H-imidazol-2-yl)pent-1-yn-3-ol (20y) 
  
Starting from pentafluoroketones 11f (58.0 mg, 0.2 mmol) and phenylacetylene (61.3 mg, 0.60 mmol) 
according to the general procedure to give 20y as a white solid (63.2 mg, 0.161 mmol, yield: 81%, Rf 
= 0.3, EtOAc/n-hexane = 1:2). Enantiomeric excess established by HPLC analysis using a Chiralpak 
AD-H column, ee = 96.8% (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 
25 C, tr (minor) = 8.1 min, tr (major) = 19.5 min). []D
25
 = 12.8 (c 0.8, CH2Cl2). 
1
H NMR (300 MHz, MeOD) δ 7.46–7.38 (m, 5H), 7.38–7.28 (m, 5H), 7.17 (d, J = 1.3 Hz, 1H), 7.13 
(d, J = 1.3 Hz, 1H). 
13
C NMR (75 MHz, MeOD) δ 142.9, 140.1, 132.8, 131.1, 130.5, 129.9, 129.6, 129.4, 128.9, 128.1, 
127.2, 122.5, 122.3, 90.3, 83.9, 71.7. 
19
F NMR (282 MHz, None) δ –78.42, –116.89, –117.84, –120.28, –121.23. 
IR (film): ν (cm1) 2246, 1597, 1498, 1457, 1445, 1330, 1212, 1179, 1154, 1142, 1124, 1097, 1075, 
1058, 988, 936, 841, 773, 756, 689, 643, 569, 537, 517, 434, 418. 
HRMS (ESI, m/z) calcd for C20H13F5N2OH [M+H]
+
: 393.1021, found: 393.1027. 
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5.4 Octahedral Chiral-at-Ruthenium Complexes for Asymmetric Catalysis 
5.4.1. Synthesis and characterization of catalysts 
a) Synthesis of the NHCs ligands 
 
2-Bromo-5-(3,5-dimethylphenyl)pyridine (S3ʹ) was synthesized following a published procedure 
with slight modifications.
17
 The 2-bromo-5-iodopyridine (S1ʹ) (925.3 mg, 5.0 mmol) was dissolved in 
2.0 mL of THF and was cooled to 78 C. n-Butyllithium (n-BuLi) (3.47 mL, 5.55 mmol, 1.6 M in 
hexane) was added over a 30 min period. The lithiate was then warmed to 40 oC and stirred for 15 
min before being cooled again to 78 C. A solution of ZnCl2 (pre-dried under vacuum) (497 mg, 3.65 
mmol) was separately prepared in 4.0 mL THF. This solution was then added to the lithiate over a 5 
min period at 78 °C. The reaction mixture was left to warm to room temperature upon which it was 
added to a solution of 1-bromo-3,5-dimethylbenzene (S2ʹ) (925 mg, 5.0 mmol) and Pd(PPh3)4 (93 mg, 
0.08 mmol, 1.60 mol%) in 5 mL THF. The final reaction mixture was degassed and heated to reflux for 
18 h. The brown solution was then cooled to room temperature and 2/3 of the THF was evaporated 
under reduced pressure and its volume replaced by CH2Cl2. The solution was then treated with a 
mixture of sat. NaHCO3 and EDTA solutions (1:1) (3  70 mL). All the aqueous phases were 
combined and extracted with CH2Cl2. The organic phases were combined, dried over MgSO4 and 
concentrated. Purification on a silica gel column (EtOAc/hexane = 1:50) resulted in the compound S3ʹ 
as a white solid (712 mg, 54% yield, Rf = 0.5, EtOAc/n-hexane = 1:10). 
1
H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 2.1 Hz, 1H), 7.797.67 (m, 1H), 7.52 (d, J = 8.2 Hz, 1H), 
7.14 (s, 2H), 7.06 (s, 1H), 2.40 (d, J = 5.7 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ 148.7, 140.8, 139.0, 137.1, 136.6, 136.4, 130.3, 128.0, 125.0, 21.5. 
IR (film): ν (cm1) 3013, 2910, 2854, 1598, 1447, 1343, 1074, 1017, 826, 694, 404. 
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HRMS (ESI, m/z) calcd for C13H13BrN [M+H]
+
: 262.0226, 264.0206, found: 262.0228, 264.0207. 
 
L1 was synthesized following a published procedure with slight modifications.
18
 1-Mesitylimidazole 
(391 mg, 2.1 mmol) and 2-bromo-5-(3,5-dimethylphenyl)pyridine (S3ʹ) (524 mg, 2.0 mmol) were 
stirred in a sealed tube at 170 C for 30 h. After cooling to room temperature, the resulting brown solid 
was washed with diethyl ether for several times until no starting materials were visible by TLC, and 
then the solvent was removed to give L1 as a white solid (498 mg, 56% yield). MP: 304 °C. 
1
H NMR (300 MHz, CDCl3) δ 11.38 (s, 1H), 9.28 (d, J = 8.4 Hz, 1H), 8.93 (s, 1H), 8.69 (s, 1H), 8.26 
(d, J = 7.1 Hz, 1H), 7.36 (s, 1H), 7.20 (s, 2H), 7.09 (s, 1H), 7.05 (s, 2H), 2.40 (s, 6H), 2.35 (s, 3H), 
2.20 (s, 6H). 
13
C NMR (75 MHz, CDCl3) δ 146.9, 144.7, 141.7, 139.1, 139.03, 138.97, 136.0, 135.9, 134.1, 130.71, 
130.67, 130.1, 125.1, 124.1, 120.3, 116.3, 21.4, 21.2, 18.0. 
IR (film): ν (cm1) 2900, 2774, 1604, 1534, 1480, 1378, 1331, 1243, 1081, 1052, 1029, 963, 864, 831, 
753, 730, 700, 669, 636, 582, 549, 413. 
HRMS (ESI, m/z) calcd for C25H26N3 [MHBr]
+
: 368.2121, found: 368.2111. 
 
L2 was prepared according to a reported literature procedure.
19 
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b) Synthesis of rac-Ru1 and rac-Ru2 
 
rac-Ru1 Complex: A solution of RuCl3•xH2O (25.0 mg, 0.12 mmol) and L1 (108 mg, 0.24 mmol) in 
ethylene glycol (2.4 mL) was heated at 200 °C for 8 h, and the reaction mixture was treated with 
saturated aqueous NH4PF6 after cooling down to room temperature. A yellow precipitate formed which 
was separated by filtration and dissolved in CH2Cl2, washed with water and dried to obtain a 
red-orange solid. To the red-orange solution in CH3CN (3 mL) was added AgPF6 (38 mg, 0.15 mmol) 
in one portion, and then stirred at 60 °C overnight. After cooling to room temperature, the mixture was 
filtered. The filtrate was collected, evaporated to dryness and purified by column chromatograph on 
silica gel (CH2Cl2/CH3CN = 10:1) to give rac-Ru1 (133 mg, 0.110 mmol, 92% yield for two steps, Rf 
= 0.4, CH3CN/CH2Cl2 = 1:10) as a pale yellow solid. MP: 241243 °C (decomp.). 
1
H NMR (300 MHz, CD2Cl2) δ 8.49 (d, J = 1.9 Hz, 2H), 8.04 (dd, J = 9.8, 2.2 Hz, 4H), 7.61 (d, J = 8.6 
Hz, 2H), 7.19 (d, J = 9.4 Hz, 6H), 6.91 (d, J = 2.3 Hz, 2H), 6.59 (d, J = 13.2 Hz, 2H), 2.47 (s, 12H), 
2.30 (s, 6H), 2.01 (s, 6H), 1.98 (s, 6H), 1.50 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 189.5, 152.2, 149.1, 140.5, 139.9, 137.0, 135.8, 135.1, 135.0, 134.3, 
134.2, 131.4, 130.3, 129.6, 125.9, 124.9, 124.8, 118.0, 111.8, 21.7, 21.1, 17.7, 17.4, 3.9. 
19
F NMR (282 
MHz, CD2Cl2) δ 71.31, 73.83. 
IR (film): ν (cm1) 2924, 1609, 1499, 1425, 1372, 1306, 1256, 1114, 1035, 932, 828, 697, 604, 554, 
438. 
rac-Ru2 Complex: A solution of RuCl3•xH2O (52.0 mg, 0.25 mmol) and L2 (172 mg, 0.50 mmol) in 
ethylene glycol (5.0 mL) was heated at 200 °C for 4 h, and the reaction mixture was treated with 
saturated aqueous NH4PF6 after cooling down to room temperature. A yellow precipitate formed which 
was separated by filtration and dissolved in CH2Cl2, washed with water and dried to obtain a yellow 
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solid. To the yellow solution in CH3CN (5 mL) was added AgPF6 (79 mg, 0.31 mmol) in one portion, 
and then stirred at 60 °C overnight. After cooling to room temperature, the mixture was filtered. The 
filtrate was collected, evaporated to dryness and purified by column chromatograph on silica gel 
(CH2Cl2/CH3CN = 10:1) to give rac-Ru2 (224 mg, 0.224 mmol, 89% yield for two steps, Rf = 0.4, 
CH3CN/CH2Cl2 = 1:10) as a pale yellow solid. MP: 184186 °C (decomp.). 
1
H NMR (300 MHz, CD2Cl2) δ 8.36 (d, J = 4.8 Hz, 2H), 7.93 (d, J = 2.3 Hz, 2H), 7.907.74 (m, 2H), 
7.47 (d, J = 8.2 Hz, 2H), 7.177.00 (m, 2H), 6.91 (d, J = 2.3 Hz, 2H), 6.75 (s, 2H), 6.52 (s, 2H), 2.28 
(s, 6H), 2.19 (s, 6H), 1.98 (s, 6H), 1.45 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 190.4, 153.2, 152.5, 140.6, 138.6, 135.6, 134.1, 134.0, 130.4, 129.8, 
125.8, 124.9, 123.3, 117.6, 111.3, 21.1, 17.6, 17.4, 3.9. 
19
F NMR (282 MHz, CD2Cl2) δ 72.21, 74.73. 
IR (film): ν (cm1) 3146, 2946, 2281, 1613, 1486, 1449, 1420, 1335, 1305, 1259, 826, 770, 741, 553, 
455. 
c) Synthesis of enantiomerically pure ruthenium catalysts 
 
Λ-(S)-Ru1 and -(R)-Ru1: A mixture of rac-Ru1 (100.0 mg, 0.083 mmol), the chiral auxiliary (S)-2ʹʹ 
or (R)-2ʹʹ (42.4 mg, 0.207 mmol) and triethylamine (84.0 mg, 0.830 mmol) in CH2Cl2 (1.37 mL) was 
heated at 60 °C for 20 h. The reaction mixture was cooled to room temperature and concentrated to 
dryness. The residue was subjected to a flash silica gel chromatography (CH3CN /CH2Cl2 = 1:200) to 
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separate the first eluting diastereomer, which was assigned as Λ-(S)-Ru1 (red solid, 35.6 mg, 0.030 
mmol, 36%) or -(R)-Ru1 (red solid, 31.8 mg, 0.027 mmol, 32%), respectively. MP: 181183 ºC 
(decomp.). 
1
H NMR (300 MHz, CD2Cl2) δ 8.67 (d, J = 2.0 Hz, 1H), 8.17 (d, J = 1.9 Hz, 1H), 7.95 (d, J = 2.3 Hz, 
1H), 7.88 (dd, J = 9.5, 2.2 Hz, 2H), 7.65 (dd, J = 8.6, 2.0 Hz, 1H), 7.52 (dd, J = 8.1, 1.8 Hz, 1H), 7.47 
(d, J = 8.6 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.107.02 (m, 3H), 6.98 (s, 2H), 6.886.89 (m, 3H), 6.84 
(d, J = 2.2 Hz, 1H), 6.54 (d, J = 8.8 Hz, 2H), 6.48 (d, J = 6.7 Hz, 3H), 6.316.22 (m, 1H), 4.32 (dd, J 
= 9.1, 3.0 Hz, 1H), 4.10 (t, J = 9.0 Hz, 1H), 3.97 (dt, J = 8.9, 3.0 Hz, 1H), 2.40 (s, 6H), 2.36 (s, 6H), 
2.30 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.96 (s, 3H), 1.60 (s, 3H), 1.42 (s, 3H), 0.58 (d, J = 6.9 Hz, 3H), 
0.420.25 (m, 1H), 0.05 (d, J = 6.8 Hz, 3H). 
13
C NMR (75 MHz, CD2Cl2) δ 197.7, 196.4, 172.0, 165.4, 153.0, 152.9, 148.7, 148.3, 139.7, 139.64, 
139.57, 139.4, 137.3, 135.8, 135.5, 135.3, 135.2, 135.0, 134.4, 134.3, 134.2, 134.0, 133.9, 130.8, 
130.5, 130.0, 129.6, 129.2, 125.8, 125.3, 124.53, 124.48, 124.0, 116.8, 116.1, 113.0, 110.9, 110.7, 
110.1, 75.3, 66.7, 30.2, 21.73, 21.71, 21.09, 21.03, 19.01, 18.8, 18.1, 17.6, 13.7. 
19
F NMR (282 MHz, CD2Cl2) δ 72.56, 75.07. 
HRMS (ESI, m/z) calcd for C62H64N7O2Ru [MPF6]
+
: 1040.4175, found: 1040.4182.  
Λ-(S)-Ru1: CD (MeOH): λ, nm (Δε, M-1cm-1) 473 (7), 407 (+34), 365 (5), 332 (+16), 291 (36), 
269 (+37), 247 (13), 227 (+27), 208 (64), 200 (+95). IR (film): ν (cm1) 3138, 2960, 2918, 1606, 
1535, 1494, 1472, 1419, 1376, 1323, 1279, 1251, 1222, 1066, 1035, 925, 837, 749, 690, 598, 555, 428, 
392. 
-(R)-Ru1: CD (MeOH): λ, nm (Δε, M-1cm-1) 471 (+6), 407 (18), 367 (+5), 334 (9), 292 (+16), 269 
(6), 249 (+9), 244 (+8). IR (film): ν (cm1) 2959, 2919, 2861, 1605, 1493, 1471, 1419, 1373, 1309, 
1252, 1223, 1150, 1066, 1034, 925, 835, 753, 689, 598, 554, 430. 
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Λ-(S)-Ru2: A mixture of rac-Ru2 (109.4 mg, 0.11 mmol), the chiral auxiliary (S)-2ʹʹ (56.0 mg, 0.27 
mmol) and triethylamine (110.5 mg, 1.09 mmol) in CH2Cl2 (1.82 mL) was heated at 60 C for 20 h. 
The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was 
subjected to a flash silica gel chromatography (CH3CN /CH2Cl2= 1:600 to 1:200) to separate the first 
eluting diastereomer (orange solid, 29.5 mg, 0.03 mmol, 28%) which was assigned as Λ-(S)-Ru2. 
-(R)-Ru2: The catalyst -(R)-Ru2 was similarly synthesized with Λ-(S)-Ru2. A mixture of rac-Ru2 
(109.4 mg, 0.11 mmol), the chiral auxiliary (R)-2ʹʹ (56.0 mg, 0.27 mmol) and triethylamine (110.5 mg, 
1.09 mmol) in CH2Cl2 (1.82 mL) was heated at 60 C for 30 h. The reaction mixture was cooled to 
room temperature and concentrated to dryness. The residue was subjected to a flash silica gel 
chromatography (CH3CN /CH2Cl2= 1:600 to 1:200) to separate the first eluting diastereomer (orange 
solid, 40.9 mg, 0.04 mmol, 38%) which was assigned as -(R)-Ru2. 
1
H NMR (300 MHz, CD2Cl2) δ 8.36 (d, J = 4.5 Hz, 1H), 7.99–7.72 (m, 3H), 7.65 (t, J = 7.5 Hz, 1H), 
7.62–7.41 (m, 2H), 7.32 (dd, J = 31.3, 8.2 Hz, 2H), 7.01–6.98 (m, 1H), 6.89–6.68 (m, 6H), 6.47 (d, J = 
18.2 Hz, 2H), 6.30–6.28 (m, 1H), 6.04 (s, 1H), 4.23–4.14 (m, 2H), 3.96 (s, 1H), 2.27–2.10 (m, 12H), 
1.54 (s, 3H), 1.35 (s, 3H), 0.51 (d, J = 6.6 Hz, 3H), 0.22–0.04 (m, 1H), –0.07 (d, J = 6.3 Hz, 1H). 
13
C NMR (75 MHz, CD2Cl2) δ 154.3, 154.2, 150.9, 139.8, 137.7, 136.5, 136.4, 135.2, 135.1, 134.8, 
134.6, 134.0, 133.4, 130.6, 130.2, 129.8, 129.7, 129.5, 125.7, 125.2, 121.4, 121.2, 116.7, 115.8, 110.6, 
109.9, 75.0, 66.4, 30.5, 21.1, 21.0, 19.1, 18.7, 18.1, 18.0, 17.5, 13.6. 
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19
F NMR (282 MHz, CD2Cl2) δ 72.62, 75.14. 
Λ-(S)-Ru2: CD (MeOH): λ, nm (Δε, M-1cm-1) 396 (+25), 352 (6), 327 (+6), 303 (11), 280 (+19), 
260 (11), 232 (+70). 
-(R)-Ru2: CD (MeOH): λ, nm (Δε, M-1cm-1) 398 (15), 353 (+7), 328 (2), 302 (+12), 280 
(10), 258 (+11), 240 (9). 
IR (film): ν (cm1) 3171, 3138, 2962, 2921, 2867, 1607, 1536, 1479, 1445, 1414, 1379, 1321, 1280, 
1252, 1225, 1155, 1130, 1069, 925, 832, 762, 685, 553, 529, 453. 
HRMS (ESI, m/z) calcd for C46H48N7O2Ru [MPF6]
+
: 832.2918, found: 832.2922. 
 
To a suspension of Λ-(S)-Ru1 (27.2 mg, 0.023 mmol), -(R)-Ru1 (20.1 mg, 0.017 mmol), Λ-(S)-Ru2 
(33.0 mg, 0.034 mmol) or -(R)-Ru2 (40.9 mg, 0.042 mmol) in CH3CN (3 mL) was added TFA (10 eq) 
in one portion and stirred at room temperature for 0.5 h. The reaction mixture was evaporated to 
dryness, redissolved in CH3CN, followed by the addition of excess NH4PF6 (30 eq), and then stirred at 
room temperature for another 0.5 h. The mixture was filtered by a thin pad of silica gel, the pale 
yellow filtrate was concentrated, and then subjected to the column chromatography on silica gel 
(CH2Cl2/CH3CN = 100:1 to 5:1) to give the enantiopure catalyst Λ-Ru1 (25.6 mg, 0.021 mmol, 92% 
yield), -Ru1 (19.5 mg, 0.016 mmol, 95% yield), Λ-Ru2 (25.8 mg, 0.026 mmol, 76% yield) or -Ru2 
(37.1 mg, 0.037 mmol, 88% yield) as pale yellow solid. All other spectroscopic data of enantiopure 
ruthenium catalysts were in agreement with the racemic catalysts.  
CD (CH3OH) for Λ-Ru1: λ, nm (Δε, M
-1
cm
-1
) 346 (+11), 328 (+4), 307 (+38), 289 (–9), 268 (+76), 
239 (–73), 226 (–26), 207 (–76). 
CD (CH3OH) for -Ru1: λ, nm (Δε, M
-1
cm
-1
) 344 (–12), 329 (–5), 306 (–39), 290 (+11), 269 (–79), 
240 (+75), 225 (+25), 206 (+77). 
CD (CH3OH) for Λ-Ru2: λ, nm (Δε, M
-1
cm
-1
) 351 (+4), 312 (4), 283 (+23), 264 (21), 235 (+23), 
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218 (1). 
CD (MeOH) for -Ru2: λ, nm (Δε, M-1cm-1) 314 (+8), 283 (22), 264 (+32), 233 (15). 
5.4.2 Assignment of the absolute configuration of enantiopure ruthenium complexes 
High quality single crystals for X-ray diffraction were obtained by converting the single enantiomer 
-Ru2 into -Ru2-DPPE. 
 
-Ru2-DPPE was obtained by reacting -Ru2 (20.0 mg, 0.02 mmol) with 
1,2-bis(diphenylphosphino)ethane (DPPE) (79.7 mg, 0.2 mmol) at room temperature for 2 hours in 
CH2Cl2 (2.0 mL). The solution was then evaporated and the resulting solid was washed with Et2O and 
a pure pale yellow solid was obtained (24.4 mg, yield: 92%).
 
MP: 217219 °C (decomp.). 
1
H NMR (300 MHz, CD2Cl2) δ 8.09 (d, J = 2.2 Hz, 2H), 7.78 (d, J = 5.3 Hz, 2H), 7.62–7.45 (m, 4H), 
7.40 (t, J = 6.8 Hz, 4H), 7.31–7.23 (m, J = 7.4, 6.2 Hz, 8H), 7.13–6.94 (m, 6H), 6.63–6.49 (m, 6H), 
6.48–6.35 (m, 4H), 3.16–3.06 (m, 2H), 2.90–2.61 (m, 2H), 2.13 (s, 6H), 1.45 (s, 6H), 1.32 (s, 6H). 
13
C NMR (75 MHz, CD2Cl2) δ 188.5, 187.4, 154.7, 153.3, 140.8, 139.7, 135.0, 134.5, 134.4, 133.6, 
133.2, 132.9, 132.8, 132.7, 131.9, 130.9, 130.6, 130.43, 130.37, 130.31, 130.25, 130.19, 130.13, 
130.08, 129.87, 129.81, 129.76, 129.2, 128.7, 123.2, 118.4, 113.3, 28.0, 27.5, 20.9, 19.0, 18.4. 
19
F NMR (282 MHz, CD2Cl2) δ 72.12, 74.64. 
IR (film): ν (cm1) 2953, 2922, 2853, 1614, 1485, 1455, 1437, 1413, 1378, 1331, 1295, 1260, 1186, 
1174, 1089, 832, 770, 740, 696, 556, 520. 
Crystals of -Ru-DPPE were obtained from slow diffusion of Et2O into a solution of the complex in 
MeOH and CH2Cl2. The obtained crystal structure of -Ru-DPPE contains a -configuration at the 
ruthenium center. 
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5.4.3. Ruthenium-catalyzed alkynylation reactions 
 
General catalytic procedure: A dried 10 mL Schlenk tube was charged with the catalyst -Ru1 
(0.51.0 mol%) and the corresponding trifluoromethyl ketones (0.20 mmol, 1.0 eq). The tube was 
purged with nitrogen, THF (0.4 mL) and Et3N (5.6 µL, 0.2 eq) were added via syringe, and followed 
by the corresponding alkynes (3.0 eq). The tube was sealed and the reaction was stirred at 60 C for 16 
h under nitrogen atmosphere. The solvent was removed and the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:50) to afford the propargyl alcohols. Racemic 
samples were obtained by using rac-Ru1. The product (S)-26a was obtained by using -Ru1 as 
catalyst. The (S)-configuration of the product 26a was assigned by comparison with published optical 
rotation and chiral HPLC retention time data.
20 
All other products were assigned accordingly. Optical 
rotation of (S)-26a: []D
25
 = 24.2 (c 1.0, CH2Cl2, 99.1% ee).  Lit.
20
: []D
25
 = –25.5 (c 1.1, CHCl3, 
88% ee for S-configuration). Chiral HPLC with (S)-26a: (Daicel Chiralcel OJ-H column, 254 nm, 
hexane/isopropanol = 90:10, flow rate 0.8 mL/min, 25 C) tr (minor) = 14.8 min, tr (major) = 34.8 min. 
Lit.
s4
: tr (minor) = 16.9 min, tr (major) = 33.4 min. 
 
(S)-1,1,1-Trifluoro-2,4-diphenylbut-3-yn-2-ol (26a) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 
0.60 mmol) according to the general procedure to give 26a as a colorless oil (52.4 mg, 0.190 mmol, 
yield: 95%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess was established by HPLC analysis 
using a Chiralcel OJ-H column, ee = 99.2% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 9.5 min, tr (major) = 25.2 min). []D
25
 = 24.2 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.86–7.83 (m, 2H), 7.61–7.52 (m, 2H), 7.51–7.33 (m, 6H), 3.11 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 135.5, 132.2, 129.70, 129.68, 128.6, 128.4, 127.4, 127.3, 123.6 (q, J = 
284.0 Hz), 121.1, 88.3, 84.6, 73.6 (q, J = 32.3 Hz). 
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19
F NMR (282 MHz, CDCl3) δ 80.26. 
HRMS (ESI, m/z) calcd for C16H10F3 [M+H–H2O]
+
: 259.0729, found: 259.0728. 
All spectroscopic data are in agreement with the literature.
20
 
 
(S)-1,1,1-Trifluoro-2-phenyl-4-(p-tolyl)but-3-yn-2-ol (26b) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-ethynyl-4-methylbenzene 
(69.7 mg, 0.60 mmol) according to the general procedure to give 26b as a colorless oil (57.3 mg, 0.197 
mmol, yield: 99%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.2% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.5 min, tr (major) = 12.3 min). []D
25
 = –29.2 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.88–7.78 (m, 2H), 7.48–7.40 (m, 5H), 7.17 (d, J = 7.9 Hz, 2H), 3.06 (s, 
1H), 2.38 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 140.1, 135.6, 132.1, 129.6, 129.4, 128.4, 127.38, 127.37, 123.6 (q, J = 
284.0 Hz), 88.5, 84.0, 73.6 (q, J = 32.3 Hz), 21.7. 
19
F NMR (282 MHz, CDCl3) δ –80.20. 
HRMS (ESI, m/z) calcd for C17H12F3 [M+H–H2O]
+
: 273.0886, found: 273.0885. 
All spectroscopic data are in agreement with the literature.
21
 
 
(S)-1,1,1-Trifluoro-2-phenyl-4-(m-tolyl)but-3-yn-2-ol (26c) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-ethynyl-3-methylbenzene 
(69.7 mg, 0.60 mmol) according to the general procedure to give 26c as a colorless oil (57.4 mg, 0.197 
mmol, yield: 99%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.2% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
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85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.9 min, tr (major) = 11.6 min). []D
25
 = –29.0 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 8.03–7.65 (m, 2H), 7.49–7.38 (m, 3H), 7.37–7.30 (m, 2H), 7.24–7.17 
(m, 2H), 3.07 (s, 1H), 2.34 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 138.4, 135.5, 132.8, 130.6, 129.6, 129.3, 128.5, 128.4, 127.4, 123.6 (q, J 
= 284.0 Hz), 120.9, 88.5, 84.2, 73.6 (q, J = 32.3 Hz), 21.3. 
19
F NMR (282 MHz, CDCl3) δ –80.26. 
IR (film): ν (cm1) 3543, 3064, 3037, 2233, 1598, 1485, 1450, 1351, 1251, 1171, 1102, 1064, 1016, 
933, 903, 783, 762, 697, 626, 589, 524, 447. 
HRMS (ESI, m/z) calcd for C17H12F3 [M+H–H2O]
+
: 273.0886, found: 273.0884. 
All spectroscopic data are in agreement with the literature.
22 
 
(S)-1,1,1-Trifluoro-2-phenyl-4-(o-tolyl)but-3-yn-2-ol (26d) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-ethynyl-2-methylbenzene 
(69.7 mg, 0.60 mmol) according to the general procedure to give 26d as a colorless oil (56.4 mg, 0.197 
mmol, yield: 99%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.2% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.5 min, tr (major) = 8.9 min). []D
25
 = –21.6 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.97–7.73 (m, 2H), 7.56–7.37 (m, 4H), 7.35–7.09 (m, 3H), 3.06 (s, 1H), 
2.47 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 141.2, 135.5, 132.5, 129.8, 129.72, 129.66, 128.4, 127.39, 127.38, 125.9, 
123.6 (q, J = 284.0 Hz), 120.9, 88.4, 87.4, 73.7 (q, J = 32.3 Hz), 20.7. 
19
F NMR (282 MHz, CD3OD) δ –80.25. 
IR (film): ν (cm1) 3543, 3067, 2922, 2228, 1599, 1486, 1451, 1351, 1242, 1175, 1124, 1097, 1063, 
1007, 933, 905, 827, 759, 713, 666, 625, 599, 537, 501, 456, 429. 
HRMS (EI, m/z) calcd for C17H13F3O: 290.0919, found: 290.0913. 
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(S)-1,1,1-Trifluoro-4-(4-methoxyphenyl)-2-phenylbut-3-yn-2-ol (26e) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 
1-ethynyl-4-methoxybenzene (79.3 mg, 0.60 mmol) according to the general procedure to give 26e as 
a pale yellow solid (60.4 mg, 0.197 mmol, yield: 99%, Rf = 0.7, EtOAc/n-hexane = 1:10). MP: 64 C. 
Enantiomeric excess established by HPLC analysis using a Chiralcel OJ-H column, ee = 99.0% 
(HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 20.1 
min, tr (major) = 22.1 min). []D
25
 = –38.8 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 8.00–7.73 (m, 2H), 7.58–7.36 (m, 5H), 7.00–6.77 (m, 2H), 3.83 (s, 3H), 
3.10 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 160.7, 135.7, 133.8, 129.6, 128.4, 127.4, 123.6 (q, J = 283.5 Hz), 114.3, 
113.1, 88.4, 83.4, 73.6 (q, J = 32.3 Hz), 55.5. 
19
F NMR (282 MHz, CDCl3) δ –80.20. 
HRMS (ESI, m/z) calcd for C17H14F3O2 [M+H]
+
: 307.0940, found: 307.0940. 
All spectroscopic data are in agreement with the literature.
23
 
 
(S)-4-(4-Bromophenyl)-1,1,1-Trifluoro-2-phenylbut-3-yn-2-ol (26f) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-bromo-4-ethynylbenzene 
(108.6 mg, 0.60 mmol) according to the general procedure to give 26f as a pale yellow oil (53.2 mg, 
0.150 mmol, yield: 75%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by 
HPLC analysis using a Chiralcel OJ-H column, ee = 97.0% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C, tr (major) = 11.8 min, tr (minor) = 18.0 min). 
[]D
25
 = –30.4 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.81–7.78 (m, 2H), 7.55–7.48 (m, 2H), 7.47–7.36 (m, 5H), 3.05 (s, 1H). 
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13
C NMR (75 MHz, CDCl3) δ 135.2, 133.6, 132.0, 129.8, 128.5, 127.3, 124.2, 123.5 (q, J = 283.8 Hz), 
120.0, 87.2, 85.7, 73.6 (q, J = 32.5 Hz). 
19
F NMR (282 MHz, CDCl3) δ –80.22. 
HRMS (APCI, m/z) calcd for C16H9BrF3 [M+H–H2O]
+
: 338.9814, found: 338.9812. 
All spectroscopic data are in agreement with the literature.
20
 
 
(S)-1,1,1-Trifluoro-4-(2-fluorophenyl)-2-phenylbut-3-yn-2-ol (26g) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-ethynyl-2-fluorobenzene 
(72.1 mg, 0.60 mmol) according to the general procedure to give 26g as a colorless oil (38.8 mg, 0.132 
mmol, yield: 66%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.4% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.8 min, tr (major) = 17.2 min). []D
25
 = –17.6 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.87–7.75 (m, 2H), 7.68–7.33 (m, 5H), 7.23–7.03 (m, 2H), 3.11 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 165.1, 161.7, 135.2, 133.9, 131.6, 131.5, 129.2, 128.4, 127.4, 124.3, 
124.2, 123.5 (q, J = 283.8 Hz), 116.0, 115.7, 110.0, 109.8, 89.6, 81.9, 73.7 (q, J = 32.3 Hz), 35.70, 
35.66, 31.50. 
19
F NMR (282 MHz, CDCl3) δ –108.91, –80.22. 
IR (film): ν (cm1) 3555, 3450, 3068, 2238, 1958, 1609, 1574, 1490, 1449, 1352, 1251, 1176, 1116, 
1063, 1008, 935, 906, 838, 760, 717, 666, 625, 584, 549, 481, 436. 
HRMS (ESI, m/z) calcd for C16H9F4O [M–H]
+
:293.0584, found: 293.0582. 
 
(S)-1,1,1-Trifluoro-2-phenyl-4-(thiophen-2-yl)but-3-yn-2-ol (26h) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 3-ethynylthiophene (64.9 
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mg, 0.60 mmol) according to the general procedure to give 26h as a pale yellow oil (49.5 mg, 0.176 
mmol, yield: 88%, Rf = 0.5, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 96.2% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
60:40, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.5 min, tr (major) = 18.4 min). []D
25
 = –46.2 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.89–7.74 (m, 1H), 7.61 (dd, J = 3.0, 1.1 Hz, 1H), 7.50–7.41 (m, 3H), 
7.33–7.31 (m, 1H), 7.20 (dd, J = 5.0, 1.1 Hz, 1H), 3.06 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 135.4, 131.0, 130.0, 129.7, 128.4, 127.3, 127.3, 126.0, 123.5 (q, J = 
283.5 Hz), 120.2, 84.4, 83.6, 73.6 (q, J = 32.3 Hz), 35.7. 
19
F NMR (282 MHz, CDCl3) δ –80.22. 
IR (film): ν (cm1) 3543.3300, 3110, 2232, 1489, 1450, 1356, 1260, 1237, 1172, 1105, 1062, 1013, 
909, 869, 828, 785, 697, 625, 593, 518. 
HRMS (ESI, m/z) calcd for C14H8F3OS [M–H]
+
: 281.0242, found: 281.0252. 
All spectroscopic data are in agreement with the literature.
20
 
 
(S)-4-(Cyclohex-1-en-1-yl)-1,1,1-Trifluoro-2-phenylbut-3-yn-2-ol (26i)
 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and 1-ethynylcyclohex-1-ene 
(63.7 mg, 0.60 mmol) according to the general procedure to give 26i as a colorless oil (54.8 mg, 0.196 
mmol, yield: 98%, Rf = 0.5, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.2% (HPLC: OJ-H, 230 nm, hexane/isopropanol = 
95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 14.5 min, tr (major) = 15.4 min). []D
25
 = –15.6 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.85–7.71 (m, 2H), 7.49–7.35 (m, 3H), 6.37–6.26 (m, 1H), 2.98 (s, 1H), 
2.28–2.06 (m, 4H), 1.78–1.55 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 138.1, 135.8, 129.5, 128.3, 127.4, 123.6 (q, J = 283.7 Hz), 119.3, 90.1, 
82.0, 73.4 (q, J = 32.3 Hz), 28.8, 25.8, 22.2, 21.4. 
19
F NMR (282 MHz, CDCl3) δ –80.98. 
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HRMS (ESI, m/z) calcd for C16H14F3O [M–H]
+
: 279.0991, found: 279.1007. 
All spectroscopic data are in agreement with the literature.
20 
 
(S)-4-Cyclohexyl-1,1,1-trifluoro-2-phenylbut-3-yn-2-ol (26j) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and ethynylcyclohexane (64.9 
mg, 0.60 mmol) according to the general procedure to give 26j as a colorless oil (54.1 mg, 0.192 
mmol, yield: 96%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H 
column, ee = 99.2% (HPLC: AD-H, 210 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, 
tr (minor) = 6.7 min, tr (major) = 9.5 min). []D
25
 = –5.4 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.89–7.67 (m, 2H), 7.55–7.33 (m, 3H), 2.89 (s, 1H), 2.70–2.42 (m, 1H), 
1.89–1.69 (m, 4H), 1.60–1.31 (m, 6H). 
13
C NMR (75 MHz, CDCl3) δ 136.0, 129.4, 128.2, 127.4, 123.6 (q, J = 283.5 Hz), 93.7, 76.5, 73.0 (q, 
J = 32.0 Hz), 32.18, 32.16, 29.0, 25.9, 24.7. 
19
F NMR (282 MHz, CDCl3) δ –80.73. 
HRMS (FD, m/z) calcd for C16H17F3O [M]
+
: 282.1231, found: 282.1148. 
All spectroscopic data are in agreement with the literature.
20
 
 
(S)-4-Cyclopropyl-1,1,1-trifluoro-2-phenylbut-3-yn-2-ol (26k) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and cyclopropylacetylene (39.7 
mg, 0.60 mmol) according to the general procedure to give 26k as a colorless oil (46.4 mg, 0.193 
mmol, yield: 97%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 97.0% (HPLC: OJ-H, 220 nm, hexane/isopropanol = 
90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 15.7 min, tr (major) = 18.1 min). []D
25
 = –42.2 (c 
1.0, CH2Cl2). 
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1
H NMR (300 MHz, CDCl3) δ 7.88–7.61 (m, 2H), 7.47–7.33 (m, 3H), 2.88 (s, 1H), 1.48–1.23 (m, 1H), 
1.07–0.70 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 135.9, 129.4, 128.2, 127.3, 123.5(q, J = 283.5 Hz), 92.8, 73.0 (q, J = 
32.0 Hz), 71.3, 8.63, 8.60, –0.50. 
19
F NMR (282 MHz, CDCl3) δ –80.49. 
HRMS (FD, m/z) calcd for C13H11F3O [M]
+
: 240.0762, found: 240.0755. 
All spectroscopic data are in agreement with the literature.
21 
 
(S)-1,1,1-Trifluoro-2-phenyloct-3-yn-2-ol (26l) 
 
Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and hex-1-yne (49.3 mg, 0.60 
mmol) according to the general procedure to give 26l as a colorless oil (50.4 mg, 0.196 mmol, yield: 
98%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC analysis using a 
Chiralcel OJ-H column, ee = 99.0% (HPLC: OJ-H, 220 nm, hexane/isopropanol = 90:10, flow rate 1.0 
mL/min, 25 C, tr (minor) = 7.6 min, tr (major) = 9.3 min). []D
25
 = –3.6° (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.80–7.67 (m, 2H), 7.57–7.34 (m, 3H), 2.90 (s, 1H), 2.34 (t, J = 7.0 Hz, 
2H), 1.67–1.53 (m, 2H), 1.53–1.39 (m, 2H), 0.98–0.93 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 135.9, 129.4, 128.2, 127.3, 123.6 (q, J = 283.5 Hz), 89.9, 76.4, 73.1 (q, 
J = 32.3 Hz), 30.3, 22.1, 18.5, 13.6. 
19
F NMR (282 MHz, CDCl3) δ –80.66. 
IR (film): ν (cm1) 3478, 3068, 2960, 2933, 2869, 2243, 1453, 1352, 1259, 1166, 1035, 994, 936, 906, 
841, 761, 725, 697, 667, 625. 
HRMS (APCI, m/z) calcd for C14H14F3 [M+H–H2O]
+
: 239.1042, found: 239.1039. 
All spectroscopic data are in agreement with the literature.
21 
 
 
 
 
(S)-1,1,1-Trifluoro-2-phenyl-4-(trimethylsilyl)but-3-yn-2-ol (26m) 
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Starting from 2,2,2-trifluoro-1-phenylethanone (34.8 mg, 0.20 mmol) and ethynyltrimethylsilane (58.9 
mg, 0.60 mmol) according to the general procedure to give 26m as a colorless oil (42.1 mg, 0.155 
mmol, yield: 77%, Rf = 0.5, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.6% (HPLC: OJ-H, 210 nm, hexane/isopropanol = 
95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 5.3 min, tr (minor) = 10.7 min). []D
25
 = –20.8 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.76–7.72 (m, 2H), 7.49–7.36 (m, 3H), 2.96 (s, 1H), 0.25 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 135.2, 129.6, 128.3, 127.3, 123.3 (q, J = 283.5 Hz)100.3, 94.5, 73.2 (q, 
J = 32.3 Hz), –0.36. 
19
F NMR (282 MHz, CDCl3) δ –80.39. 
IR (film): ν (cm1) 3471, 2963, 1492, 1452, 1347, 1253, 1175, 1129, 1068, 1015, 933, 906, 845, 761, 
697, 627, 498, 451. 
 
(S)-1,1,1-Trifluoro-4-phenyl-2-(p-tolyl)but-3-yn-2-ol (26n) 
 
Starting from 2,2,2-trifluoro-1-(p-tolyl)ethanone (37.6 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 
0.60 mmol) according to the general procedure to give 26n as a colorless oil (53.8 mg, 0.185 mmol, 
yield: 93%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC analysis 
using a Chiralcel OJ-H column, ee = 98.0% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 8.4 min, tr (major) = 17.1 min). []D
25
 = –29.0 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 2H), 7.58–7.54 (m, 2H), 7.46–7.33 (m, 3H), 
7.32–7.22 (m, 2H), 3.10 (s, 1H), 2.41 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 139.7, 132.6, 132.2, 129.3, 129.1, 128.6, 127.2, 123.6 (q, J = 283.8 Hz), 
121.2, 88.1, 84.8, 73.5 (q, J = 32.3 Hz), 21.3. 
19
F NMR (282 MHz, CDCl3) δ –80.35. 
HRMS (EI, m/z) calcd for C17H13F3O [M]
+
: 290.0918, found: 290.0925. 
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All spectroscopic data are in agreement with the literature.
20
 
 
(S)-1,1,1-Trifluoro-4-phenyl-2-(m-tolyl)but-3-yn-2-ol (26o)
 
 
Starting from 2,2,2-trifluoro-1-(m-tolyl)ethanone (37.6 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 
0.60 mmol) according to the general procedure to give 26o as a colorless oil (55.9 mg, 0.193 mmol, 
yield: 96%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC analysis 
using a Chiralcel OJ-H column, ee = 99.4% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 7.0 min, tr (major) = 26.4 min). []D
25
 = –14.8 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.71–7.59 (m, 2H), 7.61–7.52 (m, 2H), 7.47–7.30 (m, 4H), 7.29–7.22 
(m, 1H), 3.11 (s, 1H), 2.43 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 138.2, 135.4, 132.2, 130.4, 129.7, 128.6, 128.3, 127.8, 123.6 (q, J = 
283.8 Hz), 124.5, 121.2, 88.1, 84.8, 73.5 (q, J = 32.3 Hz), 21.7. 
19
F NMR (282 MHz, CDCl3) δ –80.74. 
IR (film): ν (cm1) 3543, 3470, 2923, 2861, 2232, 1603, 1488, 1445, 1351, 1242, 1181, 1150, 1110, 
1079, 1023, 950, 913, 835, 783, 756, 727, 691, 629, 587, 557, 527, 438. 
HRMS (FD, m/z) calcd for C17H13F3O [M]
+
: 290.0918, found: 290.0912. 
All spectroscopic data are in agreement with the literature.
24
 
 
(R)-1,1,1-Trifluoro-4-phenyl-2-(o-tolyl)but-3-yn-2-ol (26p)
 
 
Starting from 2,2,2-trifluoro-1-(o-tolyl)ethanone (37.6 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 
0.60 mmol) according to the general procedure to give 26p as a colorless oil (15.8 mg, 0.054 mmol, 
yield: 27%, Rf = 0.5, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC analysis 
using a Chiralcel OJ-H column, ee = 90.6% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 85:15, flow 
rate 1.0 mL/min, 25 C, tr (minor) = 7.7 min, tr (major) = 9.1 min). []D
25
 = –33.6 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.86 (d, J = 7.6 Hz, 1H), 7.58–7.48 (m, 2H), 7.45–7.20 (m, 6H), 3.05 (s, 
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1H), 2.70 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 138.0, 132.9, 132.7, 132.0, 129.7, 129.5, 128.8, 128.6, 125.9, 124.2 (q, J 
= 285.0 Hz), 121.3, 88.8, 85.2, 74.2 (q, J = 32.8 Hz), 21.9 (q, J = 2.5 Hz). 
19
F NMR (282 MHz, CDCl3) δ –79.03. 
IR (film): ν (cm1) 3544, 3063, 2931, 2229, 1599, 1488, 1448, 1350, 1242, 1174, 1124, 1083, 1051, 
1002, 916, 757, 730, 690, 657, 629, 585, 555, 524, 456. 
HRMS (ESI, m/z) calcd for C17H13F3O [M]
+
: 290.0918, found: 290.0901. 
All spectroscopic data are in agreement with the literature.
24 
 
(S)-1,1,1-Trifluoro-2-(4-methoxyphenyl)-4-phenylbut-3-yn-2-ol (26q). 
 
Starting from 2,2,2-trifluoro-1-(4-methoxyphenyl)ethanone (40.8 mg, 0.20 mmol) and 
phenylacetylene (61.3 mg, 0.60 mmol) according to the general procedure to give 26q as a colorless 
oil (55.1 mg, 0.180 mmol, yield: 90%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess 
established by HPLC analysis using a Chiralcel OJ-H column, ee = 98.8% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 13.3 min, tr (major) = 34.5 min). 
[]D
25
 = –24.6 (c 1.0, CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.6 Hz, 2H), 7.59–7.49 (m, 2H), 7.46–7.31 (m, 3H), 
7.03–6.91 (m, 2H), 3.84 (s, 3H), 3.14 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 160.7, 132.2, 129.6, 128.7, 128.6, 127.6, 123.6 (q, J = 283.5 Hz), 121.2, 
113.8, 88.1, 84.8, 73.3 (q, J = 32.3 Hz), 55.5. 
19
F NMR (282 MHz, CDCl3) δ –80.47. 
HRMS (FD, m/z) calcd for C17H13F3O2 [M]
+
: 306.0868, found: 306.0883. 
All spectroscopic data are in agreement with the literature.
20 
 
(S)-2-(4-Bromophenyl)-1,1,1-Trifluoro-4-phenylbut-3-yn-2-ol (26r) 
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Starting from 1-(4-bromophenyl)-2,2,2-trifluoroethanone (50.6 mg, 0.20 mmol) and phenyl-acetylene 
(61.3 mg, 0.60 mmol) according to the general procedure to give 26r as a colorless oil (70.2 mg, 0.198 
mmol, yield: 99%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.0% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.6 min, tr (major) = 8.1 min). []D
25
 = –15.2 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.4 Hz, 2H), 7.62–7.50 (m, 4H), 7.47–7.33 (m, 3H), 3.14 (s, 
1H). 
13
C NMR (75 MHz, CDCl3) δ 134.5, 132.2, 131.6, 129.9, 129.1, 128.7, 124.2, 123.3 (q, J = 284.0 Hz) 
120.8, 88.6, 84.0, 73.2 (q, J = 32.5 Hz). 
19
F NMR (282 MHz, CDCl3) δ –80.39. 
HRMS (FD, m/z) calcd for C16H10BrF3O [M]
+
: 353.9867, found: 353.9852. 
All spectroscopic data are in agreement with the literature.
20 
 
(S)-2-(3-Bromophenyl)-1,1,1-Trifluoro-4-phenylbut-3-yn-2-ol (26s) 
 
Starting from 1-(3-bromophenyl)-2,2,2-trifluoroethanone (50.6 mg, 0.20 mmol) and phenylacetylene 
(61.3 mg, 0.60 mmol) according to the general procedure to give 26s as a colorless oil (70.1 mg, 0.198 
mmol, yield: 99%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 98.8% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 5.9 min, tr (major) = 8.1 min). []D
25
 = –53.2 (c 1.0, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.85–7.71 (m, 1H), 7.62–7.50 (m, 3H), 7.49–7.27 (m, 4H), 
3.13 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 137.6, 132.8, 132.3, 130.5, 130.5, 129.9, 128.7, 126.1, 123.3 (q, J = 
284.0 Hz), 122.5, 120.8, 88.8, 83.9, 73.0 (q, J = 32.5 Hz). 
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19
F NMR (282 MHz, CDCl3) δ –80.22. 
HRMS (FD, m/z) calcd for C16H10BrF3O [M]
+
: 353.9867, found: 353.9848. 
All spectroscopic data are in agreement with the literature.
20
 
 
(S)-1,1,1-Trifluoro-4-phenyl-2-(4-(trifluoromethyl)phenyl)but-3-yn-2-ol (26t) 
 
Starting from 2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethanone (48.4 mg, 0.20 mmol) and 
phenylacetylene (61.3 mg, 0.60 mmol) according to the general procedure to give 26t as a colorless oil 
(68.5 mg, 0.199 mmol, yield: 99%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess 
established by HPLC analysis using a Chiralpak IG column, ee = 98.8% (HPLC: IG, 254 nm, 
hexane/isopropanol = 99:1, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.7 min, tr (major) = 12.4 min). 
[]D
25
 = –10.8 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.63–7.50 (m, 2H), 
7.48–7.33 (m, 3H), 3.21 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 139.3, 132.3, 131.9 (q, J = 32.5 Hz), 130.0, 128.7, 128.0, 127.9, 125.4 
(q, J = 3.8 Hz), 124.0 (q, J = 270.5 Hz), 123.0 (q, J = 284.0 Hz), 121.4, 88.9, 83.8, 73.2 (q, J = 32.5 
Hz). 
19
F NMR (282 MHz, CD3OD) δ –80.24, –62.85. 
IR (film): ν (cm1) 3601, 3064, 2233, 1619, 1490, 1414, 1323, 1245, 1167, 1128, 1071, 1010, 921, 840, 
800, 756, 721, 688, 631, 595, 529, 457, 408. 
HRMS (FD, m/z) calcd for C17H10F6O [M]
+
: 344.0636, found: 344.0622. 
 
(S)-1,1,1-Trifluoro-2-(naphthalen-2-yl)-4-phenylbut-3-yn-2-ol (26u) 
 
Starting from 2,2,2-trifluoro-1-(naphthalen-1-yl)ethanone (44.8 mg, 0.20 mmol) and phenylacetylene 
(61.3 mg, 0.60 mmol) according to the general procedure to give 26u as a white solid (62.5 mg, 0.192 
mmol, yield: 96%, Rf = 0.2, EtOAc/n-hexane = 1:10). MP: 59 C. Enantiomeric excess established by 
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HPLC analysis using a Chiralcel OJ-H column, ee = 98.8% (HPLC: OJ-H, 254 nm, 
hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 11.0 min, tr (major) = 22.5 min). 
[]D
25
 = –19.2 (c 1.0, CH2Cl2). 
1
H NMR (300 MHz, CDCl3) δ 8.35 (s, 1H), 8.06–7.80 (m, 4H), 7.72–7.49 (m, 4H), 7.48–7.31 (m, 3H), 
3.25 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 133.8, 132.9, 132.8, 132.3, 129.8, 128.8, 128.7, 128.2, 127.8, 127.21, 
127.16, 126.6, 124.4, 123.7 (q, J =283.8 Hz), 121.1, 88.5, 84.7, 73.7 (q, J =32.3 Hz).  
19
F NMR (282 
MHz, CDCl3) δ –79.90. 
HRMS (FD, m/z) calcd for C20H13F3O [M]
+
: 326.0918, found: 326.0915. 
All spectroscopic data are in agreement with the literature.
21
 
 
(S)-1,5-Diphenyl-3-(trifluoromethyl)pent-1-yn-3-ol (26v) 
 
Starting from 1,1,1-trifluoro-4-phenylbutan-2-one (40.4 mg, 0.20 mmol) and phenylacetylene (61.3 
mg, 0.60 mmol) according to the general procedure to give 26v as a colorless oil (26.8 mg, 0.088 
mmol, yield: 44%, Rf = 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 62.4% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
85:15, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.2 min, tr (major) = 9.1 min). []D
25
 = 26.6 (c 1.0, 
CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.56–7.47 (m, 2H), 7.43–7.19 (m, 8H), 3.11–2.96 (m, 2H), 2.65 (s, 1H), 
2.33–2.14 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 141.0, 132.2, 129.6, 128.7, 128.63, 128.61, 126.4, 124.2 (q, J =283.5 
Hz), 121.2, 88.1, 83.5, 72.4 (q, J =31.5 Hz), 36.8, 30.0. 
19
F NMR (282 MHz, CDCl3) δ –81.53. 
HRMS (FD, m/z) calcd for C18H15F3O [M]
+
:304.1075, found: 304.1070. 
All spectroscopic data were in agreement with the literature.
24
 
 
(R)-Ethyl 2-hydroxy-4-phenyl-2-(trifluoromethyl)but-3-ynoate (26w) 
Chapter 5: Experimental Part 
128 
 
 
Starting from ethyl trifluoropyruvate (34.0 mg, 0.20 mmol) and phenylacetylene (61.3 mg, 0.60 mmol) 
according to the general procedure to give 26w as a colorless oil (37.9 mg, 0.139 mmol, yield: 70%, Rf 
= 0.3, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC analysis using a Chiralcel 
OJ-H column, ee = 6.8% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 
25 C, tr (minor) = 8.1 min, tr (major) = 9.5 min). 
1
H NMR (300 MHz, CDCl3) δ 7.60–7.46 (m, 2H), 7.47–7.27 (m, 3H), 4.58–4.37 (m, 2H), 4.28 (s, 1H), 
1.40 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 166.7, 132.3, 129.8, 128.5, 121.9 (q, J =284.5 Hz), 120.8, 87.4, 79.9, 
71.9 (q, J =34.0 Hz), 65.2, 14.0. 
19
F NMR (282 MHz, CDCl3) δ –78.19. 
All spectroscopic data are in agreement with the literature.
25
 
 
(S)-1-Chloro-1,1-difluoro-2,4-diphenylbut-3-yn-2-ol (26x) 
 
Starting from 2-chloro-2,2-difluoro-1-phenylethanone (38.1 mg, 0.20 mmol) and phenylacetylene 
(61.3 mg, 0.60 mmol) according to the general procedure to give 26x as a colorless oil (57.7 mg, 0.176 
mmol, yield: 99%, Rf = 0.4, EtOAc/n-hexane = 1:10). Enantiomeric excess established by HPLC 
analysis using a Chiralcel OJ-H column, ee = 99.4% (HPLC: OJ-H, 254 nm, hexane/isopropanol = 
60:40, flow rate 1.0 mL/min, 25 C, tr (minor) = 6.9 min, tr (major) = 16.0 min). []D
25
 = –26.8 (c 1.0, 
CH2Cl2).  
1
H NMR (300 MHz, CDCl3) δ 7.88–7.85 (m, 2H), 7.61–7.52 (m, 2H), 7.51–7.33 (m, 6H), 3.30 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 135.6, 132.2, 129.7, 129.6 (t, J = 300.0 Hz), 129.2, 128.6, 128.2, 127.9, 
121.2, 88.5, 85.6, 77.4(t, J = 27.7 Hz).  
19
F NMR (282 MHz, CDCl3) δ –63.85, –64.41, –65.52, –66.08.   
HRMS (FD, m/z) calcd for C16H11ClF2O [M]
+
: 292.0466, found: 292.0450.  
All spectroscopic data are in agreement with the literature.
20 
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Procedure for the synthesis of (S)-28a 
 
A dried 10 mL Schlenk tube was charged with the catalyst -Ru2 (3.0 mg, 3 mol%) and 
1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone 27a (22.4 mg, 0.20 mmol). The tube was purged 
with nitrogen, THF (0.2 mL) and Et3N (2.8 µL, 0.2 eq) were added via syringe, and followed by 
cyclopropylacetylene (84.7 µL, 10.0 eq). The vial was sealed and the reaction was stirred at 60 C for 
48 hours under nitrogen atmosphere. The solvent was removed and the residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:50) to afford 7.1 mg (25% yield, Rf = 0.2, 
EtOAc/n-hexane = 1:5) of 27a as a light yellow solid. Racemic sample was obtained by using rac-Ru2. 
The (S)-configuration of the product (S)-28a was obtained by using -Ru2 as catalyst. The 
(S)-configuration of the product 28a was assigned by comparison with published chiral HPLC 
retention time data. Chiral HPLC with (S)-28a: (Daicel Chiralpak AD-H column, 254 nm, 
hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C) tr (major) = 7.3 min, tr (minor) = 11.9 min. 
Lit.
26
: tr (major) = 6.8 min, tr (minor) = 11.1 min. Optical rotation of (S)-28a: []D
22
 = 53.6 (c 0.5, 
CH2Cl2, 99.0% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 2.4 Hz, 1H), 7.12 (dd, J = 8.6, 2.5 Hz, 1H), 6.62 (d, J = 8.6 
Hz, 1H), 4.44 (s, 3H), 1.43–1.34 (m, 1H), 0.99–0.76 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 143.8, 130.5, 130.3, 124.2 (q, J =285.0 Hz), 123.7, 120.8, 120.7, 93.9, 
74.9 (q, J =33.0 Hz), 70.6, 8.7, 8.6, –0.5. 
19
F NMR (282 MHz, CDCl3) δ –80.82. 
All other spectroscopic data are in agreement with the literature.
26 
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Procedure for the synthesis of (S)-28b 
 
A dried 10 mL Schlenk tube was charged with 1-(5-chloro-2-nitrophenyl)-2,2,2-trifluoroethanone 27b 
(50.6 mg, 0.20 mmol). The tube was purged with nitrogen, 0.4 mL of -Ru2 in THF (1.0 mg/mL) and 
Et3N (5.6 µL, 0.2 eq) were added via syringe, and followed by cyclopropylacetylene (50.9 µL, 3.0 eq). 
The vial was sealed and the reaction was stirred at 60 C for 16 hours under nitrogen atmosphere. The 
solvent was removed and the residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:50) to afford 60.6 mg (95% yield, Rf = 0.3, EtOAc/n-hexane = 1:5) of (S)-28b as a 
light-yellow oil. Racemic sample was obtained by using rac-Ru2. The (S)-configuration of the product 
(S)-28b was obtained by using -Ru2 as catalyst. The (S)-configuration of the product (S)-28b was 
assigned by comparison with published rotation data. []D
22
 = 26.0 (c 1.0, CH2Cl2, 99.4% ee).  
Lit.
27
: []D
25
 = –22.0 (c 0.38, CHCl3, 93% ee for S-configuration).Enantiomeric excess established by 
HPLC analysis using a Chiralpak OD-H column, ee = 99.4% (HPLC: OD-H, 220 nm, 
hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 7.9 min, tr (major) = 8.8 min). 
1
H NMR (300 MHz, CDCl3) δ 7.80 (s, 1H), 7.53–7.41 (m, 2H), 3.63 (s, 1H), 1.40–1.14 (m, 1H), 
0.95–0.75 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 148.7, 137.1, 130.5, 130.1 (q, J = 2.2 Hz), 129.8, 125.6, 122.7 (q, J = 
284.8 Hz), 94.5, 71.8 (q, J = 33.8 Hz), 68.6, 8.4, –0.8. 
19
F NMR (282 MHz, CDCl3) δ –78.28.  
All other spectroscopic data are in agreement with the literature.
 27 
 
Large-scale reaction for (S)-28b: A dried 25 mL Schlenk tube was charged with the catalyst -Ru2 
(10 mg, 0.2 mol%) and 1-(5-chloro-2-nitrophenyl)-2,2,2-trifluoroethanone 27b (1.268 g, 5.0 mmol). 
The tube was purged with nitrogen, 10 mL THF and Et3N (138.6 µL, 0.2 eq) were added via syringe, 
and followed by cyclopropylacetylene (1.27 mL, 3.0 eq). The vial was sealed and the reaction was 
stirred at 60 C for 16 hours under nitrogen atmosphere. The solvent was removed and the residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 1:50) to afford 1.555 g (97% yield) of 
Chapter 5: Experimental Part 
131 
 
(S)-28b as a light-yellow oil. 
 
Procedure for the synthesis of (S)-28c 
 
A dried 10 mL Schlenk tube was charged with 1-(2,5-dichlorophenyl)-2,2,2-trifluoroethanone 27c 
(48.6 mg, 0.20 mmol). The tube was purged with nitrogen, 0.4 mL of -Ru2 in THF (1.0 mg/mL) and 
Et3N (5.6 µL, 0.2 eq) were added via syringe, and followed by cyclopropylacetylene (50.9 µL, 3.0 eq). 
The vial was sealed and the reaction was stirred at room temperature for 16 hours under nitrogen 
atmosphere. The solvent was removed and the residue was purified by flash chromatography on silica 
gel (EtOAc/hexane = 1:50) to afford 58.5 mg (95% yield, Rf = 0.5, EtOAc/n-hexane = 1:10) of (S)-28c 
as a colourless oil. Racemic sample was obtained by using rac-Ru2. The (S)-configuration of the 
product (S)-28c was obtained by using -Ru2 as catalyst. The (S)-configuration of the product 28c 
was assigned by comparison with published rotation data. []D
22
 = +1.4 (c 1.0, CH2Cl2, 95.0% ee). 
Lit.
27
: []D
25
 = +4.87 (c 1.39, CHCl3, 91% ee for S-configuration). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 95.0% (HPLC: AD-H, 220 nm, 
hexane/isopropanol = 98:2, flow rate 1.0 mL/min, 25 C, tr (major) = 11.2 min, tr (minor) = 14.0 min). 
1
H NMR (300 MHz, CDCl3) δ 7.88 (d, J = 2.4 Hz, 1H), 7.39–7.26 (m, 2H), 3.42 (s, 1H), 1.40–1.31 (m, 
1H), 0.98–0.70 (m, 4H). 
13
C NMR (75 MHz, CDCl3) δ 134.0, 132.87, 132.85, 131.3, 130.4, 130.1, 123.3 (q, J = 285.0 Hz), 
94.1, 71.9 (q, J = 33.5 Hz), 69.3, 8.2 (d, J = 5.3 Hz), –0.54. 
19
F NMR (282 MHz, CDCl3) δ –78.60.  
All other spectroscopic data are in agreement with the literature.
27 
 
Large-scale reaction for (S)-28c: A dried 25 mL Schlenk tube was charged with the catalyst -Ru2 
(8.0 mg, 0.2 mol%) and 1-(2,5-dichlorophenyl)-2,2,2-trifluoroethanone 27c (972.0 mg, 4.0 mmol). 
The tube was purged with nitrogen, 8 mL THF and Et3N (110.9 µL, 0.2 eq) were added via syringe, 
and followed by cyclopropylacetylene (1.02 mL, 3.0 eq). The vial was sealed and the reaction was 
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stirred at room temperature for 16 hours under nitrogen atmosphere. The solvent was removed and the 
residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:50) to afford 1.224 g 
(99% yield) of (S)-28c as a colorless oil. 
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Chapter 6: Appendices 
6.1 List of Abbreviations 
1
H NMR proton nuclear magnetic resonance spectroscopy 
13
C NMR carbon nuclear magnetic resonance spectroscopy 
19
F NMR fluorine nuclear magnetic resonance spectroscopy 
δ
 
chemical shift 
J coupling constant 
br broad 
s singlet 
d doublet 
t triplet 
q quartet 
m multiplet 
ppm parts per million 
AcOH acetic acid 
aq aqueous 
Ar argon 
bpy 2,2 -´bipyridine 
CD circular dichroism 
CH2Cl2 dichloromethane 
CD2Cl2 dideuteromethylenechloride 
CHCl3 chloroform 
CDCl3 deuterochloroform 
CH3CN/ MeCN acetonitrile 
conc concentrated 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
ee enantiomeric excesses 
e.g. exempli gratia (lat.: for example) 
et al. et alii (lat.: and others) 
ESI electrospray ionization 
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EtOH ethanol 
Et2O diethyl ether 
Et3N triethyl amine 
EtOAc ethyl acetate 
EWG electron withdrawing group 
h hour(s) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IR spectra infrared spectra 
Ir iridium 
L liter(s) 
M mol/liter 
m meta- 
min minute(s) 
mL milliliter(s) 
mmol millimole 
MS mass spectroscopy 
N2 nitrogen 
Nu nucleophile 
Ph phenyl 
ppy 2-phenylpyridine 
rac racemic 
Rh rhodium 
rt room temperature 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TPP tetraphenylporphine 
UV ultraviolet 
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6.6 List of Spectra of Complexes 
6.6.1 NMR spectra of enantiopure metal complexes 
 
Figure 59 
1
H NMR and 
13
C NMR spectra of rac-Ir(Se). 
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Figure 60 
1
H NMR and 
13
C NMR spectra of rac-Rh(Se). 
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Figure 61 
1
H NMR and 
13
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Figure 62 
1
H NMR and 
13
C NMR spectra of iridium auxiliary complex -(S)-3. 
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Figure 63 
1
H NMR and 
13
C NMR spectra of rhodium auxiliary complex -(R)-4.
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Figure 64 
1
H NMR and 
13
C NMR spectrum of rhodium auxiliary complex -(R)-4. 
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Figure 65 
1
H NMR and 
13
C NMR spectra of -2Rh. 
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Figure 66 
1
H NMR and 
13
C NMR spectra of -2Rh. 
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Figure 67 
1
H NMR and 
13
C NMR spectra of -2Ir. 
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Figure 68 
1
H NMR and 
13
C NMR spectra of -2Ir. 
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Figure 69 
1
H NMR and 
13
C NMR spectra of -RhPP. 
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Figure 70 
1
H NMR and 
13
C NMR spectra of -RhPP. 
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Figure 71 
1
H NMR and 
13
C NMR spectra of -IrPP. 
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Figure 72 
1
H NMR and 
13
C NMR spectra of -IrPP. 
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Figure 73 
1
H NMR and 
13
C NMR spectra of rac-Ru1. 
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Figure 74 
1
H NMR and 
13
C NMR spectra of rac-Ru2. 
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Figure 75 
1
H NMR and 
13
C NMR spectra of -(S)-Ru1. 
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Figure 76 
1
H NMR and 
13
C NMR spectra of -(S)-Ru2. 
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Figure 77 
1
H NMR and 
13
C NMR spectra of -Ru2-DPPE. 
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6.6.2 CD spectra of enantiopure metal complexes 
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Figure 78 CD spectra of complexes Λ-(S)-3 and -(S)-3 recorded in CH3OH (0.2 mM). 
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Figure 79 CD spectra of complexes Λ-Ir(Se) and -Ir(Se) recorded in CH3OH (0.2 mM). 
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Figure 80 CD spectra of complexes Λ-(R)-4 and -(R)-4 recorded in CH3OH/CH2Cl2 = 4:1 (0.2 mM). 
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Figure 81 CD spectra of complexes Λ-Rh(Se) and -Rh(Se) recorded in CH3OH (0.2 mM). 
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Figure 82 CD spectra of complexes ΛΛ-2Rh and -2Rh recorded in CH3OH (0.2 mM). 
 
Figure 83 CD spectra of complexes ΛΛ-2Ir and -2Ir recorded in CH3OH (0.2 mM). 
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Figure 84 CD spectra of complexes Λ-RhPP and -RhPP recorded in CH3OH (0.2 mM). 
 
Figure 85 CD spectra of complexes Λ-IrPP and -IrPP recorded in CH3OH (0.2 mM). 
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Figure 86 CD spectra of complexes -(S)-Ru1 and -(R)-Ru1 recorded in CH3OH (0.2 mM). 
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Figure 87 CD spectra of complexes -Ru1 and -Ru1 recorded in CH3OH (0.2 mM). 
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Figure 88 CD spectra of complexes -(S)-Ru2 and -(R)-Ru2 recorded in CH3OH (0.2 mM). 
200 300 400 500 600
-40
-30
-20
-10
0
10
20
30
40
50
 ?

 
(M
-1
c
m
-1
)
(nm)
 -Ru2
 -Ru2
 
Figure 89 CD spectra of complexes -Ru2 and -Ru2 recorded in CH3OH (0.2 mM). 
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6.6.3 HPLC spectra of compounds 
 
 
Figure 90 HPLC traces for the racemic reference complex Δ/Λ-Ru1 and Λ-Ru1. HPLC conditions: 
HPLC column on an Agilent 1200 Series HPLC System. The column temperature was 25 °C and 
UV-absorption was measured at 254 nm. Solvent A = 0.1% TFA, solvent B = MeCN (Daicel Chiralpak 
IB (250 × 4.6 mm), with a linear gradient of 35% to 45% B in 180 min, flow rate = 0. 6 mL/min). HPLC 
trace for the complex Integration of peak areas > 100:1 e.r. 
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Figure 91 HPLC traces (Daicel Chiralpak AD-H column) of rac-20a (reference) and (R)-20a. Area 
integration = 97.5:2.4 (95.1% ee). 
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Figure 92 HPLC traces (Daicel Chiralpak AD-H column) of rac-20b (reference) and (R)-20b. Area 
integration = 98.5:1.5 (97.0% ee). 
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Figure 93 HPLC traces (Daicel Chiralpak AD-H column) of rac-20c (reference) and (R)-20c. Area 
integration = 99.8:0.2 (99.6% ee). 
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Figure 94 HPLC traces (Daicel Chiralpak AD-H column) of rac-20d (reference) and (R)-20d. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 95 HPLC traces (Daicel Chiralpak AD-H column) of rac-20e (reference) and (R)-20e. Area 
integration > 99 (> 99% ee). 
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Figure 96 HPLC traces (Daicel Chiralpak AD-H column) of rac-20f (reference) and (R)-20f. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 97 HPLC traces (Daicel Chiralpak AD-H column) of rac-20g (reference) and (R)-20g. Area 
integration > 99 (> 99% ee). 
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Figure 98 HPLC traces (Daicel Chiralpak AD-H column) of rac-20h (reference) and (R)-20h. Area 
integration = 99.3:0.7 (98.6% ee). 
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Figure 99 HPLC traces (Daicel Chiralpak AD-H column) of rac-20i (reference) and (R)-20i. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 100 HPLC traces (Daicel Chiralpak AD-H column) of rac-20j (reference) and (R)-20j. Area 
integration > 99 (>99% ee). 
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Figure 101 HPLC traces (Daicel Chiralpak AD-H column) of rac-20k (reference) and (R)-20k. Area 
integration = 99.5:0.5 (99.0% ee). 
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Figure 102 HPLC traces (Daicel Chiralpak AD-H column) of rac-20l (reference) and (R)-20l. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 103 HPLC traces (Daicel Chiralpak AD-H column) of rac-20m (reference) and (R)-20m. Area 
integration = 98.7:1.3 (97.4% ee). 
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Figure 104 HPLC traces (Daicel Chiralpak AD-H column) of rac-20n (reference) and (R)-20n. Area 
integration > 99 (>99% ee). 
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Figure 105 HPLC traces (Daicel Chiralpak AD-H column) of rac-20o (reference) and (R)-20o. Area 
integration > 99 (>99% ee). 
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Figure 106 HPLC traces (Daicel Chiralpak OJ-H column) of rac-20p (reference) and (R)-20p. Area 
integration = 99.5:0.5 (99.0% ee). 
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Figure 107 HPLC traces (Daicel Chiralpak AD-H column) of rac-20q (reference) and (R)-20q. Area 
integration = 98.5:1.5 (97.0% ee). 
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Figure 108 HPLC traces (Daicel Chiralpak AD-H column) of rac-20r (reference) and (R)-20r. Area 
integration = 97.2:2.8 (94.4% ee). 
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Figure 109 HPLC traces (Daicel Chiralpak AD-H column) of rac-20s (reference) and (R)-20s. Area 
integration = 96.9:3.1 (93.8% ee). 
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Figure 110 HPLC traces (Daicel Chiralpak AD-H column) of rac-20t (reference) and (R)-20t. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 111 HPLC traces (Daicel Chiralpak OD-H column) of rac-20u (reference) and (R)-20u. Area 
integration > 99 (>99% ee). 
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Figure 112 HPLC traces (Daicel Chiralpak AD-H column) of rac-20v (reference) and (R)-20v. Area 
integration = 98.3:1.7 (96.6% ee). 
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Figure 113 HPLC traces (Daicel Chiralpak AD-H column) of rac-20w (reference) and (R)-20w. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 114 HPLC traces (Daicel Chiralpak AD-H column) of rac-20x (reference) and (R)-20x. Area 
integration= 97.1:2.9 (94.3% ee).  
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Figure 115 HPLC traces (Daicel Chiralpak AD-H column) of rac-20y (reference) and (R)-20y. Area 
integration = 98.4:1.6 (96.8% ee). 
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Figure 116 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26a (reference) and (S)-26a. Area 
integration = 99.6:0.4 (99.2% ee). 
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Figure 117 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26b (reference) and (S)-26b. Area 
integration = 99.6:0.4 (99.2% ee). 
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Figure 118 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26c (reference) and (S)-26c. Area 
integration = 99.6:0.4 (99.2% ee). 
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Figure 119 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26d (reference) and (S)-26d. Area 
integration = 99.6:0.4 (99.2% ee). 
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Figure 120 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26e (reference) and (S)-26e. Area 
integration = 99.5:0.5 (99.0% ee). 
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Figure 121 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26f (reference) and (S)-26f. Area 
integration = 98.5:1.5 (97.0% ee). 
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Figure 122 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26g (reference) and (S)-26g. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 123 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26h (reference) and (S)-26h. Area 
integration = 98.1:1.9 (96.2% ee). 
Chapter 6: Appendices 
208 
 
 
 
Figure 124 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26i (reference) and (S)-26i. Area 
integration = 99.6:0.4 (99.2% ee). 
Chapter 6: Appendices 
209 
 
 
 
Figure 125 HPLC traces (Daicel Chiralpak AD-H column) of rac-26j (reference) and (S)-26j. Area 
integration = 99.6:0.4 (99.2% ee). 
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Figure 126 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26k (reference) and (S)-26k. Area 
integration = 98.5:1.5 (97.0% ee). 
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Figure 127 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26l (reference) and (S)-26l. Area 
integration = 99.5:0.5 (99.0% ee). 
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Figure 128 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26m (reference) and (S)-26m. Area 
integration = 99.8:0.2 (99.6% ee). 
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Figure 129 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26n (reference) and (S)-26n. Area 
integration = 99.1:0.9 (98.2% ee). 
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Figure 130 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26o (reference) and (S)-26o. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 131 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26p (reference) and (R)-26p. Area 
integration = 95.3:4.7 (90.6% ee). 
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Figure 132 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26q (reference) and (S)-26q. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 133 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26r (reference) and (S)-26r. Area 
integration = 99.5:0.5 (99.0% ee). 
 
 
Chapter 6: Appendices 
218 
 
 
 
Figure 134 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26s (reference) and (S)-26s. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 135 HPLC traces (Daicel Chiralpak IG column) of rac-26t (reference) and (S)-26t. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 136 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26u (reference) and (S)-26u. Area 
integration = 99.4:0.6 (98.8% ee). 
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Figure 137 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26v (reference) and (S)-26v. Area 
integration = 81.2:18.8 (62.4% ee). 
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Figure 138 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26w (reference) and (R)-26w. Area 
integration = 53.4:46.6 (6.8% ee). 
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Figure 139 HPLC traces (Daicel Chiralcel OJ-H column) of rac-26x (reference) and (S)-26x. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 140 HPLC traces (Daicel Chiralpak AD-H column) of rac-28a (reference) and (S)-28a. Area 
integration = 99.5:0.5 (99.0% ee). 
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Figure 141 HPLC traces (Daicel Chiralpak OD-H column) of rac-28b (reference) and (S)-28b. Area 
integration = 99.7:0.3 (99.4% ee). 
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Figure 142 HPLC traces (Daicel Chiralpak AD-H column) of rac-28c (reference) and (S)-28c. Area 
integration = 97.5:2.5 (95.0% ee). 
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6.7 List of Crystal Structure Data 
 
Figure 143 Crystal structure of rac-Ir(Se). ORTEP drawing with 50% probability thermal ellipsoids. 
The counteranion is omitted for clarity. 
 
Table 7 Crystal Data and Structure Refinement for rac-Ir(Se). 
 
Crystal data: 
 
Identification code  z649_0m 
Habitus, colour  block, yellow 
Crystal size 0.37 x 0.30 x 0.16 mm
3
 
Crystal system  Monoclinic 
Space group  P21 Z = 4 
Unit cell dimensions a = 17.0086(8) Å = 90°. 
 b = 16.2286(7) Å = 91.595(2)°. 
 c = 17.2753(8) Å  = 90°. 
Volume 4766.6(4) Å
3
 
Cell determination  9705 peaks with Theta 2.4 to 27.6°. 
Empirical formula  C41H44Cl6F6IrN4PSe2 
Moiety formula  C38H38IrN4Se2, F6P, 3(CH2Cl2) 
Formula weight  1300.59 
Density (calculated) 1.812 Mg/m
3
 
Absorption coefficient 4.757 mm
-1
 
F(000) 2536 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.116 to 27.600°. 
Index ranges -22<=h<=22, -21<=k<=21, -22<=l<=22 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 202475 
Independent reflections 21990 [R(int) = 0.0366] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  21415[I > 2(I)]  
Reflections used for refinement  21990 
Absorption correction Numerical Mu From Formula 
Max. and min. transmission 0.52 and 0.18 
Flack parameter (absolute struct.)   -0.0038(13)  
Largest diff. peak and hole 1.313 and -1.177 e.Å
-3
 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calc. positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)  
Data / restraints / parameters 21990 / 37 / 1145 
Goodness-of-fit on F
2
 1.110 
R index (all data) wR2 = 0.0584 
R index conventional  [I>2sigma(I)] R1 = 0.0250 
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Figure 144 Crystal structure of -RhPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 8 Crystal Data and Structure Refinement for -RhPP. 
 
Crystal data: 
 
Identification code  z244_0m 
Habitus, colour  needle, colourless 
Crystal size 0.46 x 0.18 x 0.09 mm
3
 
Crystal system  Monoclinic 
Space group  P21 Z = 8 
Unit cell dimensions a = 16.3796(9) Å = 90°. 
 b = 18.1551(9) Å = 93.249(2)°. 
 c = 27.7174(15) Å  = 90°. 
Volume 8229.2(8) Å
3
 
Cell determination  9925 peaks with Theta 2.4 to 25.2°. 
Empirical formula  C40.80H43.60Cl1.60F6N4PRh 
Moiety formula  C40H42N4 Rh, F6P, 0.8(CH2Cl2) 
Formula weight  894.55 
Density (calculated) 1.444 Mg/m
3
 
Absorption coefficient 0.619 mm
-1
 
F(000) 3661 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.184 to 25.334°. 
Index ranges -19<=h<=19, -21<=k<=21, -33<=l<=33 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 187023 
Independent reflections 29991 [R(int) = 0.1334] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  24833[I>2sigma(I) ]  
Reflections used for refinement  29991 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.95 and 0.84 
Flack parameter (absolute struct.)   0.019(8) 
Largest diff. peak and hole 1.392 and -1.061 e.Å
-3
 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 29991 / 2029 / 2009 
 Restraints for anisotropic thermal parameters 
(“RIGU”) 
Goodness-of-fit on F
2
 1.065 
R index (all data) wR2 = 0.1222 
R index conventional  [I>2sigma(I)] R1 = 0.0557 
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Figure 145 Crystal structure of -RhPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 9 Crystal Data and Structure Refinement for -RhPP. 
 
Crystal data: 
 
Identification code  z339-zwei_0m 
Habitus, colour  nugget, red 
Crystal size 0.69 x 0.32 x 0.20 mm
3
 
Crystal system  Orthorhombic 
Space group  P212121 Z = 8 
Unit cell dimensions a = 15.3828(5) Å = 90°. 
 b = 22.8555(9) Å = 90°. 
 c = 25.3802(10) Å  = 90°. 
Volume 8923.2(6) Å
3
 
Cell determination  9665 peaks with Theta 2.2 to 25.3°. 
Empirical formula  C42H46Cl4F6N4PRh 
Moiety formula  C40H42N4Rh, F6P, 2(CH2Cl2) 
Formula weight  996.51 
Density (calculated) 1.484 Mg/m
3
 
Absorption coefficient 0.718 mm
-1
 
F(000) 4064 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.220 to 25.315°. 
Index ranges -18<=h<=18, -26<=k<=27, -30<=l<=30 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 66861 
Independent reflections 16195 [R(int) = 0.0589] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  14816[I>2sigma(I) ]  
Reflections used for refinement  16195 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.87 and 0.74 
Flack parameter (absolute struct.)   0.005(9) 
Largest diff. peak and hole 0.381 and -1.027 e.Å
-3
 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 16195 / 663 / 1121 
Goodness-of-fit on F
2
 1.110 
R index (all data) wR2 = 0.0807 
R index conventional  [I>2sigma(I)] R1 = 0.0396 
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Figure 146 Crystal structure of -IrPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 10 Crystal Data and Structure Refinement for -IrPP. 
 
Crystal data: 
 
Identification code  z97_0m 
Habitus, colour  plate, yellow 
Crystal size 0.20 x 0.14 x 0.06 mm
3
 
Crystal system  Monoclinic 
Space group  P21 Z = 8 
Unit cell dimensions a = 16.3847(13) Å = 90°. 
 b = 18.1929(15) Å = 93.095(2)°. 
 c = 27.453(2) Å  = 90°. 
Volume 8171.4(11) Å
3
 
Cell determination  9347 peaks with Theta 2.3 to 25.2°. 
Empirical formula  C40.88H43.75Cl1.75F6IrN4P 
Moiety formula  C40H42IrN4, F6P, 0.88 (CH2Cl2) 
Formula weight  990.25 
Density (calculated) 1.610 Mg/m
3
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Absorption coefficient 3.483 mm
-1
 
F(000) 3942 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.193 to 25.356°. 
Index ranges -19<=h<=19, -21<=k<=21, -33<=l<=31 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 112143 
Independent reflections 29568 [R(int) = 0.0532] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  27002[I>2sigma(I) ]  
Reflections used for refinement  29568 
Absorption correction Numerical 
Max. and min. transmission 0.82 and 0.57 
Flack parameter (absolute struct.)   0.055(8) 
Largest diff. peak and hole 4.835 and -1.145 e.Å
-3
 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 29568 / 1774 / 2007 
Goodness-of-fit on F
2
 1.089 
R index (all data) wR2 = 0.1121 
R index conventional  [I>2sigma(I)] R1 = 0.0484 
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Figure 147 Crystal structure of -IrPP. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 11 Crystal Data and Structure Refinement for -IrPP. 
 
Crystal data: 
 
Identification code  z98b_0m 
Habitus, colour  plate, yellow 
Crystal size 0.25 x 0.12 x 0.05 mm
3
 
Crystal system  Orthorhombic 
Space group  P21212 Z = 4 
Unit cell dimensions a = 15.3905(7) Å = 90°. 
 b = 22.8141(13) Å = 90°. 
 c = 12.6639(6) Å  = 90°. 
Volume 4446.6(4) Å
3
 
Cell determination  9601 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C42H46Cl4 F6IrN4P 
Moiety formula  C40H42IrN4, F6P, 2(CH2Cl2) 
Formula weight  1085.80 
Density (calculated) 1.622 Mg/m
3
 
Absorption coefficient 3.339 mm
-1
 
F(000) 2160 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.222 to 25.284°. 
Index ranges -18<=h<=17, -14<=k<=27, -13<=l<=15 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 15571 
Independent reflections 7935 [R(int) = 0.0296] 
Completeness to theta = 25.242° 99.6 %  
Observed reflections  7212[I>2sigma(I) ]  
Reflections used for refinement  7935 
Absorption correction Numerical 
Max. and min. transmission 0.85 and 0.53 
Flack parameter (absolute struct.)   0.007(5) 
Largest diff. peak and hole 1.257 and -0.575 e.Å
-3
 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) 
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 7935 / 0 / 530 
Goodness-of-fit on F
2
 0.966 
R index (all data) wR2 = 0.0608 
R index conventional  [I>2sigma(I)] R1 = 0.0301 
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Figure 148 Crystal structure of 20l. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 12 Crystal Data and Structure Refinement for 20l. 
 
Crystal data: 
 
Identification code  z341_0m 
Habitus, colour  needle, colourless 
Crystal size 0.36 x 0.18 x 0.16 mm
3
 
Crystal system  Orthorhombic 
Space group  P212121 Z = 8 
Unit cell dimensions a = 10.9456(3) Å = 90°. 
 b = 12.5890(4) Å = 90°. 
 c = 21.7213(6) Å  = 90°. 
Volume 2993.07(15) Å
3
 
Cell determination  9966 peaks with Theta 2.5 to 25.2°. 
Empirical formula  C14H10BrF3N2O 
Moiety formula  C14H10BrF3N2O 
Formula weight  359.15 
Density (calculated) 1.594 Mg/m
3
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Absorption coefficient 2.778 mm
-1
 
F(000) 1424 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.466 to 25.317°. 
Index ranges -13<=h<=13, -15<=k<=15, -26<=l<=26 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 22310 
Independent reflections 5384 [R(int) = 0.0530] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4902[I>2sigma(I) ]  
Reflections used for refinement  5384 
Absorption correction Numerical  
Max. and min. transmission 0.67 and 0.35 
Flack parameter (absolute struct.)   0.027(8) 
Largest diff. peak and hole 0.235 and -0.270 e.Å
-3
 
Solution  Direct methods  
Refinement  Full-matrix least-squares on F
2
  
Treatment of hydrogen atoms  CH calc. positions, constr., OH located, isotr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 5384 / 189 / 454 
Goodness-of-fit on F
2
 1.055 
R index (all data) wR2 = 0.0556 
R index conventional  [I>2sigma(I)] R1 = 0.0290 
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Figure 149 Crystal structure of rac-Ru1. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 13 Crystal Data and Structure Refinement for rac-Ru1. 
 
Crystal data: 
 
Identification code  z1020c_0m 
Habitus, colour  needle, colourless 
Crystal size 0.62 x 0.13 x 0.11 mm
3
 
Crystal system  Monoclinic 
Space group  C2/c Z = 4 
Unit cell dimensions a = 19.8615(9) Å = 90°. 
 b = 22.9601(10) Å = 95.504(2)°. 
 c = 13.8009(6) Å  = 90°. 
Volume 6264.5(5) Å
3
 
Cell determination  9919 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C56H60Cl4F12N8P2Ru 
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Moiety formula  C54H5N8Ru, 2(F6P), 2(CH2Cl2) 
Formula weight  1377.93 
Density (calculated) 1.461 Mg/m
3
 
Absorption coefficient 0.551 mm
-1
 
F(000) 2808 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  230(2) K 
Theta range for data collection 2.312 to 25.297°. 
Index ranges -23<=h<=23, -27<=k<=27, -16<=l<=16 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.37A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.37A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 47978 
Independent reflections 5694 [R(int) = 0.0442] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4994[I > 2σ(I)]  
Reflections used for refinement  5694 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.94 and 0.87 
Largest diff. peak and hole 0.382 and -0.389 e.Å
-3
 
Solution  dual space algorithm 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)  
Data / restraints / parameters 5694 / 191 / 473 
Goodness-of-fit on F
2
 1.065 
R index (all data) wR2 = 0.0951 
R index conventional  [I>2sigma(I)] R1 = 0.0370 
 
Chapter 6: Appendices 
241 
 
 
Figure 150 Crystal structure of -Ru2-DPPE. ORTEP drawing with 50% probability thermal ellipsoids. 
The hexafluorophosphate counteranion is omitted for clarity. 
 
Table 14 Crystal Data and Structure Refinement for -Ru2-DPPE. 
 
Crystal data: 
 
Identification code  z1056_0m_sq 
Habitus, colour  plate, colourless 
Crystal size 0.31 x 0.30 x 0.14 mm
3
 
Crystal system  Monoclinic 
Space group  P21 Z = 2 
Unit cell dimensions a = 14.2760(6) Å = 90°. 
 b = 15.7178(7) Å = 103.244(2)°. 
 c = 14.3256(6) Å  = 90°. 
Volume 3129.0(2) Å
3
 
Cell determination  9151 peaks with Theta 2.6 to 27.5°. 
Empirical formula  C60H58F12N6P4Ru [+ solvent] 
Moiety formula  C60H58N6P2Ru, 2(F6P) [+ solvent] 
 Disordered solvent has been “squeezed”  
Formula weight  1316.07 
Density (calculated) 1.397 Mg/m
3
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Absorption coefficient 0.431 mm
-1
 
F(000) 1344 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.231 to 27.546°. 
Index ranges -18<=h<=18, -20<=k<=20, -18<=l<=18 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.37A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.37A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 71723 
Independent reflections 14432 [R(int) = 0.0431] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  13176[I > 2(I)]  
Reflections used for refinement  14432 
Extinction coefficient  X = 0.0009(2) 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.94 and 0.89 
Flack parameter (absolute struct.)   -0.023(6)  
Largest diff. peak and hole 0.343 and -0.343 e.Å
-3
 
Solution  Dual space algorithm 
Refinement  Full-matrix least-squares on F
2
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2016/6 (Sheldrick, 2016)  
 DIAMOND (Crystal Impact)  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)  
Data / restraints / parameters 14432 / 280 / 810 
Goodness-of-fit on F
2
 1.023 
R index (all data) wR2 = 0.0563 
R index conventional  [I>2sigma(I)] R1 = 0.0278 
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Statement 
 
gemäß § 10, Abs. 1 der Promotionsordnung der mathematisch-naturwissenschaftlichen 
Fachbereiche und des Medizinischen Fachbereichs für seine mathematisch- 
naturwissenschaftlichen Fächer der Philipps-Universität Marburg vom 15.07.2009 
 
Ich erkläre, dass eine Promotion noch an keiner anderen Hochschule als der Philipps- 
Universität Marburg, Fachbereich Chemie, versucht wurde und versichere, dass ich meine 
vorgelegte Dissertation 
 
Design of Novel Octahedral Stereogenic-at-Metal Complexes for 
Applications in Asymmetric Catalysis 
selbst und ohne fremde Hilfe verfasst, nicht andere als die in ihr angegebenen Quellen oder 
Hilfsmittl benutzt, alle vollständig oder sinngemäß übernommenen Zitate als solche 
gekennzeichnet sowie die Dissertation in der vorliegenden oder ähnlichen Form noch bei keiner 
anderen in- oder ausländischen Hochschule anlässlich eines Promotionsgesuchs oder zu 
anderen Prüfungszwecken eingereicht habe. 
 
 
 
Yu Zheng 
Marburg, den 3.1.2018
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